TYK2 INHIBITORS AND USES THEREOF

Selective TYK2 inhibitors address the challenge of minimizing side effects in treating TYK2-mediated disorders by specifically targeting TYK2, providing effective treatment for autoimmune and inflammatory disorders with reduced off-target effects.

JP7586829B2Active Publication Date: 2024-11-19アルミス インコーポレイテッド

Patent Information

Application Number
JP2021552136
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-05
Filing Date
2020-03-10
Publication Date
2024-11-19
Estimated Expiration
2040-03-10

AI Technical Summary

Technical Problem

Current treatments for TYK2-mediated disorders, such as autoimmune diseases, inflammatory disorders, and cancers, lack selective inhibitors that minimize side effects on other JAK kinases, particularly JAK2, leading to potential off-target effects.

Method used

Development of compounds that selectively inhibit TYK2 activity, reducing the risk of side effects by targeting TYK2 specifically while minimizing interference with JAK2, thereby providing therapeutic benefits for TYK2-mediated disorders.

Benefits of technology

The compounds effectively treat TYK2-mediated disorders with reduced side effects by selectively inhibiting TYK2, offering potential therapeutic benefits for autoimmune disorders, inflammatory disorders, and cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586829000001
    Figure 0007586829000001
  • Figure 0007586829000002
    Figure 0007586829000002
  • Figure 0007586829000003
    Figure 0007586829000003
Patent Text Reader

Abstract

Described herein are compounds useful for treating TYK2-mediated disorders. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This patent application claims the benefit of U.S. Provisional Patent Application No. 62 / 816,698, filed March 11, 2019, U.S. Provisional Patent Application No. 62 / 835,376, filed April 17, 2019, U.S. Provisional Patent Application No. 62 / 877,741, filed July 23, 2019, and U.S. Provisional Patent Application No. 62 / 931,119, filed November 5, 2019, each of which is incorporated herein by reference in its entirety.

[0002] Described herein are compounds that inhibit nonreceptor-protein kinase 2 ("TYK2"), also known as tyrosine kinase 2, methods for making the compounds, pharmaceutical compositions and medicaments containing the compounds, and methods for using the compounds. [Background technology]

[0003] TYK2 is a non-receptor tyrosine kinase member of the Janus kinase (JAK) family of protein kinases. The mammalian JAK family consists of four members: TYK2, JAK1, JAK2, and JAK3. JAK proteins, including TYK2, are essential for cytokine signaling. TYK2 associates with the cytoplasmic domains of type I and type II cytokine receptors and type I and type III interferon receptors and is activated by these receptors upon cytokine binding. Cytokines involved in TYK2 activation include interferons (e.g., IFN-α, IFN-β, IFN-κ, IFN-δ, IFN-ε, IFN-τ, IFN-ω, and IFN-ζ (also known as limitin)) and interleukins (e.g., IL-4, IL-6, IL-10, IL-11, IL-12, IL-13, IL-22, IL-23, IL-27, IL-31, oncostatin M, ciliary neurotrophic factor, cardiotrophin 1, cardiotrophin-like cytokines, and LIF). Activated TYK2 then phosphorylates additional signaling proteins, such as members of the STAT family, including, for example, STAT1, STAT2, STAT4, and STAT6.

[0004] Activation of TYK2 by IL-23 has been associated with inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. A genome-wide association study of 2,622 psoriasis patients identified an association between disease susceptibility and TYK2. Knockout or tyrphostin inhibition of TYK2 significantly reduced both IL-23- and IL-22-induced dermatitis.

[0005] TYK2 also plays a role in respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and cystic fibrosis. Goblet cell hyperplasia (GCH) and mucus hypersecretion are mediated by IL-13-induced TYK2 activation, which in turn activates STAT6.

[0006] Reduced TYK2 activity protects joints from collagen antibody-induced arthritis, a model of human rheumatoid arthritis. Mechanistically, reduced Tyk2 activity reduces the production of Th1 / Th17-associated cytokines and matrix metalloproteinases, as well as other key markers of inflammation.

[0007] TYK2 knockout mice were completely resistant to experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), and showed no CD4 T cell infiltration in the spinal cord compared with controls, suggesting that TYK2 is essential for the development of pathogenic CD4-mediated disease in MS. This corroborates previous studies linking increased TYK2 expression with MS susceptibility. Loss-of-function mutations in TYK2 result in reduced demyelination and increased remyelination of neurons. This also suggests a role for TYK2 inhibitors in the treatment of MS and other demyelinating disorders of the CNS.

[0008] TYK2 is the only signaling messenger common to both IL-12 and IL-23. TYK2 knockout reduced footpad thickness induced by methylated BSA injection, imiquimod-induced psoriasis-like dermatitis, and dextran sulfate sodium- or 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice.

[0009] Linkage and association studies of systemic lupus erythematosus (SLE, an autoimmune disorder) with various type I IFN signaling genes have demonstrated a strong and significant correlation between loss-of-function mutations in TYK2 and a reduced prevalence of SLE in families with affected members. Genome-wide association studies of individuals with SLE compared with unaffected cohorts have demonstrated a highly significant correlation between the TYK2 locus and SLE.

[0010] TYK2 has been shown to play a critical role in sustaining tumor surveillance, and TYK2 knockout mice have been shown to exhibit impaired cytotoxic T cell responses and accelerated tumor progression. However, these effects correlate with efficient suppression of natural killer (NK) and cytotoxic T lymphocytes, suggesting that TYK2 inhibitors may be well suited for the treatment of autoimmune disorders or transplant rejection. While other JAK family members, such as JAK3, have similar roles in the immune system, TYK2 has been proposed as a superior target because it participates in fewer, more closely related signaling pathways, potentially reducing off-target effects.

[0011] Studies of T-cell acute lymphoblastic leukemia (T-ALL) have shown that T-ALL is highly dependent on IL-10 via TYK2 through STAT1-mediated signaling, sustaining cancer cell survival through upregulation of the anti-apoptotic protein BCL2. Knocking down TYK2, but not other JAK family members, reduced cell proliferation. Specific activating mutations in TYK2 that promote cancer cell survival include mutations in the FERM domain (G36D, S47N, and R425H), JH2 domain (V731I), and kinase domain (E957D and R1027H). However, TYK2 enzymes characterized by kinase-dead mutations (M978Y or M978F) in addition to the activating mutation (E957D) failed to transform cancer cells, identifying the requirement for the kinase function of TYK2 for enhanced cancer cell survival.

[0012] Therefore, selective inhibition of TYK2 has been proposed as a suitable target for patients with IL-10- and / or BCL2-dependent tumors, such as those in 70% of adult T-cell leukemia cases. TYK2-mediated STAT3 signaling has also been shown to mediate neuronal cell death induced by amyloid-β (Aβ) peptides. Reduced TYK2 phosphorylation of STAT3 after Aβ administration reduces neuronal cell death. Increased STAT3 phosphorylation has been observed in postmortem brains of Alzheimer's patients.

[0013] Inhibition of the JAK-STAT signaling pathway has also been implicated in hair growth and reversal of hair loss associated with alopecia areata.

[0014] Therefore, compounds that inhibit the activity of TYK2, particularly those with selectivity over JAK2, would be beneficial and should produce a pharmacological response that successfully treats one or more of the conditions described herein without the side effects associated with inhibition of JAK2.

[0015] Therefore, there is a need to provide novel inhibitors that have more potent or advantageous pharmaceutically relevant properties, such as selectivity over other JAK kinases (particularly JAK2). Summary of the Invention

[0016] Disclosed herein is a compound of formula (II) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: L is a linker of 4 to 10 atoms, and one or more R L optionally replaced by Each R L are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon L are taken together to form oxo, cycloalkyl or heterocycloalkyl, or two R on different carbons L together form a cycloalkyl or heterocycloalkyl; Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Each R A are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)ORb ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo, Each R A1 are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo, n is 0 to 4, [ka] is a single or double bond, X 1 and X 2 is -N- or -C=, where X 1 or X 2 One of them is -N- and the other is -C=, Y 8 is CR 8 or N, Y 6 is CR 6 or N, Y 3 is CR 3 or N, Y 9 is CR 9 or N, R 3 , R 6 , R 8 and R 9 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c Rd ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R 4 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a optionally replaced by Each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo, R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; R 7is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; Each R a are independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R b are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R c and R dare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0017] Disclosed herein are compounds of formula (IIa) below, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof: [ka]

[0018] Disclosed herein are compounds of formula (IIb) below, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof: [ka]

[0019] Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, and a pharmaceutically acceptable excipient.

[0020] Also disclosed herein is a method of inhibiting the TYK2 enzyme in a patient or biological sample, the method comprising contacting the patient or biological sample with a compound disclosed herein or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.

[0021] Also disclosed herein are methods of treating a TYK2-mediated disorder, the methods comprising administering to a patient in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder. In some embodiments, the disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling.

[0022] Incorporation by Reference All publications, patents, and patent applications mentioned herein are hereby incorporated by reference for the specific purposes identified herein. DETAILED DESCRIPTION OF THE INVENTION

[0023] definition As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "an agent" includes a plurality of such agents, and a reference to "the cell" includes a reference to one or more cells (or cells) and equivalents thereof known to those of skill in the art, and so forth. When ranges are used herein with respect to physical properties, e.g., molecular weight, or chemical properties, e.g., chemical formula, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about," when referring to a numerical value or numerical range, indicates that the referenced number or numerical range is approximate within experimental variation (or within statistical experimental error); therefore, in some instances, the number or numerical range will vary from 1% to 15% of the stated number or numerical range. The term "comprising" (and related terms such as, for example, "comprising," or "having," or "containing") is not intended to exclude that in other particular embodiments, the embodiment, such as, for example, any composition of matter, composition of matter, method, or process described herein, "consists of" or "consists essentially of" the described features.

[0024] As used in this specification and the appended claims, unless specified to the contrary, the following terms have the meanings indicated below.

[0025] "Aliphatic chain" refers to a linear chemical moiety composed only of carbon and hydrogen. In some embodiments, an aliphatic chain is saturated. In some embodiments, an aliphatic chain is unsaturated. In some embodiments, an unsaturated aliphatic chain contains one unsaturation. In some embodiments, an unsaturated aliphatic chain contains two or more unsaturations. In some embodiments, an unsaturated aliphatic chain contains two unsaturations. In some embodiments, an unsaturated aliphatic chain contains one double bond. In some embodiments, an unsaturated aliphatic chain contains two double bonds.

[0026] "Oxo" refers to =O.

[0027] "Alkyl" refers to an optionally substituted straight-chain or optionally substituted branched-chain saturated hydrocarbon monoradical having 1 to about 10 carbon atoms, or 1 to 6 carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl, and hexyl, as well as longer alkyl groups such as heptyl, octyl, and the like. Wherever a numerical range appears herein, such as "C1-C6 alkyl," it means that the alkyl group in question consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms; however, this definition also applies to appearances of the term "alkyl" where no numerical range is specified. In some embodiments, alkyl is any of C1-C6 alkyl groups. 10The alkyl group is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF, -OH, -OMe, -NH, or -NO. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -CF, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.

[0028] "Alkenyl" refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon double bonds and having from 2 to about 10 carbon atoms, preferably from 2 to about 6 carbon atoms. It is understood that the group may be in either the cis or trans conformation about the double bond, and both isomers are included. Examples include, but are not limited to, ethenyl (-CH=CH), 1-propenyl (-CHCH=CH), isopropenyl [-C(CH)=CH], butenyl, 1,3-butadienyl, and the like. Wherever a numerical range appears herein, such as "C2-C6 alkenyl," it means that the alkenyl group can consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms; however, this definition also applies when the term "alkenyl" is used without a specified numerical range. In some embodiments, alkenyl refers to any of C2-C6 alkenyls. 10Alkenyl is C2-C9 alkenyl, C2-C8 alkenyl, C2-C7 alkenyl, C2-C6 alkenyl, C2-C5 alkenyl, C2-C4 alkenyl, C2-C3 alkenyl, or C2 alkenyl. Unless otherwise specifically stated herein, alkenyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkenyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkenyl is optionally substituted with halogen.

[0029] "Alkynyl" refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon triple bonds and having from 2 to about 10 carbon atoms, more preferably from 2 to about 6 carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, and the like. Wherever it appears herein, a numerical range, such as "C2-C6 alkynyl," means that the alkynyl group can consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although this definition also applies to appearances of the term "alkynyl" where no numerical range is specified. In some embodiments, alkynyl refers to any of C2-C6 alkynyl groups. 10alkynyl, C2-C9 alkynyl, C2-C8 alkynyl, C2-C7 alkynyl, C2-C6 alkynyl, C2-C5 alkynyl, C2-C4 alkynyl, C2-C3 alkynyl, or C2 alkynyl. Unless otherwise specifically stated herein, alkynyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkynyl is optionally substituted with halogen.

[0030] "Alkylene" refers to a straight or branched divalent hydrocarbon chain. Unless specifically stated otherwise in this specification, alkylene groups can be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, alkylene is optionally substituted with halogen.

[0031] "Alkoxy" means a group of the formula -OR a where R ais an alkyl radical as defined. Unless otherwise specifically stated herein, an alkoxy group can be optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkoxy is optionally substituted with oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, an alkoxy is optionally substituted with halogen.

[0032] "Aminoalkyl" refers to an alkyl radical, as defined above, substituted with one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Examples of aminoalkyl include aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.

[0033] "Aryl" refers to a radical derived from a hydrocarbon ring system containing hydrogen, 6 to 30 carbon atoms, and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system and may include fused (when fused to a cycloalkyl or heterocycloalkyl ring, the aryl is attached through an aromatic ring atom) or bridged ring systems. In some embodiments, an aryl is a 6- to 10-membered aryl. In some embodiments, an aryl is a 6-membered aryl. Aryl radicals include, but are not limited to, aryl radicals derived from anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene hydrocarbon ring systems. In some embodiments, an aryl is phenyl. Unless otherwise specifically stated herein, aryl can be optionally substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, aryl is optionally substituted with halogen.

[0034] "Cycloalkyl" refers to a partially or fully saturated, monocyclic or polycyclic carbocyclic ring, which may include fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is attached through a non-aromatic ring atom) or bridged ring systems. Representative cycloalkyls include, but are not limited to, cycloalkyls containing 3 to 15 carbon atoms (C3-C4). 15 cycloalkyl), 3 to 10 carbon atoms (C3-C 10Examples of monocyclic cycloalkyls include cycloalkyls having 3 to 8 carbon atoms (C3-C8 cycloalkyl), 3 to 6 carbon atoms (C3-C6 cycloalkyl), 3 to 5 carbon atoms (C3-C5 cycloalkyl), or 3 to 4 carbon atoms (C3-C4 cycloalkyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of polycyclic cycloalkyl or carbocycle include adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Examples of partially saturated cycloalkyl include cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise specifically stated herein, cycloalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, cycloalkyl is optionally substituted with halogen.

[0035] "Deuteroalkyl" refers to an alkyl radical, as defined above, substituted with one or more deuterium atoms. In some embodiments, the alkyl is substituted with one deuterium atom. In some embodiments, the alkyl is substituted with one, two, or three deuterium atoms. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuterium atoms. Examples of deuteroalkyls include CD3, CHD, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3.

[0036] "Haloalkyl" refers to an alkyl radical, as defined above, substituted with one or more halogen atoms. In some embodiments, the alkyl is substituted with one, two, or three halogen atoms. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six halogens. Examples of haloalkyl include trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. In some embodiments, the haloalkyl is trifluoromethyl.

[0037] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo. In some embodiments, the halogen is fluoro or chloro. In some embodiments, the halogen is fluoro.

[0038] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. A heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. In one embodiment, a heteroalkyl is a C1-C6 heteroalkyl, where the heteroalkyl consists of 1 to 6 carbon atoms and one or more non-carbon atoms, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof, in which case the heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyls include, for example, -CHOCH3, -CHCHOCH3, -CHCHOCHCHOCH3, or -CH(CH3)OCH3. Unless otherwise specifically stated herein, heteroalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroalkyl is optionally substituted with halogen.

[0039] "Hydroxyalkyl" refers to an alkyl radical, as defined above, substituted with one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Examples of hydroxyalkyl include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl.

[0040] "Heterocycloalkyl" refers to a 3- to 24-membered partially saturated or fully saturated cyclic radical containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur. In some embodiments, a heterocycloalkyl contains 1 or 2 heteroatoms selected from nitrogen and oxygen. Unless specifically stated otherwise in the specification, a heterocycloalkyl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused (when fused to an aryl or heteroaryl ring, the heterocycloalkyl is attached through a non-aromatic ring atom) or bridged ring systems. The nitrogen, carbon, or sulfur atom in the heterocycloalkyl radical can be optionally oxidized, and the nitrogen atom can be optionally quaternized. Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls containing 2 to 15 carbon atoms (C2-C3). 15 heterocycloalkyl), 2 to 10 carbon atoms (C2-C 10Examples of heterocycloalkyl include heterocycloalkyls having 2 to 8 carbon atoms (C2-C8 heterocycloalkyl), 2 to 6 carbon atoms (C2-C6 heterocycloalkyl), 2 to 5 carbon atoms (C2-C5 heterocycloalkyl), or 2 to 4 carbon atoms (C2-C4 heterocycloalkyl). In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered heterocycloalkyl. Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4- Examples of heterocycloalkyl include piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all cyclic carbohydrates, including, but not limited to, monosaccharides, disaccharides, and oligosaccharides. When referring to the number of carbon atoms in a heterocycloalkyl, it is understood that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that make up the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring).Unless otherwise specifically stated herein, a heterocycloalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, a heterocycloalkyl is optionally substituted with halogen.

[0041] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from atoms other than carbon, such as oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. A heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a C1-C6 heteroalkyl. Unless specifically stated otherwise herein, a heteroalkyl is optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.

[0042] "Heteroaryl" refers to a 5- to 14-membered ring system radical containing a hydrogen atom, 1 to 13 carbon atoms, 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. The heteroaryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, and the ring system can include fused (when fused to a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems. The nitrogen, carbon, or sulfur atoms in the heteroaryl radical can be optionally oxidized, and the nitrogen atom can be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl.Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, These include isoindolyl, indolinyl, isoindonyi, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specifically stated herein, heteroaryl is optionally substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroaryl is optionally substituted with halogen.

[0043] As used herein, the terms "treat," "prevent," "ameliorate," and "inhibit," as well as derivatives thereof, do not necessarily imply 100% or complete treatment, prevention, amelioration, or inhibition. Rather, there are various degrees of such treatment, prevention, amelioration, and inhibition, which one of ordinary skill in the art would recognize as having potential benefit or therapeutic effect. In this regard, the methods of the present disclosure can provide any level or amount of treatment, prevention, amelioration, or inhibition in a mammal. For example, a disorder, including its symptoms or condition, can be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. Furthermore, the treatment, prevention, amelioration, or inhibition provided by the methods disclosed herein can include treatment, prevention, amelioration, or inhibition of one or more conditions or symptoms of a disorder, such as, for example, cancer or an inflammatory disease. Also for purposes of this specification, "treating," "preventing," "ameliorating," or "inhibiting" includes delaying the onset of a disorder or the development of a symptom or condition thereof.

[0044] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient quantity of a compound disclosed herein being administered that will alleviate to some extent one or more of the symptoms or conditions of the disease being treated, such as, for example, cancer or an inflammatory disease. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to produce a clinically meaningful reduction in disease symptoms. In some embodiments, an appropriate "effective" amount in any individual case is determined using techniques such as, for example, a dose escalation study.

[0045] As used herein, the term "TYK2-mediated" disorder, disease, and / or condition means any disease or other deleterious condition in which TYK2 or a variant thereof is known to play a role. Accordingly, another embodiment relates to treating or lessening the severity of one or more diseases in which TYK2 or a variant thereof is known to play a role. Such TYK2-mediated disorders include, but are not limited to, autoimmune disorders, inflammatory disorders, proliferative disorders, endocrine disorders, neurological disorders, and transplant-related disorders.

[0046] compound Described herein are compounds useful for treating TYK2-mediated disorders. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder.

[0047] Disclosed herein are compounds of formula (I) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: Ring A is an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, or an optionally substituted heteroaryl; X is CR 8 or N, R 1 is -S(=O)R 10 ,-S(=O)2R 10 ,-S(=O)2NR 12 R 13 ,-C(=O)R 10 ,-C(=O)OR 11 ,-C(=O)NR 12 R 13optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C1-C6 deuteroalkyl; R 3 , R 6 , and R 8 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR boptionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl; R 4 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 5 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C1-C6 deuteroalkyl; R 7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C1-C6 deuteroalkyl; Each R 10 are independently optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R 11are independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R 12 and R 13 are independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; or R 12 and R 13 taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl; Each R a are independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R bare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; and Each R c and R d are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0048] Disclosed herein are compounds of formula (I) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: Ring A is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is selected from the group consisting of one or more R A optionally replaced by Each R A are independently deuterium, halogen, -CN, -OR 15 ,-SR 15 ,-S(=O)R 14 ,-S(=O)2R 14 ,-NO2,-NR 16 R 17 ,-NHS(=O)2R 14 ,-S(=O)2NR 16 R 17 ,-C(=O)R 14 ,-OC(=O)R 14 ,-C(=O)OR 15 ,-OC(=O)OR 15 ,-C(=O)NR 16 R 17 ,-OC(=O)NR 16 R 17 ,-NR 15 C(=O)NR 16 R 17 ,-NR 15 C(=O)R 14 ,-NR 15 C(=O)OR 15 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo, Each R A1 are independently deuterium, halogen, -CN, -OR 15 ,-SR 15 ,-S(=O)R 14 ,-S(=O)2R 14,-NO2,-NR 16 R 17 ,-NHS(=O)2R 14 ,-S(=O)2NR 16 R 17 ,-C(=O)R 14 ,-OC(=O)R 14 ,-C(=O)OR 15 ,-OC(=O)OR 15 ,-C(=O)NR 16 R 17 ,-OC(=O)NR 16 R 17 ,-NR 15 C(=O)NR 16 R 17 ,-NR 15 C(=O)R 14 ,-NR 15 C(=O)OR 15 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo, Each R 14 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 14a optionally replaced by Each R 14a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 14a together to form oxo, Each R 15 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 15a optionally replaced by Each R 15a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c Rd ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 15a together to form oxo, Each R 16 and R 17 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 16a optionally replaced by or R 16 and R 17 together with the nitrogen atom to which they are attached, form one or more R 16b forming an optionally substituted heterocycloalkyl with Each R 16a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16a together to form oxo, Each R 16b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NRb C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16b together to form oxo, X is CR 8 or N, R 1 is -S(=O)R 10 ,-S(=O)2R 10 ,-S(=O)2NR 12 R 13 ,-C(=O)R 10 ,-C(=O)OR 11 ,-C(=O)NR 12 R 13 , C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 1a optionally replaced by Each R 1a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 1b or two R on the same carbon 1a together to form oxo, Each R 1b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 1b together to form oxo, R 2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; R 3 , R 6 , and R 8 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R 4is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a optionally replaced by Each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo, R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; R 7 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; Each R 10is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 10a optionally replaced by Each R 10a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 10a together to form oxo, Each R 11are independently hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 11a optionally replaced by Each R 11a are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 11a together to form oxo, Each R 12 and R 13are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 12a optionally replaced by Each R 12a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 12a together to form oxo, or R 12 and R 13 together with the nitrogen atom to which they are attached, form one or more R12b forming a heterocycloalkyl optionally substituted with Each R 12b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 12b together to form oxo, Each R aare independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R b are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R c and R d are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0049] In some embodiments of compounds of Formula (I), ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each of which contains one or more R A In some embodiments of compounds of Formula (I), ring A is heterocycloalkyl, aryl, or heteroaryl; each optionally substituted with one or more R A In some embodiments of the compounds of Formula (I), ring A is optionally substituted with one or more R A In some embodiments of the compounds of Formula (I), ring A is aryl or heteroaryl; each of which is substituted with one or more R A In some embodiments of the compounds of Formula (I), ring A is optionally substituted with one or more R A In some embodiments of compounds of Formula (I), ring A is phenyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl, each optionally substituted with one or more R A is replaced by

[0050] In some embodiments of the compounds of Formula (I), each R A are independently deuterium, halogen, -CN, -OR 15 ,-SR 15 ,-S(=O)R 14 ,-S(=O)2R 14 ,-NO2,-NR 16 R 17 ,-NHS(=O)2R 14 ,-S(=O)2NR 16 R 17 ,-C(=O)R 14 ,-OC(=O)R 14 ,-C(=O)OR 15,-OC(=O)OR 15 ,-C(=O)NR 16 R 17 ,-OC(=O)NR 16 R 17 ,-NR 15 C(=O)NR 16 R 17 ,-NR 15 C(=O)R 14 ,-NR 15 C(=O)OR 15 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0051] In some embodiments of the compounds of Formula (I), each R A are independently deuterium, halogen, -CN, -OR 15 ,-NR 16 R 17 ,-C(=O)R 14 ,-C(=O)OR 15 ,-C(=O)NR 16 R 17 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0052] In some embodiments of the compounds of Formula (I), each R A are independently deuterium, halogen, -CN, -OR 15 , -NR 16 R 17 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0053] In some embodiments of the compounds of Formula (I), each R A1 are independently deuterium, halogen, -CN, -OR 15 ,-SR 15 ,-S(=O)R 14 ,-S(=O)2R 14 ,-NO2,-NR 16 R 17 ,-NHS(=O)2R 14 ,-S(=O)2NR 16 R 17 ,-C(=O)R 14 ,-OC(=O)R 14 ,-C(=O)OR 15 ,-OC(=O)OR 15 ,-C(=O)NR 16 R 17 ,-OC(=O)NR 16 R 17 ,-NR 15 C(=O)NR 16 R 17 ,-NR 15 C(=O)R 14 ,-NR 15 C(=O)OR 15, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo.

[0054] In some embodiments of the compounds of Formula (I), each R A1 are independently deuterium, halogen, -CN, -OR 15 ,-NR 16 R 17 ,-C(=O)R 14 ,-C(=O)OR 15 ,-C(=O)NR 16 R 17 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo.

[0055] In some embodiments of the compounds of Formula (I), each R A1 are independently deuterium, halogen, -CN, -OR 15 ,-NR 16 R 17 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon A1 together to form oxo.

[0056] In some embodiments of the compounds of Formula (I), each R 14is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 14a is optionally replaced by

[0057] In some embodiments of the compounds of Formula (I), each R 14 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 14a is optionally replaced by

[0058] In some embodiments of the compounds of Formula (I), each R 14 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, and heterocycloalkyl is independently selected from one or more R 14a is optionally replaced by

[0059] In some embodiments of the compounds of Formula (I), each R 14a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NRc R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 14a together to form oxo.

[0060] In some embodiments of the compounds of Formula (I), each R 14a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 14a together to form oxo.

[0061] In some embodiments of the compounds of Formula (I), each R 15are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 15a is optionally replaced by

[0062] In some embodiments of the compounds of Formula (I), each R 15 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently selected from one or more R 15a is optionally replaced by

[0063] In some embodiments of the compounds of Formula (I), each R 15 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, or heterocycloalkyl is independently selected from one or more R 15a is optionally replaced by

[0064] In some embodiments of the compounds of Formula (I), each R 15a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 15a together to form oxo.

[0065] In some embodiments of the compounds of Formula (I), each R 15a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 15a together to form oxo.

[0066] In some embodiments of the compounds of Formula (I), each R 15a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)Ra ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 15a together to form oxo.

[0067] In some embodiments of the compounds of Formula (I), each R 16 and R 17 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 16a is optionally replaced by

[0068] In some embodiments of the compounds of Formula (I), each R 16 and R 17 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently selected from one or more R 16a is optionally replaced by

[0069] In some embodiments of the compounds of Formula (I), each R 16 and R 17are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, or heterocycloalkyl independently is selected from one or more R 16a is optionally replaced by

[0070] In some embodiments of the compounds of Formula (I), each R 16a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16a together to form oxo.

[0071] In some embodiments of the compounds of Formula (I), each R 16a are independently deuterium, halogen, -CN, -OR b,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16a together to form oxo.

[0072] In some embodiments of the compounds of Formula (I), each R 16a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 16a together to form oxo.

[0073] In some embodiments of the compounds of Formula (I), R 16 and R 17 together with the nitrogen atom to which they are attached, form one or more R 16b to form an optionally substituted heterocycloalkyl.

[0074] In some embodiments of the compounds of Formula (I), each R 16b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16b together to form oxo.

[0075] In some embodiments of the compounds of Formula (I), each R 16b are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 16b together to form oxo.

[0076] In some embodiments of the compounds of Formula (I), each R 16b are independently deuterium, halogen, -CN, -OR b ,-NRc R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 16b together to form oxo.

[0077] In some embodiments of the compounds of Formula (I), X is N. In some embodiments of the compounds of Formula (I), X is CR 8 is.

[0078] In some embodiments of the compounds of Formula (I), R 1 is -S(=O)R 10 ,-S(=O)2R 10 ,-S(=O)2NR 12 R 13 ,-C(=O)R 10 ,-C(=O)OR 11 ,-C(=O)NR 12 R 13 , C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 1a is optionally replaced by

[0079] In some embodiments of the compounds of Formula (I), R 1 is -C(=O)R 10, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently selected from one or more R 1a In some embodiments of the compounds of Formula (I), R 1 is -C(=O)R 10 In some embodiments of the compounds of Formula (I), R 1 is C1-C6 alkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 1a In some embodiments of the compounds of Formula (I), R 1 is one or more R 1a In some embodiments of the compounds of Formula (I), R 1 is -C(=O)R 10 or one or more R 1a is heteroaryl optionally substituted with

[0080] In some embodiments of the compounds of Formula (I), each R 1a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 1b or two R on the same carbon 1a together to form oxo.

[0081] In some embodiments of the compounds of Formula (I), each R 1a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 1b or two R on the same carbon 1a together to form oxo.

[0082] In some embodiments of the compounds of Formula (I), each R 1a are independently deuterium, halogen, -CN, -OR b ,-NRc R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, and heterocycloalkyl independently represents one or more R 1b or two R on the same carbon 1a together to form oxo.

[0083] In some embodiments of the compounds of Formula (I), each R 1b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon1b together to form oxo.

[0084] In some embodiments of the compounds of Formula (I), each R 1b are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 1b together to form oxo.

[0085] In some embodiments of the compounds of Formula (I), each R 1b are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 1b together to form oxo.

[0086] In some embodiments of the compounds of Formula (I), each R 10is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 10a is optionally replaced by

[0087] In some embodiments of the compounds of Formula (I), each R 10 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 10a is optionally replaced by

[0088] In some embodiments of the compounds of Formula (I), each R 10 is independently C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, or heterocycloalkyl is independently selected from one or more R 10a is optionally replaced by

[0089] In some embodiments of the compounds of Formula (I), each R 10a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 10a together to form oxo.

[0090] In some embodiments of the compounds of Formula (I), each R 10a are independently deuterium, halogen, -CN, -OR b ,-NO2,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 10a together to form oxo.

[0091] In some embodiments of the compounds of Formula (I), each R 10aare independently deuterium, halogen, -CN, -OR b ,-NO2,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 10a together to form oxo.

[0092] In some embodiments of the compounds of Formula (I), each R 11 are independently hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 11a is optionally replaced by

[0093] In some embodiments of the compounds of Formula (I), each R 11 are independently hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R 11a is optionally replaced by

[0094] In some embodiments of the compounds of Formula (I), each R 11are independently hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, and heterocycloalkyl is independently selected from one or more R 11a is optionally replaced by

[0095] In some embodiments of the compounds of Formula (I), each R 11a are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 11a together to form oxo.

[0096] In some embodiments of the compounds of Formula (I), each R 11a are independently hydrogen, deuterium, halogen, -CN, -ORb ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 11a together to form oxo.

[0097] In some embodiments of the compounds of Formula (I), each R 11a are independently hydrogen, deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 11a together to form oxo.

[0098] In some embodiments of the compounds of Formula (I), each R 12 and R 13 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently is selected from the group consisting of one or more R 12a is optionally replaced by

[0099] In some embodiments of the compounds of Formula (I), each R 12 and R 13 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently selected from one or more R 12a is optionally replaced by

[0100] In some embodiments of the compounds of Formula (I), each R 12 and R 13 are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, and heterocycloalkyl is independently selected from one or more R 12a is optionally replaced by

[0101] In some embodiments of the compounds of Formula (I), each R 12a are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)Ra ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 12a together to form oxo.

[0102] In some embodiments of the compounds of Formula (I), each R 12a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 12a together to form oxo.

[0103] In some embodiments of the compounds of Formula (I), each R 12a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 12a together to form oxo.

[0104] In some embodiments of the compounds of Formula (I), R 12 and R 13 together with the nitrogen atom to which they are attached, form one or more R 12b to form an optionally substituted heterocycloalkyl.

[0105] In some embodiments of the compounds of Formula (I), each R 12b are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, or two R on the same carbon 12b together to form oxo.

[0106] In some embodiments of the compounds of Formula (I), each R 12b are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)Ra ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 12b together to form oxo.

[0107] In some embodiments of the compounds of Formula (I), each R 12b are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 12b together to form oxo.

[0108] In some embodiments of the compounds of Formula (I), R 2 is hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of compounds of Formula (I), R 2 is hydrogen, or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), R 2 is hydrogen.

[0109] In some embodiments of the compounds of Formula (I), R 3 , R 6 and R 8 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments of compounds of Formula (I), R 3 , R 6 and R 8 are independently hydrogen, deuterium, halogen, -CN, -OR b , -NR c R d , -C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of the compounds of Formula (I), R 3 , R 6 and R 8 is independently hydrogen, deuterium, halogen, or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), R 3 , R 6 and R 8 is hydrogen.

[0110] In some embodiments of the compounds of Formula (I), R 4is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a is optionally replaced by

[0111] In some embodiments of the compounds of Formula (I), R 4 is hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a is optionally replaced by

[0112] In some embodiments of the compounds of Formula (I), R 4 is hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, or heterocycloalkyl is selected from the group consisting of one or more R 4a is optionally replaced by

[0113] In some embodiments of the compounds of Formula (I), R 4 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl.

[0114] In some embodiments of the compounds of Formula (I), R 4is hydrogen, C1-C6 alkyl, or C1-C6 deuteroalkyl.

[0115] In some embodiments of the compounds of Formula (I), R 4 is hydrogen or one or more R 4a In some embodiments of the compounds of Formula (I), R 4 is one or more R 4a is C1-C6 alkyl optionally substituted with

[0116] In some embodiments of the compounds of Formula (I), R 4 is hydrogen, or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), R 4 is C1-C6 alkyl.

[0117] In some embodiments of the compounds of Formula (I), each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo.

[0118] In some embodiments of the compounds of Formula (I), each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 4a together to form oxo.

[0119] In some embodiments of the compounds of Formula (I), each R 4a are independently deuterium, halogen, -CN, -OR b , -NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 4a together to form oxo.

[0120] In some embodiments of the compounds of Formula (I), R 5 is hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of compounds of Formula (I), R 5 is hydrogen, or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), R 5 is hydrogen.

[0121] In some embodiments of the compounds of Formula (I), R 7 is hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of compounds of Formula (I), R 7 is hydrogen, or C1-C6 alkyl. In some embodiments of the compounds of Formula (I), R 7 is hydrogen.

[0122] In some embodiments of the above-described compounds, each R ais independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of the above-described compounds, each R a are independently C1-C6 alkyl.

[0123] In some embodiments of the above-described compounds, each R b are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R b is independently hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of the above-described compounds, each R b is independently hydrogen or C1-C6 alkyl. In some embodiments of the above compounds, each R b is hydrogen. In some embodiments of the above compounds, each R b are independently C1-C6 alkyl.

[0124] In some embodiments of the above-described compounds, each R c and R dare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R c and R d is independently hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of the above-described compounds, each R c and R d is independently hydrogen or C1-C6 alkyl. In some embodiments of the above compounds, each R c and R d is hydrogen. In some embodiments of the above compounds, each R c and R d are independently C1-C6 alkyl.

[0125] In some embodiments of the compounds of Formula (I), each ring A, R A , R 14 , R 15 , R 16 , R 17 , R 1 , R 4 , R 10 , R 11 , R 12 , R 13 , R a , R b , R c , and R d is optionally substituted with 1, 2, 3, or 4 substituents independently as defined herein. In some embodiments of the compounds of Formula (I), each ring A, R A , R 14 , R 15 , R 16 , R 17 , R 1 , R 4 , R 10 , R 11 , R12 , R 13 , R a , R b , R c , and R d is optionally substituted with 1, 2, or 3 substituents independently as defined herein. In some embodiments of the compounds of Formula (I), each ring A, R A , R 14 , R 15 , R 16 , R 17 , R 1 , R 4 , R 10 , R 11 , R 12 , R 13 , R a , R b , R c , and R d is independently optionally substituted with 1 or 2 substituents as defined herein. In some embodiments of the compounds of Formula (I), each ring A, R A , R 14 , R 15 , R 16 , R 17 , R 1 , R 4 , R 10 , R 11 , R 12 , R 13 , R a , R b , R c , and R d is independently optionally substituted with one substituent, as defined herein.

[0126] Disclosed herein is a compound of formula (II) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: L is an optionally substituted linker of 4 to 10 atoms; Ring A is an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, or an optionally substituted heteroaryl; [ka] is a single or double bond, X 1 and X 2 is -N- or -C=, where X 1 or X 2 One of them is -N- and the other is -C=, Y 8 is CR 8 or N, Y 6 is CR 6 or N, Y 3 is CR 3 or N, Y 9 is CR 9 or N, R 3 , R 6 , R 8 , and R 9 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR boptionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl; R 4 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 deuteroalkyl, optionally substituted C1-C6 hydroxyalkyl, optionally substituted C1-C6 aminoalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 5 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C1-C6 deuteroalkyl; R 7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, or optionally substituted C1-C6 deuteroalkyl; Each R a are independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R b are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; and Each R c and R d are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0127] Disclosed herein is a compound of formula (II) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: L is a linker of 4 to 10 atoms, and one or more R L optionally replaced by Each R L are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon L are taken together to form oxo, cycloalkyl or heterocycloalkyl, or two R on different carbons L together form a cycloalkyl or heterocycloalkyl; Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Each R A are independently deuterium, halogen, -CN, -OR b ,-SR b,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo, Each R A1 are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo, n is 0 to 4, [ka] is a single or double bond, X 1 and X 2 is -N- or -C=, where X 1 or X 2 One of them is -N- and the other is -C=, Y 8 is CR 8 or N, Y 6 is CR 6 or N, Y 3 is CR 3 or N, Y 9 is CR 9 or N, R 3 , R 6 , R 8 and R 9 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR cR d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R 4 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a optionally replaced by Each R 4a are independently deuterium, halogen, -CN, -OR b , -NR c R d , -C(=O)R a , -C(=O)OR b , -C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo, R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; R 7 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; Each R a are independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R bare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; and Each R c and R d are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0128] Disclosed herein is a compound of formula (II) below, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] During the ceremony: L is a linker of 4 to 10 atoms, and one or more R L optionally replaced by Each R L are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon L together form oxo, cycloalkyl or heterocycloalkyl, or two R on adjacent carbons L together form a cycloalkyl or heterocycloalkyl; Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Each R A are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo, Each R A1 are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR cR d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo, n is 0 to 4, [ka] is a single or double bond, X 1 and X 2 is -N- or -C=, where X 1 or X 2 One of them is -N- and the other is -C=, Y 8 is CR 8 or N, Y 6 is CR 6 or N, Y 3 is CR 3 or N, Y 9 is CR 9 or N, R 3 , R 6 , R 8 and R 9 are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R 4 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a optionally replaced by Each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo, R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; R 7 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; Each R a are independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; Each R bare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; and Each R c and R d are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, C-C alkenyl, C-C alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl; or R c and R d together with the nitrogen atom to which they are attached form a heterocycloalkyl optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl.

[0129] In some embodiments of the compound of Formula (II) or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, the compound is of Formula (IIa): [ka]

[0130] In some embodiments of the compound of Formula (II) or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, the compound is of Formula (IIb): [ka]

[0131] In some embodiments of compounds of Formula (II), (IIa) or (IIb), Y 9 is N. In some embodiments of the compounds of Formula (II), Y 9 is CR 9 is.

[0132] In some embodiments of compounds of Formula (II), (IIa) or (IIb), Y 8 is N. In some embodiments of the compounds of Formula (II), Y 8 is CR 8 is.

[0133] In some embodiments of the compound of Formula (II), (IIa) or (IIb), or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, the compound is of Formula (IIc): [ka]

[0134] In some embodiments of the compound of Formula (II), (IIa) or (IIb), or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, the compound is of Formula (IId): [ka]

[0135] In some embodiments of compounds of Formula (II) or (IIa)-(IId), Y 6 is CR 6 In some embodiments of the compounds of Formula (II), Y 6 is N.

[0136] In some embodiments of compounds of Formula (II) or (IIa)-(IId), Y 3 is CR 3 In some embodiments of the compounds of Formula (II), Y 3 is N.

[0137] In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is heterocycloalkyl, aryl, or heteroaryl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is heterocycloalkyl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is aryl or heteroaryl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is heteroaryl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is aryl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is phenyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl. In some embodiments of the compounds of Formula (II) or (IIa)-(IId), ring A is bicyclic heteroaryl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), Ring A is indole, indazole, benzimidazole, benzotriazole, benzofuran, benzothiazole, benzisothiazole, benzoxazole, benzisoxazole, or benzothiophene.

[0138] In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 0 to 3. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 0 to 2. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 0 or 1. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 0. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 1. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 2. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 3. In some embodiments of the compound of Formula (II) or (IIa)-(IId), n is 4.

[0139] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0140] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0141] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b ,-NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl independently represents one or more R A1 or two R on the same carbon A together to form oxo.

[0142] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; or two R on the same carbon A together to form oxo.

[0143] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl; or two R on the same carbon A together to form oxo.

[0144] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -OR b or C1-C6 alkyl; or two R A together to form oxo.

[0145] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -ORb , -NR c R d , -C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl.

[0146] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -CN, -OR b , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl.

[0147] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A are independently deuterium, halogen, -OR b , or C1-C6 alkyl.

[0148] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A1 are independently deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo.

[0149] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A1 are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon A1 together to form oxo.

[0150] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R A1 are independently deuterium, halogen, -CN, -OR b , -NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon A1 together to form oxo.

[0151] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 3 , R 6 , R 8 and R 9are independently hydrogen, deuterium, halogen, -CN, -OR b ,-SR b ,-S(=O)R a ,-S(=O)2R a ,-NO2,-NR c R d ,-NHS(=O)2R a ,-S(=O)2NR c R d ,-C(=O)R a ,-OC(=O)R a ,-C(=O)OR b ,-OC(=O)OR b ,-C(=O)NR c R d ,-OC(=O)NR c R d ,-NR b C(=O)NR c R d ,-NR b C(=O)R a ,-NR b C(=O)OR b , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 3 , R 6 , R 8 and R 9 are independently hydrogen, deuterium, halogen, -CN, -OR b , -NR c R d , -C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 3 , R 6 , R 8 and R 9is independently hydrogen, deuterium, halogen, or C1-C6 alkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 3 , R 6 , R 8 and R 9 is hydrogen.

[0152] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a is optionally replaced by

[0153] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, C-C hydroxyalkyl, C-C aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, where each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is selected from the group consisting of one or more R 4a is optionally replaced by

[0154] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, C-C alkyl, C-C heteroalkyl, C-C haloalkyl, C-C deuteroalkyl, cycloalkyl, or heterocycloalkyl, where each alkyl, cycloalkyl, or heterocycloalkyl is selected from the group consisting of one or more R 4a is optionally replaced by

[0155] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl.

[0156] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, C1-C6 alkyl, or C1-C6 deuteroalkyl.

[0157] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen or one or more R 4a In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is one or more R 4a is C1-C6 alkyl optionally substituted with

[0158] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is hydrogen, or C1-C6 alkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 4 is C1-C6 alkyl.

[0159] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4a are independently deuterium, halogen, -CN, -OR b , -NR c R d , -C(=O)R a , -C(=O)OR b , -C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or two R on the same carbon 4a together to form oxo.

[0160] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4a are independently deuterium, halogen, -CN, -OR b ,-NR c R d ,-C(=O)R a ,-C(=O)OR b ,-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 4a together to form oxo.

[0161] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R 4a are independently deuterium, halogen, -CN, -OR b , -NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 deuteroalkyl, cycloalkyl, or heterocycloalkyl, or two R on the same carbon 4a together to form oxo.

[0162] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 5is hydrogen, or C1-C6 alkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 5 is hydrogen.

[0163] In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 7 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 7 is hydrogen, or C1-C6 alkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), R 7 is hydrogen.

[0164] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L C optionally substituted with 2-10 an alkylene chain, wherein up to four carbon atoms of L are optionally and independently —NR L -,-S-,-O-,-OC(=O)-,-C(=O)O-,-C(=O)-,-C(=O)NR L -,-NR L C(=O)-, -S(=O)2NR L -,-NR L S(=O)2-, -NR L C(=O)NR L It is substituted by -, -S(O)-, or -S(O)2-.

[0165] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L C optionally substituted with 2-10 an alkylene chain, wherein up to four carbon atoms of L are optionally and independently —NR L Substituted by -, -S-, -O-, -C(=O)-, -S(O)-, or -S(O)2-.

[0166] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L C optionally substituted with 2-10 an alkylene chain, wherein up to four carbon atoms of L are optionally and independently —NR L It is substituted with -, -O-, or -C(=O)-.

[0167] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L is a linker of 4 to 10 atoms optionally substituted with

[0168] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L is a 4-8 atom linker optionally substituted with

[0169] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is selected from the group consisting of one or more R L is a 4-6 atom linker optionally substituted with

[0170] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-10 atom linker containing 4-10 carbons and 0-4 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R L is optionally replaced by

[0171] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-10 atom linker containing 3-9 carbons and 1-2 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R L is optionally replaced by

[0172] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-8 atom linker containing 4-8 carbons and 0-4 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R Lis optionally replaced by

[0173] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-8 atom linker containing 3-7 carbons and 1-2 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R L is optionally replaced by

[0174] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-6 atom linker containing 4-6 carbons and 0-4 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R L is optionally replaced by

[0175] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is a 4-6 atom linker containing 3-5 carbons and 1-2 heteroatoms selected from oxygen and nitrogen, and the linker is selected from one or more R L is optionally replaced by

[0176] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R L are independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl, or two R on the same carbon L are taken together to form oxo or cycloalkyl, or two R L together form a cycloalkyl.

[0177] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R L are independently deuterium, halogen, -CN, -OR b , -NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl, or two R on the same carbon Ltogether to form oxo.

[0178] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R L are independently deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl, or two R on the same carbon L together to form oxo.

[0179] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R L are independently deuterium, halogen, or C1-C6 alkyl, or two R L together to form oxo.

[0180] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each R L are independently deuterium or halogen, or two R on the same carbon L together to form oxo.

[0181] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is [ka] where Z 1 and Z 2 are independently -O-, -S-, or -NR Z and each R Z are independently hydrogen or C1-C6 alkyl, and L 1 and L 2 independently, one or more R L is C1-C6 alkylene optionally substituted with

[0182] In some embodiments, [ka] In some embodiments, [ka] is equivalent to

[0183] In some embodiments of compounds of Formula (II) or (IIa)-(IId), Z 1 and Z 2 are independently -O- or -NR Z and each R Z is independently hydrogen or C1-C6 alkyl. In some embodiments of compounds of Formula (II) or (IIa)-(IId), Z 1 and Z 2 are independently -O- or -NR Z and each R Z is hydrogen.

[0184] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L 1 and L 2 independently, one or more R L is C1-C3 alkylene optionally substituted with In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is [ka] is.

[0185] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is [ka] is.

[0186] In some embodiments of compounds of Formula (II) or (IIa)-(IId), L is [ka] is.

[0187] In some embodiments of the above-described compounds, each R a is independently C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 deuteroalkyl. In some embodiments of the above-described compounds, each R a are independently C1-C6 alkyl.

[0188] In some embodiments of the above-described compounds, each R b are independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R b is independently hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of the above-described compounds, each R b is independently hydrogen or C1-C6 alkyl. In some embodiments of the above compounds, each R b is hydrogen. In some embodiments of the above compounds, each R b are independently C1-C6 alkyl.

[0189] In some embodiments of the above-described compounds, each R c and R dare independently hydrogen, C-C alkyl, C-C haloalkyl, C-C deuteroalkyl, or cycloalkyl, where each alkyl and cycloalkyl is independently optionally substituted with one or more oxo, deuterium, halogen, —CN, —OH, —OMe, —NH, —C(═O)Me, —C(═O)OH, —C(═O)OMe, C-C alkyl, or C-C haloalkyl. In some embodiments of the above-described compounds, each R c and R d is independently hydrogen, C-C alkyl, C-C haloalkyl, or C-C deuteroalkyl. In some embodiments of the above-described compounds, each R c and R d is independently hydrogen or C1-C6 alkyl. In some embodiments of the above compounds, each R c and R d is hydrogen. In some embodiments of the above compounds, each R c and R d are independently C1-C6 alkyl.

[0190] In some embodiments of compounds of Formula (II) or (IIa)-(IId), each L, R L , R A , R 4 , R a , R b , R c , and R d is independently substituted with one, two, three, or four substituents as defined herein. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each L, R L , R A , R 4 , R a , R b , R c , and R d is independently optionally substituted with one, two, or three substituents as defined herein. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each L, R L , R A , R 4 , Ra , R b , R c , and R d is independently optionally substituted with one or two substituents as defined herein. In some embodiments of compounds of Formula (II) or (IIa)-(IId), each L, R L , R A , R 4 , R a , R b , R c , and R d is independently optionally substituted with one substituent, as defined herein.

[0191] In some embodiments of a compound of Formula (II) or (IIa)-(IId), the compound is:

[0192] In some embodiments of a compound of Formula (II) or (IIa)-(IId), the compound is: [ka] [ka] [ka] [ka] [ka] [ka]

[0193] In some embodiments of a compound of Formula (II) or (IIa)-(IId), the compound is: [ka]

[0194] Further forms of the compounds disclosed herein Isomers / stereoisomers In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as corresponding mixtures thereof. In some circumstances, the compounds described herein have one or more chiral centers, with each center existing in the R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, as well as corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomers resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. In some embodiments, separable complexes are preferred. In some embodiments, diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, diastereomers are separated by chiral chromatography, or preferably by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomer is then recovered along with the resolving agent.

[0195] labeled compound In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those enumerated herein but differ in that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that may be incorporated into the compounds described herein, or their solvates or stereoisomers, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, each of which may be, for example, 2 H, 3 H, 13 C. 14 C. l5 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36 Compounds described herein that contain the aforementioned isotopes and / or other isotopes of other atoms, as well as pharmaceutically acceptable salts, solvates, or stereoisomers thereof, are within the scope of the present disclosure. 3 H and 14 Certain isotopically labeled compounds, into which radioactive isotopes such as 3C are incorporated, are useful in drug and / or substrate tissue distribution assays. 3 H, and carbon-14, i.e. 14 Isotopes such as C are particularly preferred for their ease of preparation and detectability. 2Substitution with heavy isotopes such as H offers certain therapeutic benefits resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof is prepared by any suitable method.

[0196] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0197] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[0198] In some embodiments, the compounds described herein possess acidic or basic groups with which any of a number of inorganic or organic bases, and inorganic and organic acids, can react to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting the purified compound in its free form with the appropriate acid or base and isolating the formed salt.

[0199] Examples of pharmaceutically acceptable salts include salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such as acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, etc. Salt, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, gamma-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxybenzoate, ... Included are salts such as cetane sulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogen phosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylateundeconate, and xylenesulfonate.

[0200] Additionally, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, chloro ... Included are organic acids such as enoic acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.

[0201] In some embodiments, the compounds described herein containing free acid groups are reacted with a suitable base, such as a hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include alkali or alkaline earth salts, such as lithium, sodium, potassium, calcium, and magnesium and aluminum salts. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 alkyl)4.

[0202] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It is understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water- or oil-soluble or dispersible products are obtained by such quaternization.

[0203] solvate In some embodiments, the compounds described herein exist as solvates. The present disclosure provides methods of treating diseases by administering such solvates. The present disclosure further provides methods of treating diseases by administering such solvates as pharmaceutical compositions.

[0204] Solvates contain either stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments, are formed during the crystallization process using pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water. Alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be easily prepared or formed during the processes described herein. Furthermore, the compounds provided herein can exist in unsolvated and solvated forms. Generally, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0205] tautomers In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that can be interchanged by the migration of a hydrogen atom, accompanied by the switch of a single bond and an adjacent double bond. In bonding configurations where tautomerization is possible, a chemical equilibrium of tautomers will exist. All tautomers of the compounds disclosed herein are expected. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH.

[0206] Preparation of compounds The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" include Acros Organics (Pittsburgh, PA), Aldrich Chemical Co. (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, UK), BDH, Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chem Service Inc. (West Chester, PA), Crescent Chemical Co. (Hauppage, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, UK), Lancaster Synthesis (Wyndham, NH), Maybridge Chemical Co. Ltd. (Cornwall, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CT), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hannover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).

[0207] Suitable reference books and articles detailing the synthesis of, or providing references to articles describing the preparation of, reactants useful in preparing the compounds described herein include, for example, "Synthetic Organic Chemistry," John Wiley & Sons, Inc., New York; S.R. Sandler et al., "Organic Functional Group Preparations," 2nd ed., Academic Press, New York, 1983; H.O. House, "Modern Synthetic Reactions," 2nd ed., W.A. Benjamin, Inc. Menlo Park, Calif. 1972; T.L.G. Gilchrist, "Heterocyclic Chemistry," 2nd ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure," 4th ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and articles detailing the synthesis of, or providing references to articles describing the preparation of, reactants useful in the preparation of the compounds described herein include, for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", 2nd Edition, Revised and Expanded Edition (1994) John Wiley & Sons, ISBN: 3-527-29074-5; Hoffman, RV "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J."Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG "Organic Chemistry" 7th edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, "Intermediate Organic "Chemistry of Functional Groups," 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia" (1999) John Wiley & Sons, ISBN: 3-527-29645-X, 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, over 55 volumes; and "Chemistry of Functional Groups," John Wiley & Sons, 73 volumes.

[0208] Specific reactants and similar reactants are optionally identified through an index of known chemicals compiled by the Chemical Abstract Service of the American Chemical Society. This service is available at most public and university libraries, as well as online. Known chemicals that are not commercially available in catalogs are optionally prepared by custom chemical synthesis companies. Standard chemical supply companies (e.g., those listed above) offer custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P.H. Stahl & C.G. Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.

[0209] Pharmaceutical Composition In certain embodiments, the compounds described herein are administered as pure chemicals. In some embodiments, the compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier), which is selected according to the selected route of administration and standard pharmaceutical procedures, for example, as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Edition, Mack Pub. Co., Easton, PA (2005)).

[0210] Accordingly, provided herein are pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

[0211] In certain embodiments, the compounds provided herein are substantially pure in that they contain less than about 5%, or less than about 1%, or less than about 0.1% of other small organic molecules, such as, for example, unreacted intermediates or synthetic by-products produced in one or more of the steps of the synthetic method.

[0212] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose, as well as the appropriate duration and frequency of administration, are determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition in an amount sufficient to provide therapeutic and / or preventive benefits (e.g., more frequent complete or partial remissions, or improved clinical outcomes such as prolonged disease-free survival and / or overall survival, or reduced severity of symptoms). The optimal dose is generally determined using experimental models and / or clinical trials. The optimal dose depends on the patient's body weight, weight, or blood volume.

[0213] In some embodiments, the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, pulmonary, intradermal, intrathecal, epidural, and intranasal administration. Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ocular administration. In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection. In some embodiments, the pharmaceutical composition is formulated as a tablet, pill, capsule, liquid, inhalant, nasal spray solution, suppository, suspension, gel, colloid, dispersion, suspension, solution, emulsion, ointment, lotion, eye drop, or ear drop. In some embodiments, the pharmaceutical composition is formulated as a tablet.

[0214] Appropriate doses and dosing regimens are determined by conventional range-finding techniques known to those skilled in the art. Generally, treatment is initiated with a low dose that is less than the optimal dose of the compounds disclosed herein. The dosage is then increased by small increments until the optimal effect under the circumstances is achieved. In some embodiments, the method involves administering about 0.1 μg to about 50 mg of at least one compound described herein per kg of subject body weight. For a 70 kg patient, a dosage of about 10 μg to about 200 mg of the compounds disclosed herein is typically used, depending on the subject's physiological response.

[0215] By way of example only, dosages of the compounds described herein for the methods of treating the diseases described herein range from about 0.001 to about 1 mg per kg of subject body weight per day, such as about 0.001 mg, about 0.002 mg, about 0.005 mg, about 0.010 mg, about 0.015 mg, about 0.020 mg, about 0.025 mg, about 0.050 mg, about 0.075 mg, about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.5 mg, about 0.75 mg, or about 1 mg per kg of body weight per day. In some embodiments, the dose of a compound described herein for the described methods is from about 1 to about 1000 mg per kg of body weight of the subject being treated per day, such as about 1 mg, about 2 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 500 mg, about 750 mg, or about 1000 mg per day.

[0216] Treatment method The compounds disclosed herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, are useful for inhibiting the kinase activity of one or more enzymes. In some embodiments, the kinase inhibited by the compounds and methods is TYK2.

[0217] Provided herein are compounds that are inhibitors of TYK2 and are therefore useful in the treatment of one or more disorders associated with the activity of TYK2 or its mutants.

[0218] Provided herein are methods for treating a disease or disorder, wherein the disease or disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder, the method comprising administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0219] In some embodiments, the disease or disorder is an autoimmune disorder. In some embodiments, the disease or disorder is selected from type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, psoriasis, Behcet's disease, POEMS syndrome, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.

[0220] In some embodiments, the disease or disorder is an inflammatory disorder, hi some embodiments, the inflammatory disorder is rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, hepatomegaly, Crohn's disease, ulcerative colitis, or inflammatory bowel disease.

[0221] In some embodiments, the disease or disorder is a proliferative disorder. In some embodiments, the proliferative disorder is a blood cancer. In some embodiments, the proliferative disorder is leukemia. In some embodiments, the leukemia is T-cell leukemia. In some embodiments, the T-cell leukemia is T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the proliferative disorder is polycythemia vera, myelofibrosis, or essential thrombocythemia.

[0222] In some embodiments, the disease or disorder is an endocrine disorder. In some embodiments, the endocrine disorder is polycystic ovary syndrome, Crouzon syndrome, or type 1 diabetes.

[0223] In some embodiments, the disease or disorder is a neurological disorder, hi some embodiments, the neurological disorder is Alzheimer's disease.

[0224] In some embodiments, the proliferative disorder is associated with one or more activating mutations in TYK2. In some embodiments, the activating mutation in TYK2 is a mutation in the FERM domain, JH2 domain, or kinase domain. In some embodiments, the activating mutation in TYK2 is selected from G36D, S47N, R425H, V731I, E957D, and R1027H.

[0225] In some embodiments, the disease or disorder is transplant-related. In some embodiments, the transplant-related disease or disorder is transplant rejection or graft-versus-host disease.

[0226] In some embodiments, the disease or disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling. In some embodiments, the disease or disorder is associated with type I interferon signaling. In some embodiments, the disease or disorder is associated with IL-10 signaling. In some embodiments, the disorder is associated with IL-12 signaling. In some embodiments, the disease or disorder is associated with IL-23 signaling.

[0227] Provided herein are methods for treating inflammatory or allergic conditions of the skin, such as psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acne vulgaris, and other inflammatory or allergic conditions of the skin.

[0228] Provided herein are methods for treating other diseases or conditions, such as diseases or conditions that have an inflammatory component, e.g., ocular diseases and conditions such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose, including allergic rhinitis, and inflammatory diseases involving an autoimmune response or having an autoimmune component or etiology, including autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell aplasia, and idiopathic thrombocytopenia), systemic inflammatory diseases, and the like. Lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), Sjögren's syndrome, keratoconjunctivitis sicca and vernal conjunctivitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryopyrin-associated periodic syndrome, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (e.g., with and without nephrotic syndrome, including idiopathic nephrotic syndrome or minimal change nephropathy), chronic granulomatous disease, endometriosis, leptospirosis kidney disease, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle weakness, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behcet's disease , incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndromes, asthma (allergic and non-allergic, mild, moderate, severe, bronchitic, and exercise-induced), acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivity, anaphylaxis, sinusitis, ocular allergies, silica-induced disease, COPD (damage, airway inflammation, bronchial hyperresponsiveness, remodeling, or decreased disease progression), pulmonary disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation associated with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease,Lichen planus, type 1 or type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, Crohn's disease, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Henoch's disease - Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis or vulvitis.

[0229] In some embodiments, the inflammatory disease is acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), cryopyrin-associated periodic syndromes (CAPS), or osteoarthritis.

[0230] In some embodiments, the inflammatory disease is a Th1 or Th17-mediated disease. In some embodiments, the Th17-mediated disease is selected from systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease (including Crohn's disease or ulcerative colitis).

[0231] In some embodiments, the inflammatory disease is Sjogren's syndrome, an allergic disorder, osteoarthritis, an eye condition such as ocular allergy, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, or a disease affecting the nose such as allergic rhinitis.

[0232] Combination treatment In certain examples, the compounds described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, are administered in combination with a second therapeutic agent.

[0233] In some embodiments, the benefit experienced by the patient is increased by administering one of the compounds described herein with a second therapeutic agent (including a treatment regimen) that also has a therapeutic benefit.

[0234] In one particular embodiment, a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is co-administered with a second therapeutic agent, wherein the compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and the second therapeutic agent modulate different aspects of the disease, disorder, or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.

[0235] In either instance, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient is either a simple addition of the two therapeutic agents, or the patient experiences a synergistic benefit.

[0236] In certain embodiments, when a compound disclosed herein is administered in combination with a second therapeutic agent, different therapeutically effective doses of the compound disclosed herein are utilized in the formulation of pharmaceutical compositions and / or in treatment regimens. The therapeutically effective doses of the pharmaceutical and other agents used in combination treatment regimens are optionally determined by means similar to those described above for the active agent itself. Further, the prevention / treatment methods described herein include the use of metronomic dosing, i.e., providing lower doses more frequently to minimize toxic side effects. In some embodiments, combination treatment regimens include treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is initiated before, during, or after treatment with a second agent described herein, and continues during or until any time after the end of treatment with the second agent. Also included are therapies in which a compound described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a second agent used in combination are administered simultaneously or at different times and / or at decreasing or increasing intervals during the treatment period. Combination treatments further include cyclical treatments that are started and stopped at different times to aid in the clinical management of the patient.

[0237] It is understood that the dosage regimen for treating, preventing, or ameliorating the condition for which relief is sought will be adjusted according to various factors (e.g., the disease, disorder, or condition suffered by the subject; the age, weight, sex, diet, and medical condition of the subject).Thus, in some cases, the dosage regimen actually used will vary, and in some embodiments, will deviate from the dosage regimen described herein.

[0238] For the combination therapies described herein, the dosage of the co-administered compound will vary depending on the type of co-agent employed, the specific agent employed, the disease or condition being treated, etc. In additional embodiments, when co-administered with a second therapeutic agent, the compounds provided herein are administered either simultaneously or sequentially with the second therapeutic agent.

[0239] In combination therapy, the multiple therapeutic agents (one of which is one of the compounds described herein) can be administered in any order, or simultaneously. When administration is simultaneous, the multiple therapeutic agents can, for example, be provided in a single, unified form or in multiple forms (e.g., as a single pill or as two separate pills).

[0240] The compounds described herein, or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, and combination therapies, may be administered before, during, or after the onset of a disease or condition, and the timing of administering compositions containing the compounds may vary. Thus, in one embodiment, the compounds described herein are used as prophylactics and are administered continuously to subjects prone to developing a disease or condition to prevent the onset of the disease or condition. In another embodiment, the compounds and compositions are administered to a subject during or as soon as possible after the onset of symptoms. In certain embodiments, the compounds described herein are administered as soon as possible after the onset of a disease or condition is detected or suspected, and for as long as necessary to treat the disease. In some embodiments, the duration of treatment required varies, and the duration of treatment is tailored to the specific needs of each subject. For example, in certain embodiments, the compounds described herein or formulations containing the compounds are administered for at least two weeks, from about one month to about five years.

[0241] In some embodiments, the compounds described herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, are administered in combination with an adjuvant. In one embodiment, the therapeutic efficacy of one of the compounds described herein is enhanced by the administration of an adjuvant (i.e., the adjuvant itself has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). [Example]

[0242] Example 1: General Procedure for the Synthesis of Example Compound 1 [ka]

[0243] Step 1: Example 1b To a solution of Example 1a (11.0 g, 63.74 mmol) in methanol (200 mL) was added NaOMe (6.88 g, 127.48 mmol). The reaction mixture was stirred at 70° C. for 6 hours. The mixture was quenched with HO (1 L), forming a pink precipitate. The solid was collected by filtration and dried under vacuum to give Example 1b (9.0 g, 84.0% yield) as a pink solid. LCMS [M+1] + =169.1.

[0244] Step 2: Example 1c To a mixture of Example 1b (5.0 g, 29.76 mmol) in CCl (100 mL) was added NBS (6.36 g, 35.71 mmol) and AIBN (0.98 g, 5.95 mmol). The reaction mixture was stirred at 80 °C under N protection for 16 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 1c (2.8 g, 38.2% yield) as a yellow solid. LCMS[M+1] + =247.1.

[0245] Step 3: Example 1d To a solution of tert-butyl (2-hydroxyethyl)carbamate (1.29 g, 8.02 mmol) in THF (30 mL) was added NaH (320 mg, 8.02 mmol) in portions at 0° C. The mixture was stirred at the same temperature for 30 minutes, and then Example 1c (1.8 g, 7.29 mmol) in THF was added dropwise. The reaction mixture was stirred at room temperature for 4 hours. The solvent was removed, and the residue was purified by silica gel flash column chromatography to obtain the product Example 1d (600 mg, 25.2% yield) as a yellow oil. LCMS [M+1-100] + =328.2.

[0246] Step 4: Example 1e To a solution of Example 1d (600 mg, 3.3 mmol) in DCM (5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 2 hours. The solution was concentrated in vacuo to give the crude product Example 1e (710 mg, 113.8%, crude) as a yellow oil, which was used directly in the next step without purification. LCMS [M+1] + =228.2.

[0247] Step 5: Example 1h To a solution of Example 1f (2.0 g, 7.69 mmol) in EtOH (40 mL) was added CHNH (7.7 mL, 2 M in MeOH, 15.38 mmol) and KCO (2.12 g, 15.38 mmol). The reaction mixture was stirred at room temperature for 4 hours. The mixture was poured into H0 (200 mL), forming a white precipitate. The solid was collected by filtration and dried in vacuo to give the product Example 1h (1.85 g, 94.4% yield) as a white solid. LCMS [M+1] + =255.2.

[0248] Step 6: Example 1i To a solution of Example 1h (1.85 g, 7.26 mmol) in dioxane (40 mL) was added BocO (1.9 g, 8.72 mmol), TEA (1.09 g, 10.89 mmol), and DMAP (44 mg, 0.36 mmol). The reaction mixture was stirred at room temperature for 4 hours. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the product Example 1i (2.3 g, 89.3% yield) as an off-white solid. LCMS [M+1] + =355.2.

[0249] Step 7: Example 1j To a mixture of Example 1i (800 mg, 2.25 mmol) in toluene (10 mL) was added TBTO (2.96 g, 4.51 mmol). The reaction mixture was stirred at 120° C. under N protection for 24 hours. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 1j (620 mg, 84.3% yield) as a yellow solid. LCMS [M+1] + =327.2.

[0250] Step 8: Example 1l To a solution of Example 1j (500 mg, 1.53 mmol) in DCM (10 mL) was added SOCl2 (728 mg, 6.12 mmol), and the reaction mixture was stirred at room temperature for 1 hour. The solvent was removed, and the residue was diluted with DCM. This was added dropwise to a solution of Example 1e (565 mg, 1.53 mmol) and TEA (773 mg, 7.65 mmol) in DCM (10 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 hour and then concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 1l (180 mg, 22.0% yield) as an off-white solid. LCMS [M+1] + =536.3.

[0251] Step 9: Example 1m To a mixture of Example 1l (160 mg, 0.299 mmol) in MeOH (30 mL) was added Pd / C (16 mg) under N protection. The suspension was degassed under vacuum, purged with H, and stirred at room temperature under a H balloon for 30 minutes. The solid was filtered, and the filtrate was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 1m (82 mg, 54.2% yield) as a yellow solid. LCMS [M+1] + =506.2.

[0252] Step 10: Example 1n To a solution of Example 1m (80 mg, 0.16 mmol) in 1,4-dioxane (5 mL) was added CsCO (103 mg, 0.32 mmol) and 3rd-t-Bu-Xphos-Pd (14 mg, 0.016 mmol). The reaction mixture was stirred at 90 °C under N for 16 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 1n (50 mg, 67.4% yield) as an off-white solid. LCMS [M+1] + =470.2.

[0253] Step 11: Example 1 To a solution of Example 1n (50 mg, 0.11 mmol) in DCM (2 mL) was added TFA (0.5 mL). The reaction mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was purified by preparative HPLC to give the desired product, Example 51 (17.0 mg, 43.2% yield), as a white solid. LCMS [M+1]+ = 370.2. 1 H NMR(300MHz,DMSO-d6)δ 9.14(s,1H),8.57(d,1H),8.14(s,1H),8.06(brs,1H),7.93(d,1H),7.75(d,1H),5 .95(s,1H),4.53(s,2H),3.97(s,3H),3.59(t,2H),3.36-3.32(m,2H),2.92(d,3H). Example 2: General Procedure for the Synthesis of Example Compound 2 [ka]

[0254] Step 1: Example 2b To a solution of Example 2a (10.0 g, 59.8 mmol, 1.0 equiv.) in CCl (200 mL) was added NBS (10.8 g, 60.4 mmol, 1.01 equiv.) and AIBN (1.96 g, 12.0 mmol, 0.20 equiv.). The reaction mixture was stirred at 80 °C under N for 18 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 2b (7.2 g, 49% yield) as a yellow solid. LCMS[M+1] + =245.2.

[0255] Step 2: Example 2d To a solution of Example 2b (1.0 g, 4.06 mmol, 1.0 equiv.) and Example 2c (720 mg, 4.47 mmol, 1.1 equiv.) in DMF (20 mL) was added NaH (244 mg, 60% in mineral oil, 6.1 mmol, 1.5 equiv.) in several portions at 0° C. The reaction mixture was stirred at room temperature for 4 hours and then poured into a saturated aqueous solution of NH4Cl (40 mL), which was extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine, dried over Na2SO4, and concentrated. The crude product was purified by silica gel flash column chromatography to give the product Example 2d (1.2 g, 90% yield) as a yellow oil. LCMS [M+1] + =327.2.

[0256] Step 3: Example 2e To a solution of Example 2d (800 mg, 2.5 mmol, 1.0 equiv) in DCM (8 mL) was added HCl / dioxane (1 mL, 4 M in dioxane). The reaction solution was stirred at room temperature for 2 hours. Upon completion, the reaction mixture was concentrated to give the product Example 2e (660 mg, 83% yield) as a yellow solid. LCMS [M+1] + =227.2

[0257] Step 4: Example 2g To a solution of Example 2f (1.0 g, 2.8 mmol, 1.0 equiv., from Example 1i) in toluene (15 mL) was added TBTO (3.3 g, 5.6 mmol, 2.0 equiv.). The reaction mixture was stirred at reflux under N for 24 h. After concentration, the residue was purified by silica gel flash column chromatography to give the product Example 2g (800 mg, 82% yield) as a yellow solid. LCMS [M+1] + =327.2.

[0258] Step 5: Example 2h To a solution of Example 2g (452 ​​mg, 1.7 mmol, 0.8 equiv.) in DCM (10 mL) were added SOCl2 (1.04 g, 8.8 mmol, 4.0 equiv.) and DMF (0.2 mL), and the reaction mixture was stirred at room temperature for 0.5 h. After the reaction was completed, it was concentrated in vacuo to give the crude product, which was diluted with DCM and then added dropwise to a solution of Example 2e (700 mg, 2.2 mmol, 1.0 equiv.) and TEA (1.1 g, 11.0 mmol, 5.0 equiv.) in DCM (10 mL) at 0 °C. The resulting mixture was stirred at room temperature for 0.5 h. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the product Example 2h (300 mg, 3% yield) as a yellow solid. LCMS [M+1] + =535.3.

[0259] Step 6: Example 2i To a solution of Example 2h (170 mg, 0.30 mmol, 1.0 equiv) in MeOH (30 mL) was added Pd / C (17 mg). The suspension was degassed under vacuum, purged with H2, and stirred at room temperature under a H2 balloon for 0.5 h. The solid was filtered, and the filtrate was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 2i (107 mg, 71% yield) as a yellow oil. LCMS[M+1] + =505.2.

[0260] Step 7: Example 2j To a solution of Example 2i (100 mg, 0.20 mmol, 1.0 equiv.) in dioxane (5 mL) was added CsCO (130.4 mg, 0.40 mmol, 2.0 equiv.) and tert-Bu-Xphos-Pd (17.8 mg, 0.02 mmol, 0.1 equiv.). The reaction mixture was stirred at 80° C. under N protection for 2 hours. The solid was filtered, the filtrate was concentrated, and the residue was purified by preparative TLC to give Example 2j (50 mg, 53% yield) as a yellow solid. LCMS[M+1] + =469.3.

[0261] Step 8: Example 2 To a solution of Example 2j (50 mg, 0.10 mmol, 1.0 equiv) in DCM (2 mL) was added HCl / dioxane (1 mL, 4 M in THF) dropwise at 0° C. The reaction mixture was stirred at room temperature for 2 hours. After completion, the reaction mixture was concentrated and the residue was purified by preparative HPLC to give the desired product, Example 2 (17.0 mg, 46% yield) as a pale yellow solid. LCMS [M+1 + =369.2. 1 H NMR(300MHz,DMSO-d6)δ 8.91(s,1H),8.32(d,1H),8.22(brs,1H),8.12(s,1H),7.82(q,1H),7.00(d,1H),6.92(dd ,1H),5.95(s,1H),4.50(s,2H),3.88(s,3H),3.57(t,2H),3.44-3.32(m,2H),2.92(d,3H). Example 3: General Procedure for the Synthesis of Example Compound 3 [ka]

[0262] Step 1: Example 3c To a solution of Example 3a (2.0 g, 11.69 mmol, 1.0 equiv.) and Example 3b (2.45 g, 14.03 mmol, 1.2 equiv.) in dry THF (20 mL) was added PPh3 (3.69 g, 14.03 mmol, 1.2 equiv.) and DBAD (3.22 g, 14.03 mmol, 1.2 equiv.) under N2 at 0 °C, followed by stirring at room temperature for 2 h. The solvent was removed in vacuo, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 3c (2.5 g, 64.9% yield), as a white solid. LCMS [M+1] + =327.3

[0263] Step 2: Example 3d To a solution of Example 3c (1.0 g, 3.06 mmol, 1.0 equiv) in MeOH (10 mL) was added 10% Pd / C (100 mg) under N protection. The suspension was degassed under vacuum and purged with H three times. The mixture was stirred under a H balloon at room temperature for 1 hour. The suspension was filtered through a Celite pad, and the filter cake was washed with MeOH. The combined filtrate was concentrated in vacuo to give the desired product, Example 3d (900 mg, 99.1% yield), as a colorless oil. LCMS [M+1] + =297.3

[0264] Step 3: Example 3f To a mixture of Example 3d (100 mg, 0.28 mmol, 1.0 equiv.), Example 3e (108.7 mg, 0.40 mmol, 1.5 equiv., from Example 1i), and CsCO (183.6 mg, 0.56 mmol, 2.0 equiv.) in dioxane (5 mL) was added Pd(OAc) (6.4 mg, 0.028 mmol, 0.1 equiv.) and BINAP (35.1 mg, 0.056 mmol, 0.2 equiv.). The mixture was degassed with N three times and stirred at 90 °C for 18 h. The reaction was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 3f (130 mg, 75.9% yield), as a light brown solid. LCMS [M+1] + =615.4

[0265] Step 4: Example 3g To a solution of Example 3f (130 mg, 1.78 mmol, 1.0 equiv) in EtOH (30 mL) and HO (10 mL) was added NaOH (12.7 mg, 1.5 mmol, 1.0 equiv) at 0° C. The mixture was stirred at 80° C. for 16 h. The solvent was removed to give crude Example 3g (160 mg, quantitative) as a white solid. LCMS [M+1] + =587.4

[0266] Step 5: Example 3h To a solution of Example 3g (160 mg, 0.27 mmol, 1.0 equiv) in MeOH (2 mL) was added HCl / dioxane (1.0 mL, 4 M in dioxane), which was stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was treated with EtOAc (30 mL) to give crude Example 3h (150 mg, quantitative) as a white solid. LCMS [M+1] + =387.4.

[0267] Step 6: Example 3 To a solution of Example 3h (crude, 135 mg, 0.30 mmol, 1.0 equiv.), DIEA (196.7 mg, 1.52 mmol, 5.0 equiv.) in DMF (10 mL) was added HATU (138.6 mg, 0.37 mmol, 1.2 equiv.). The mixture was stirred at room temperature for 1 hour. EtOAc (40 mL) was added to the reaction mixture, which was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated. The residue was purified by preparative HPLC to give the desired product, Example 3 (3.3 mg, 3.1% yield), as a white solid. LCMS [M+1] + =369.1. 1 H NMR(300MHz,DMSO-d6)δ 8.87(s,1H),8.44(s,1H),8.25-8.11(m,2H),7.88(s,1H),6.98(s,1H),6.51(s,1H),6.07( s,1H),4.32-4.21(m,2H),3.84(s,3H),3.22-3.15(m,2H),2.92(s,3H),2.02-1.81(m,2H). Example 4: General Procedure for the Synthesis of Example Compound 4 [ka]

[0268] Step 1: Example 4c To a solution of Example 4a (1 g, 5.92 mmol) in THF (10 mL) was added Example 4b (1.04 g, 5.92 mmol) and PPh3 (1.86 g, 7.1 mmol). The mixture was cooled to 0 °C, and DIAD (1.4 g, 7.1 mmol) was added dropwise. The resulting mixture was stirred at room temperature under N2 for 1 hour. The reaction mixture was extracted with EtOAc (50 mL × 2). The combined organic phase was washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give Example 4c (3 g, crude) as a yellow oil. LCMS[M+1-100] + =227.1

[0269] Step 2: Example 4d To a solution of Example 4c (crude, 3 g, 9.2 mmol) in DCM (20 mL) was added TFA (10 mL). The mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated. The residue was extracted with DCM (50 mL x 2) and H2O. The aqueous layer was alkalized with NaHCO3 and extracted with DCM (50 mL x 2). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give Example 4d (700 mg, 34% yield) as a yellow oil. LCMS [M+1] + =227.1. 1 H NMR (400 MHz, chloroform-d) δ 7.39 (d, 1H), 7.10 (dd, 1H), 7.01 (d, 1H), 4.04 (t, 2H), 3.90 (s, 3H), 2.91 (t, 2H), 1.92 (p, 2H).

[0270] Step 3: Example 4f To a solution of Example 4e (10 g, 77.5 mmol) in MeOH (100 mL) was added NaHCO3 (13 g, 155.0 mmol) at 0 °C. Br2 (18.6 g, 116.3 mmol) was then added dropwise, and the resulting mixture was stirred at room temperature overnight. Half of the solvent volume was removed under reduced pressure. The remainder was poured into ice water. The solid formed was collected and dried to give Example 4f (14.5 g, 90% yield) as a red solid. LCMS [M+1] + =209.9. 1H NMR(400MHz,DMSO-d6)δ7.98(s,1H),6.96(s,2H).

[0271] Step 4: Example 4h To a solution of Example 4f (14.5 g, 69.7 mmol) in EtOH (100 mL) was added Example 4g ​​(16.7 g, 111.5 mmol). The mixture was stirred overnight at 80° C. under N2. The reaction mixture was concentrated. The residue was purified by silica gel chromatography to give Example 4h (7 g, 39% yield) (36% brominated and 64% chlorinated) as a yellow solid. LCMS [M+1] + =260.0 / 306.0. 1 H NMR (400 MHz, chloroform-d) δ 8.37 (d, 1H), 7.57 (s, 0.36 H), 7.38 (s, 0.64 H), 4.46 (q, 2H), 1.43 (t, 3H).

[0272] Step 5: Example 4j To a solution of Example 4h (640 mg, 2.46 mmol) in dioxane (6 mL) was added Example 4i (409 mg, 2.71 mmol) and TEA (497 mg, 4.92 mmol). The mixture was stirred under N at 90 °C for 2 h. The reaction mixture was concentrated to give a sludge, which was triturated with H O (5 mL) to give a solid, which was filtered, washed with H O, and then taken up in DCM (20 mL). The solution was dried over Na SO , filtered, and the filtrate was concentrated under reduced pressure to give Example 4j (880 mg, 82% yield) as a yellow solid. LCMS [M+1] + =375.1. 1 H NMR (400 MHz, chloroform-d) δ 8.10 (s, 1H), 7.15 (d, 2H), 6.85 (d, 2H), 6.10 (s, 1H), 5.48 (s, 2H), 4.43 (q, 2H), 3.78 (s, 3H), 3.16 (s, 3H), 1.41 (t, 3H).

[0273] Step 6: Example 4k To a solution of Example 4j (680 mg, 1.81 mmol) in THF / MeOH / H2O (9 mL / 9 mL / 6 mL) was added LiOH.H2O (305 mg, 7.25 mmol). The mixture was stirred at room temperature overnight. The THF / MeOH was removed in vacuo, and the resulting solution was adjusted to pH = 4 using 1 M HCl. The mixture was extracted with DCM (30 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give Example 4k (760 mg, 93% yield) as a yellow solid. LCMS [M+1] + =347.1.

[0274] Step 7: Example 4l To a solution of Example 4k (660 mg, 1.9 mmol) in DMF (6 mL) was added Example 4d (430 mg, 1.9 mmol), TEA (576 mg, 5.7 mmol), and HATU (867 mg, 2.28 mmol). The mixture was stirred under N at room temperature for 2 hours. The reaction mixture was extracted with EtOAc (30 mL x 2). The combined organic phase was washed with brine, dried over NaSO, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give Example 4l (960 mg, 87% yield) as a yellow solid. LCMS [M+1] + =555.2.

[0275] Step 8: Example 4m To a solution of Example 4l (30 mg, 0.054 mmol) in THF / HOAc (0.5 mL / 0.05 mL) was added Zn (35 mg, 0.54 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was alkalized with aqueous NaHCO3 and extracted with DCM (10 mL x 2). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give Example 4m (30 mg, crude) as a yellow oil. LCMS [M+1] + =525.2.

[0276] Step 9: Example 4n To a solution of Example 4m (30 mg, 0.06 mmol) in dioxane (2 mL) was added Cs2CO3 (37 mg, 0.11 mmol) and tert-Bu-Xphos-Pd (5 mg, 0.006 mmol). The mixture was stirred under N2 at 90 °C for 2 h. The reaction mixture was extracted with DCM (10 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give Example 4n (40 mg, crude) as a yellow oil. LCMS [M+1] + =489.2.

[0277] Step 10: Example 4 To a solution of Example 4n (crude, 0.06 mmol) in DCM (1 mL) was added HCl / EtOAc (0.3 mL). The mixture was stirred at room temperature for 2 hours. The mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC to give Example 4 (5.1 mg, 23% yield) as a yellow solid. LCMS [M+1] + =369.1. 1 H NMR (400 MHz, chloroform-d) δ 8.82 (s, 1H), 8.10-8.07 (m, 2H), 7.00 (s, 1H), 6.87 (d, 1H), 6.65 (s, 1H), 6.57 (dd, 1H), 5.66 (s, 1H), 4.33 (t, 2H), 3.91 (s, 3H), 3.50-3.44 (m, 2H), 3.06 (d, 3H), 2.12-2.03 (m, 2H). Example 5: [ka]

[0278] Step 1: Example 5b To a solution of Example 5a (10.0 g, 56.8 mmol, 1.0 equiv) in MeOH (50 mL) was added NaOMe (4.6 g, 85.2 mmol, 1.5 equiv) at 0° C. The reaction mixture was stirred at 50° C. for 2 hours. The mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5a (1.5 g, 14.1% yield), as a yellow solid. LCMS [M+1] + =189.1.

[0279] Step 2: Example 5c A solution of Example 5b (1.5 g, 13.58 mmol, 1.0 equiv) in HBr / AcOH (20 mL) was stirred at 100° C. for 16 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with H2O (20 mL) and basified with saturated aqueous NaHCO3 to pH 8. This aqueous solution was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5c (1.0 g, 57.5% yield), as a yellow solid. LCMS [M+1] + =219.1.

[0280] Step 3: Example 5e To a solution of Example 5c (900 mg, 4.13 mmol, 1.0 equiv.) and Example 5d (867 mg, 4.95 mmol, 1.2 equiv.) in dry DCM (20 mL) was added PPh3 (1.3 g, 4.95 mmol, 1.2 equiv.) followed by DBAD (1.13 g, 4.95 mmol, 1.2 equiv.) under N2 at 0 °C. The reaction mixture was stirred at room temperature for 3 h. The solvent was removed in vacuo, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 5e (950 mg, 61.4% yield), as a yellow solid. LCMS [M+1] + =376.2.

[0281] Step 4: Example 5f To a solution of Example 5e (950 mg, 2.54 mmol, 1.0 equiv) in MeOH (20 mL) was added NaOMe (412 mg, 7.62 mmol, 3.0 equiv). The reaction mixture was stirred at 65° C. for 2 hours. The mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the product Example 5f (700 mg, 84.5% yield) as a yellow solid. LCMS [M+1] + =328.3.

[0282] Step 5: Example 5g To a solution of Example 5f (650 mg, 1.98 mmol, 1.0 equiv) in MeOH (20 mL) was added 10% Pd / C (60 mg) under N protection. The mixture was degassed with H three times and stirred under a H balloon for 1 h at room temperature. The solid was filtered. The filtrate was concentrated in vacuo to give the desired product, Example 5g (550 mg, 93.2% yield), as a colorless oil. LCMS [M+1] + =298.3.

[0283] Step 6: Example 5i To a mixture of Example 5f (5.0 g, 38.75 mmol, 1.0 equiv.) and NaHCO3 (9.76 g, 116.2 mmol, 3.0 equiv.) in MeOH (30 mL) was added Br2 (7.4 g, 46.51 mmol, 1.2 equiv.) dropwise at 0 °C. After the addition, it was warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5i (3.5 g, 43.6% yield), as a yellow solid. LCMS [M+1] + =208.1.

[0284] Step 7: Example 5k To a solution of Example 5i (3.5 g, 16.9 mmol, 1.0 equiv.) in EtOH (50 mL) was added Example 5j (5.07 g, 33.8 mmol, 2.0 equiv.), which was stirred at 80° C. for 16 hours. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5k (1.2 g, 34.2% yield), as a white solid. LCMS [M+1] + =260.1.

[0285] Step 8: Example 5l To a mixture of Example 5k (1.2 g, 4.61 mmol, 1.0 equiv.) and KCO (1.08 g, 13.8 mmol, 3.0 equiv.) in THF (20 mL), methanamine hydrochloride (467 mg, 6.91 mmol, 1.5 equiv.) was added and stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5l (1.05 g, 87.5% yield), as a yellow solid. LCMS [M+1] + =255.2.

[0286] Step 9: Example 5m To a solution of Example 5l (1.05 g, 3.92 mmol, 1.0 equiv.), EtN (1.19 g, 11.76 mmol, 3.0 equiv.), and DMAP (47.5 mg, 0.39 mmol, 0.1 equiv.) in DCM (15 mL) was added BocO (1.27 g, 5.88 mmol, 1.5 equiv.) at 0 °C, and the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5m (1.1 g, 75.3% yield), as a white solid. LCMS [M+1] + =355.2.

[0287] Step 10: Example 5n To a mixture of Example 5m (350 mg, 0.99 mmol, 1.0 equiv.), Example 5g (352 mg, 1.18 mmol, 1.2 equiv.), and CsCO (643 mg, 20.0 mmol, 2.0 equiv.) in dioxane (10 mL) was added Pd(OAc) (22 mg, 0.099 mmol, 0.1 equiv.) and BINAP (134 mg, 0.198 mmol, 0.2 equiv.). The mixture was degassed with N three times and then heated to 90 °C for 16 h. The reaction was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 5n (290 mg, 47.7% yield), as a light brown solid. LCMS [M+1] + =616.4.

[0288] Step 11: Example 5o To a solution of Example 5n (280 mg, 0.46 mmol, 1.0 equiv) in EtOH (2.5 mL) and HO (0.8 mL) at 0 °C, NaOH (36.5 mg, 0.91 mmol, 2.0 equiv) was added. The mixture was heated to 80 °C and stirred for 16 h. The reaction mixture was concentrated in vacuo to give the crude product Example 5o (360 mg, crude, quantitative) as a white solid. LCMS [M+1] + =588.4.

[0289] Step 12: Example 5p To a solution of Example 5o (350 mg, 0.596 mmol, 1.0 equiv) in DCM (2 mL) was added HCl / dioxane (1.0 mL, 4 M in dioxane) and stirred at room temperature for 1 h. The mixture was concentrated in vacuo and treated with EtOAc (30 mL) to give crude Example 5p (160 mg, 58.4% yield) as a white solid. LCMS [M+1] + =388.4.

[0290] Step 13: Example 5 To a solution of Example 5p (160 mg, 0.35 mmol, 1.0 equiv) and DIEA (135 mg, 1.04 mmol, 3.0 equiv) in DMF (5 mL) was added HATU (199 mg, 0.52 mmol, 1.5 equiv). The mixture was stirred at room temperature for 2 hours. EtOAc (10 mL) was added to the reaction mixture and washed with brine (10 mL x 2). The organic layer was concentrated in vacuo. The residue was purified by preparative HPLC to give the desired product, Example 5 (4.3 mg, 3.3% yield), as a white solid. LCMS [M+1] + =370.2. 1 H NMR(300MHz,DMSO-d6)δ 8.71(s,1H),8.63(d,1H),8.60-8.57(m,1H),7.83(s,1H),7.58-7.55(m,1H),7.43(d,1H),6. 33(s,1H),4.33-4.29(m,2H),3.94(s,3H),3.27-3.26(m,2H),2.88(d,3H),1.95-1.86(m,2H). Example 6: [ka]

[0291] Step 1: Example 6f To a solution of Example 6i (2.0 g, 5.6 mmol, 1.0 equiv.) in toluene (20 mL) was added TBTO (6.7 g, 11.2 mmol, 2.0 equiv.). The mixture was heated to 110° C. and stirred for 16 hours. The mixture was concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 6f (1.7 g, 88.5% yield), as a yellow solid. LCMS [M+1] + =327.2.

[0292] Step 2: Example 6c To a solution of Example 6b (1.18 g, 7.34 mmol, 1.2 equiv.) in DMF (10 mL) was added NaH (539 mg, 60% in mineral oil, 13.5 mmol, 2.2 equiv.) in several portions at 0 °C. After stirring for 0.5 h, a solution of Example 6a (1.5 g, 6.12 mmol, 1.0 equiv.) in DMF (20 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with saturated aqueous NH4Cl (50 mL) at 0 °C and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 6c (1.1 g, 55.2% yield), as a yellow solid. LCMS [M+1] + =327.3.

[0293] Step 3: Example 6d Example 6c (500 mg, 1.53 mmol, 1.0 equiv) was dissolved in MeOH (10 mL) and 5% Pd / C (100 mg) was added under N protection. The system was evacuated and then refilled with hydrogen. The mixture was stirred at room temperature under a H balloon for 1 hour. The reaction mixture was filtered and the filtrate was concentrated to give the desired product, Example 6d (450 mg, 99.3% yield), as a colorless oil. LCMS [M+1] + =297.3.

[0294] Step 4: Example 6e To a solution of Example 6d (450 mg, 1.52 mmol, 1.0 equiv) in DCM (10 mL) was added HCl / dioxane (3 mL, 4 M). The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated in vacuo to give the desired product, Example 6e (300 mg, 85.2% yield), as a white solid. LCMS [M+1] + =197.3.

[0295] Step 5: Example 6g To a solution of Example 6f (320 mg, 0.98 mmol, 1.0 equiv) in DCM (15 mL) was added DIEA (760 mg, 5.88 mmol, 6.0 equiv) and HATU (448 mg, 1.17 mmol, 1.2 equiv). After stirring for 0.5 h, Example 6e (316 mg, 1.17 mmol, 1.2 equiv) was added. The reaction solution was stirred at room temperature for 2 h. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 6g (220 mg, 44.4% yield), as a yellow solid. LCMS [M+1] + =505.4.

[0296] Step 6: Example 6h To a solution of Example 6g (170 mg, 0.33 mmol, 1.0 equiv.) in dioxane (10 mL) was added Cs2CO3 (219 mg, 0.67 mmol, 2.0 equiv.) and tert-Bu-Xphos Pd (30 mg, 0.033 mmol, 0.1 equiv.). The reaction mixture was stirred under N2 at 80 °C for 2 h. The reaction solution was concentrated in vacuo. The crude product was purified by preparative TLC to give the desired product, Example 6h (110 mg, 69.6% yield), as a yellow solid. LCMS [M+1] + =469.4.

[0297] Step 7: Example 6 To a solution of Example 6h (110 mg, 0.17 mmol, 1.0 equiv) in DCM (5 mL) was added HCl / dioxane (1 mL, 4 M in dioxane) at 0° C. The solution was stirred at room temperature for 0.5 h and then concentrated. The crude product was dissolved in MeOH and basified to pH ∼8 by adding Na2CO3 (aq). The mixture was concentrated and the residue was purified by preparative TLC to give the desired product Example 6 (55 mg, 63.6% yield) as an off-white solid. LCMS [M+1] + =369.4. 1 H NMR(300MHz,DMSO-d6)δ 8.76(brs,1H),8.42(s,1H),8.07(d,1H),7.81(s,1H),7.45-7.37(m,1H),7.01(d,1H),6.90(dd ,1H),6.22(s,1H),4.50(s,2H),3.88(s,3H),3.57-3.54(m,2H),3.45-3.37(m,2H),2.89(d,3H). Example 7: [ka]

[0298] Step 1: Example 7b To a mixture of Example 7a (21.0 g, 0.126 mol) in CCl (400 mL) was added NBS (23.5 g, 0.132 mol) and AIBN (4.1 g, 0.025 mol). The reaction mixture was stirred at 80 °C for 16 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 7b (18.5 g, 59.8% yield) as a yellow solid.

[0299] Step 2: Example 7d To a solution of Example 7c (2.13 g, 12.2 mmol) in THF (50 mL), NaH (0.81 g, 60% in mineral oil, 20.3 mmol) was added portionwise at 0 °C. The mixture was stirred at the same temperature for 10 minutes, and then Example 7b (2.0 g, 8.1 mmol) in THF was added dropwise. The reaction mixture was stirred at room temperature for 3 hours. The mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the product Example 7d (1.1 g, 39.8% yield) as a yellow oil. LCMS [M+1-100] + =241.2.

[0300] Step 3: Example 7e To a solution of Example 7d (1.0 g, 2.94 mmol) in MeOH (50 mL) was added 5% Pd / C (100 mg) under N protection. The suspension was degassed under vacuum and purged with H three times. The mixture was stirred under a H balloon at room temperature for 2 hours. The solid was filtered, and the filtrate was concentrated to give the product Example 7e (900 mg, 98.8% yield) as a yellow oil. LCMS [M+Na] + =333.4.

[0301] Step 4: Example 7f To a solution of Example 7e (500 mg, 1.6 mmol) in DCM (10 mL) was added HCl / dioxane (2 mL, 4 M in dioxane, 8.0 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to give the product Example 7f (480 mg, crude, quantitative) as a yellow oil. LCMS [M+1] + =211.2.

[0302] Step 5: Example 7h To a solution of Example 7g (324 mg, 0.99 mmol, from Example 6f) in DCM (20 mL) was added DIEA (1.0 g, 7.95 mmol) and HATU (415 mg, 1.1 mmol). After stirring for 10 minutes, Example 7f (450 mg, 2.14 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed and the crude product was purified by silica gel chromatography to give the desired product, Example 7h (200 mg, 24.3% yield), as a yellow solid. LCMS [M+1] + =519.2.

[0303] Step 6: Example 7i To a solution of Example 7h (200 mg, 0.39 mmol) in dioxane (10 mL) was added CsCO (251 mg, 0.77 mmol) and tert-Bu-Xphos-Pd (34 mg, 0.04 mmol). The reaction mixture was stirred at 80 °C under N for 3 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 7i (105 mg, 56.4% yield) as a yellow solid. LCMS [M+1] + =483.2.

[0304] Step 7: Example 7 To a solution of Example 7i (100 mg, 0.2 mmol) in DCM (5 mL) was added HCl / dioxane (1.0 mL, 4 M in dioxane, 4.0 mmol). The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo. The residue was dissolved in MeOH (5 mL) and basified with NaHCO3 to pH 8. To the mixture was added DCM (100 mL). The mixture was filtered through a silica gel column. The filtrate was concentrated to give the desired product, Example 7 (38.0 mg, 47.9% yield), as a white solid. LCMS [M+1] + =383.3. 1H NMR(300MHz,DMSO-d6)δ 8.78(d,1H),8.44(s,1H),8.15(d,1H),7.81(s,1H),7.41(d,1H),7.02(d,1H),6.89(dd,1H),6.22(s,1H),4.65( d,1H),4.38(d,1H),4.05-3.94(m,1H),3.89(s,3H),3.48(dd,1H),3.29-3.22(m,1H),2.88(d,3H),1.14(d,3H). Example 8: [ka]

[0305] Step 1: Example 8c To a solution of Example 8b (2.13 g, 12.20 mmol, 1.5 equiv) in THF (50 mL) was added NaH (813 mg, 60% in mineral oil, 20.33 mmol, 2.5 equiv) in several portions at 0 °C. After stirring for 30 min, a solution of Example 8a (2.0 g, 8.13 mmol, 1.0 equiv) in THF (10 mL) was added to the above solution. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with saturated aqueous NH4Cl (25 mL) at 0 °C and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 8c (980 mg, 35.4% yield), as a yellow solid. LCMS [M+1] + =341.3.

[0306] Step 2: Example 8d Example 8c (980 mg, 2.88 mmol, 1.0 equiv) was dissolved in MeOH (20 mL) and, under N protection, 5% Pd / C (500 mg) was added. The suspension was evacuated and then refilled with hydrogen three times. The mixture was stirred under a H balloon at room temperature for 1 h. The solid was filtered and the filtrate was concentrated to give the desired product, Example 8d (935 mg, crude, quantitative) as a brown solid. LCMS [M+1] + =311.4. Step 3: Example 8e To a solution of Example 8d (835 mg, 2.69 mmol, 1.0 equiv) in DCM (12 mL) was added HCl / dioxane (3 mL, 4 M in dioxane). The reaction mixture was stirred at room temperature for 2 hours. The solvent was concentrated in vacuo to give the crude product Example 8e (980 mg, crude, quantitative) as a yellow solid. LCMS [M+1] + =211.3

[0307] Step 4: Example 8g To a solution of Example 8f (300 mg, 0.92 mmol, 1.0 equiv., from Example 6f) in DCM (10 mL) was added DIEA (947 mg, 7.34 mmol, 8.0 equiv.) and HATU (383 mg, 1.01 mmol, 1.1 equiv.). After stirring for 30 minutes, Example 8e (340 mg, 1.38 mmol, 1.5 equiv.) was added to the solution. The reaction was stirred at room temperature for 2 hours. The solvent was concentrated, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 8g (160 mg, 33.6% yield), as a yellow oil. LCMS [M+1] + =519.3.

[0308] Step 5: Example 8h To a solution of Example 8g (150 mg, 0.29 mmol, 1.0 equiv.) in dioxane (10 mL) was added CsCO (188 mg, 0.58 mmol, 2.0 equiv.) and tert-Bu-Xphos-Pd (27 mg, 0.029 mmol, 0.1 equiv.). The reaction mixture was stirred at 80° C. under N for 2 hours. The reaction solution was filtered, and the filtrate was concentrated. The crude product was purified by preparative TLC to give the desired product, Example 8h (90 mg, 64.5% yield), as a yellow solid. LCMS [M+1] + =483.4.

[0309] Step 6: Example 8 To a solution of Example 8h (80 mg, 0.17 mmol, 1.0 equiv) in DCM (3 mL) was added HCl / dioxane (1 mL, 4 M in dioxane) at 0° C. The reaction was stirred at room temperature for 30 minutes and then concentrated. The crude product was dissolved in MeOH, and Na2CO3 (excess) was added and stirred at room temperature for 10 minutes. The solid was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 8 (40.0 mg, 63.1% yield) as an off-white solid. LCMS [M+1] + =383.3. 1 H NMR(300MHz,DMSO-d6)δ 8.73(s,1H),8.42(s,1H),8.10(d,1H),7.81(s,1H),7.40(d,1H),7.00(d,1H),6.92(dd,1H),6.21(s,1H),4.64(d, 1H),4.42(d,1H),3.88(s,3H),3.65-3.49(m,1H),3.42-3.35(m,1H),3.27-3.14(m,1H),2.89(d,3H),1.20(d,3H). Example 9: [ka]

[0310] Step 1: Example 9b To a solution of Example 9a (10.0 g, 50.8 mmol, 1.0 equiv.) in dry THF (100 mL) was added BH3.Me2S (6.1 mL, 10 M in DMS, 61.0 mmol, 1.2 equiv.) dropwise at room temperature. The solution was stirred at 70 °C for 3 hours. After cooling to room temperature, 3 M aqueous HCl was added dropwise to the reaction solution until no more effervescence was observed. The resulting mixture was extracted with EtOAc (100 mL × 3). The combined organic layers were washed with saturated aqueous Na2CO3, followed by brine, dried over Na2SO4, and concentrated in vacuo to give the product Example 9b (8.7 g, 94% yield) as an off-white solid. LCMS [M-18+1] + =166.2

[0311] Step 2: Example 9c To a solution of Example 9b (2.6 g, 14.2 mmol, 1.0 equiv.) in dry DCM (60 mL) was added PBr (7.7 g, 28.4 mmol, 2.0 equiv.) dropwise and stirred at room temperature for 2 hours. The reaction was diluted with DCM (100 mL), and aqueous NaCO was added to the solution until a neutral pH was achieved. The resulting mixture was extracted with DCM (100 mL x 2). The combined organic layers were washed with brine, dried over NaSO, and concentrated in vacuo to give the product Example 9c (3.3 g, 95% yield) as an off-white solid. LCMS [M+1] + =246.1.

[0312] Step 3: Example 9e To a solution of Example 9d (1.47 g, 9.15 mmol, 1.5 equiv) in dry THF (10 mL) was added NaH (610 mg, 60% in mineral oil, 15.25 mmol, 2.5 equiv) in portions at 0 °C, and the mixture was stirred for 30 min. Then, a solution of Example 9c (1.50 g, 6.1 mmol, 1.0 equiv) in THF (5 mL) was added dropwise. The mixture was stirred at room temperature for 1 h, then quenched with water (15 mL) and extracted with EtOAc (30 mL × 2). The combined organic layers were washed with brine, dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 9e (1.1 g, 55% yield), as a yellow oil. LCMS [M+1] + =327.3.

[0313] Step 4: Example 9f To a solution of Example 9e (1.1 g, 3.4 mmol, 1.0 equiv) in MeOH (25 mL), 5% Pd / C (200 mg) was added under N protection, and the suspension was degassed under vacuum and purged with H three times. The mixture was stirred under a H balloon at room temperature for 2 hours. The solid was filtered, and the filtrate was concentrated to give the desired product, Example 9f (950 mg, 94% yield), as a yellow oil. LCMS [M+1] + =297.3.

[0314] Step 5: Example 9g To a solution of Example 9f (400 mg, 1.35 mmol, 1.0 equiv) in DCM (10 mL) was added HCl / dioxane (4 M in dioxane, 2 mL). The solution was stirred at room temperature for 2 hours and then concentrated to give the product (650 mg, crude, quantitative) as a yellow oil. LCMS [M+1] + =197.3 Step 6: Example 9i To a solution of Example 9h (250 mg, 0.77 mmol, 1.0 equiv., from Example 6f) and DIEA (695.3 mg, 5.39 mmol, 7.0 equiv.), HATU (352 mg, 0.92 mmol, 1.2 equiv.) was added, which was stirred at room temperature for 10 minutes. Example 9g (452 ​​mg, 2.31 mmol, 3.0 equiv.) was then added. The mixture was stirred at room temperature for 2 hours, and the solvent was removed. The residue was purified by silica gel flash column chromatography to give the desired product, Example 9i (280 mg, 72% yield), as a yellow oil. LCMS [M+1] + =505.3.

[0315] Step 7: Example 9j To a solution of Example 9i (100 mg, 0.20 mmol, 1.0 equiv.) in dioxane (5 mL) was added CsCO (130 mg, 0.40 mmol, 2.0 equiv.) and tert-Bu-Xphos-Pd (17.4 mg, 0.02 mmol, 0.1 equiv.). The reaction mixture was stirred at 110 °C under N for 4 h. After cooling to room temperature, the reaction solution was filtered and the filtrate was concentrated. The crude product was purified by preparative TLC to give the desired product, Example 9j (30 mg, 32% yield), as a yellow solid. LCMS [M+1] + =469.2.

[0316] Step 8: Example 9 To a solution of Example 9j (20 mg, 0.043 mmol, 1.0 equiv) in DCM (6 mL) was added HCl / dioxane (2 mL, 4 M in dioxane), which was stirred at room temperature for 1 hour and then concentrated. The residue was diluted with MeOH (5 mL) and K2CO3 (excess) was added. The mixture was stirred at room temperature for 30 minutes. The solid was filtered, the filtrate was concentrated, and the residue was purified by preparative TLC to give the desired product, Example 9 (10.5 mg, 66% yield), as a white solid. LCMS [M+1] + =369.3. 1 H NMR(300MHz,DMSO-d6)δ 9.88(s,1H),7.78(s,1H),7.58(s,1H),7.48(d,1H),7.26(t,1H),7.16(d,1H),7.03(d,1H),6.08(s,1H),4.87(s,2H),3.80(s,5H),3.63 -3.53(m,2H),2.92(d,3H). Example 10: [ka]

[0317] Step 1: Example 10c To a solution of Example 10b (1.85 g, 10.6 mmol) in THF (20 mL) was added NaH (718 mg, 60% in mineral oil, 17.9 mmol) in several portions at 0 °C. After stirring for 0.5 h, a solution of Example 10a (2.0 g, 8.16 mmol, from Example 7b) in THF (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with saturated aqueous NH4Cl (50 mL) at 0 °C and extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (50 mL × 3), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 10c (2.5 g, 89.9% yield), as a yellow solid. LCMS [M+1] + =341.3.

[0318] Step 2: Example 10d Example 10c (2.5 g, 7.35 mmol) was dissolved in MeOH (30 mL) and 5% Pd / C (250 mg) was added under N protection. The system was evacuated and then refilled with hydrogen three times. The mixture was stirred at room temperature under a H balloon for 1 hour. The reaction mixture was filtered and the filtrate was concentrated to give the desired product, Example 10d (1.5 g, 65.8% yield), as a colorless oil. LCMS [M+1] + =311.3. Step 3: Example 10e To a solution of Example 10d (1.0 g, 3.22 mmol) in DCM (15 mL) was added HCl / dioxane (2 mL, 4 M in dioxane, 8 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated in vacuo to give the desired product, Example 10e (700 mg, 79.3% yield), as a white solid. LCMS [M+1] + =211.2.

[0319] Step 4: Example 10g To a solution of Example 10f (519 mg, 1.84 mmol, from Example 6f) in DCM (10 mL) was added DIEA (950 mg, 7.38 mmol) and HATU (559 mg, 1.47 mmol). After stirring for 0.5 h, Example 10e (400 mg, 1.23 mmol) was added. The reaction solution was stirred at room temperature for 2 h. The solvent was removed and the residue was purified by silica gel flash column chromatography to give the desired product, Example 10g (210 mg, 32.9% yield), as a yellow solid. LCMS [M+1] + =519.3.

[0320] Step 5: Example 10h To a solution of Example 10g (195 mg, 0.38 mmol) in dioxane (30 mL) was added CsCO (245 mg, 0.75 mmol) and tert-Bu-Xphos-Pd (33 mg, 0.04 mmol). The reaction mixture was stirred at 85 °C under N for 5 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 10h (95 mg, 52.3% yield) as a yellow solid. LCMS [M+1] + =483.2.

[0321] Step 6: Example 10 To a solution of Example 10h (95 mg, 0.2 mmol) in DCM (5 mL) was added HCl / dioxane (1 mL, 4 M in dioxane, 4 mmol). The reaction mixture was stirred at room temperature for 5 hours and then concentrated in vacuo. The residue was dissolved in MeOH (5 mL) and basified with NaHCO3 (pH = 8). DCM (100 mL) was added to the mixture and the solid was filtered. The filtrate was concentrated to give the desired product, Example 10 (50.0 mg, 66.4% yield) as a white solid. LCMS [M+1] + =383.3. 1 H NMR(300MHz,DMSO-d6)δ 8.76(d,1H),8.45(s,1H),8.15(d,1H),7.82(s,1H),7.41(d,1H),7.01(d,1H),6.88(dd,1H),6.23(s,1H),4.62 (d,1H),4.35(d,1H),4.05-3.93(m,1H),3.89(s,3H),3.54-3.46(m,1H),3.25(t,1H),2.88(d,3H),1.12(d,3H). Example 11: [ka]

[0322] Step 1: Example 11c To a solution of Example 11b (2.63 g, 15 mmol) in THF (50 mL) was added NaH (1.0 g, 60% in mineral oil, 25 mmol) in several portions at 0 °C. After stirring for 10 min, a solution of Example 11a (2.46 g, 10 mmol, from Example 7b) in THF (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 3 h. The reaction was quenched with saturated aqueous NH4Cl (20 mL) at 0 °C, extracted with EtOAc (50 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 11c (2.6 g, 76.5% yield), as a yellow solid. LCMS [M+1] + =341.3.

[0323] Step 2: Example 11d Example 11c (1.5 g, 4.4 mmol) was dissolved in MeOH (30 mL), and then 5% Pd / C (150 mg) was added under N protection. The system was evacuated and then refilled with hydrogen three times. The mixture was stirred at room temperature under a H balloon for 2 hours. The reaction mixture was filtered, and the filtrate was concentrated to give the desired product, Example 11d (1.35 g, 98.7% yield), as a yellow oil. LCMS [M+1] + =311.3.

[0324] Step 3: Example 11e To a solution of Example 11d (600 mg, 1.9 mmol) in DCM (6 mL) was added HCl / dioxane (2 mL, 4 M in dioxane, 8 mmol). The reaction mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated in vacuo to give the desired product, Example 11e (580 mg, crude, quantitative) as a yellow oil. LCMS [M+1] + =211.2.

[0325] Step 4: Example 11g To a solution of Example 11f (418 mg, 1.3 mmol, from Example 6f) in DCM (30 mL) was added DIEA (1.3 g, 10.3 mmol) and HATU (730 mg, 1.9 mmol). After stirring for 0.5 h, Example 11e (580 mg, 2.0 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed and the residue was purified by silica gel flash column chromatography to give the desired product, Example 11g (240 mg, 36.1% yield), as a yellow solid. LCMS [M+1] + =519.3.

[0326] Step 5: Example To a solution of Example 11g (240 mg, 0.46 mmol) in dioxane (10 mL) was added CsCO (302 mg, 0.92 mmol) and tert-Bu-Xphos-Pd (41 mg, 0.05 mmol). The reaction mixture was stirred at 85 °C under N for 5 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product Example 11h (140 mg, 62.7% yield) as a yellow solid. LCMS[M+1] + =483.2.

[0327] Step 6: Example 11: To a solution of Example 11h (140 mg, 0.29 mmol) in DCM (5 mL) was added HCl / dioxane (1 mL, 4 M in dioxane, 4 mmol). The reaction mixture was stirred at room temperature for 5 hours and then concentrated in vacuo. The residue was dissolved in MeOH (5 mL) and basified with NaHCO3 (pH = 8). To the mixture was added DCM (100 mL). The solid was filtered and the filtrate was concentrated to give the desired product, Example 11 (70.0 mg, 66.4% yield), as an off-white solid. LCMS [M+1] + =383.3. 1 H NMR(300MHz,DMSO-d6)δ 8.76(d,1H),8.45(s,1H),8.15(d,1H),7.82(s,1H),7.43(d,1H),7.01(d,1H),6.89(dd,1H),6.23(s,1H),4. 64(d,1H),4.37(d,1H),4.05-3.92(m,1H),3.89(s,3H),3.46(dd,1H),3.25(t,1H),2.89(d,3H),1.13(d,3H). Example 12: [ka]

[0328] Step 1: Example 12b To a solution of Example 12a (30.0 g, 179 mmol) in CCl (150 mL) was added BPO (4.4 g, 17.9 mmol) and NBS (38.15 g, 216 mmol), which was stirred at 80 °C overnight. After cooling, the mixture was then diluted with DCM, washed with water, dried over Na SO and concentrated under reduced pressure to give Example 12b (37.0 g, 84.4% yield) as a yellow solid, which was used in the next step without purification. LCMS [M+1] + =246.0. 1 H NMR (400 MHz, chloroform-d) δ 7.87 (d, 1H), 7.57 (dd, 1H), 7.07 (d, 1H), 4.46 (s, 2H), 3.96 (d, 3H).

[0329] Step 2: Example 12d To a solution of Example 12b (2.46 g, 10.0 mmol) in THF (20 mL) was added NaH (400 mg, 60% in mineral oil, 10.0 mmol) at 0° C., and the mixture was stirred for 0.5 hours. Then, Example 12c (1.75 g, 10.0 mmol) was added, and the resulting mixture was stirred at room temperature for 6 hours. The mixture was quenched with aqueous NH4Cl, extracted with EtOAc, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give Example 12d (3.3 g, 96.8% yield) as a yellow solid. LCMS [M+1-100] + =241.1.

[0330] Step 3: Example 12e A suspension of Example 12d (688 mg, 2.0 mmol) and 10% Pd / C (34 mg) in MeOH (10 mL) was stirred at room temperature under a H balloon for 2 h. The suspension was filtered, and the filtrate was concentrated under reduced pressure to give Example 12e (640 mg, 103% crude yield) as a yellow solid, which was used in the next step without purification.

[0331] Step 4: Example 12f To a solution of Example 12e (400 mg, 1.3 mmol) in dioxane (2 mL) was added HCl / dioxane (1.0 mL, 4 M in dioxane), which was stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was treated with EtOAc (30 mL) to give crude Example 12f (340 mg, 124% crude yield) as a white solid, which was used in the next step without purification.

[0332] Step 5: Example 12h To a solution of Example 12f (340 mg, 0.65 mmol), Example 12g (423 mg, 1.3 mmol, from Example 6f), and TEA (810 mg, 8.1 mmol) in DCM (10 mL) was added HATU (616 mg, 1.62 mmol). The mixture was stirred at room temperature for 1 hour. EtOAc (40 mL) was added to the reaction mixture, which was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 12h (500 mg, 59% yield), as a white solid. LCMS [M+1] + =519.2.

[0333] Step 6: Example 12i To a mixture of Example 12h (500 mg, 0.97 mmol), CsCO (652 mg, 2.0 mmol) in dioxane (10 mL) was added tert-t-Bu-Xphos-Pd (89 mg, 0.1 mmol). The mixture was degassed with N three times and stirred at 80 °C for 3 h. The mixture was diluted with DCM, washed with water, dried over NaSO, and concentrated under reduced pressure to give Example 12i (450 mg, crude yield 93.3%) as a white solid, which was used in the next step without purification. LCMS [M+1] + =483.3

[0334] Step 7: Example 12 To a solution of Example 12i (200 mg, 0.42 mmol) in dioxane (2 mL), HCl / dioxane (1.0 mL, 4 M in dioxane) was added and stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired product, Example 12 (4.9 mg, 3.0% yield), as a white solid. LCMS [M+1] + =383.3. 1 H NMR(400MHz,DMSO-d6)δ 8.90(s,1H),8.32(s,1H),8.22(d,1H),8.08(s,1H),7.80(d,1H),6.97(d,1H),6.88(d,1H), 5.91(s,1H),4.54(d,1H),4.37(d,1H),3.85(s,3H),3.44(d,1H),2.89(d,3H),1.11(d,3H). Example 13: [ka]

[0335] Step 1: Example 13b To a solution of Example 13a (10.0 g, 0.05 mol) in MeOH (150 mL) was added NaBH4 (4.87 g, 0.13 mol) in several portions. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the product Example 13b (8.5 g, 84.1% yield) as a yellow oil. LCMS [M+1] + =198.2.

[0336] Step 2: Example 13c To a solution of Example 13b (1.97 g, 10.0 mmol) in DCM (50 mL) was added PBr (5.4 g, 20.0 mmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was diluted with DCM (100 mL) and washed with saturated aqueous NaHCO (50 mL × 2). The organic layer was dried over anhydrous NaSO and concentrated in vacuo to give the product Example 13c (2.3 g, 88.5% yield) as a yellow oil.

[0337] Step 3: Example 13e To a solution of Example 13d (2.0 g, 12.5 mmol) in THF (50 mL), NaH (0.5 g, 60% in mineral oil, 12.5 mmol) was added portionwise at 0° C. The mixture was stirred at the same temperature for 10 minutes, and then Example 13c (1.3 g, 5.0 mmol) in THF was added dropwise. The reaction mixture was stirred at room temperature for 3 hours. The mixture was quenched with saturated NH4Cl (30 mL) and extracted with EtOAc (50 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the product Example 13e (810 mg, 47.6% yield) as a yellow oil. LCMS [M+1-100] + =241.2.

[0338] Step 4: Example 13f Example 13e (800 mg, 2.4 mmol) was mixed with MeOH (30 mL) and, under N2 protection, 5% Pd / C (150 mg) was added. The system was evacuated and then refilled with hydrogen three times. The mixture was stirred under a H2 balloon at room temperature for 2 hours. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 13f (420 mg, 57.6% yield) as a yellow oil. LCMS [M+1] + =311.3.

[0339] Step 5: Example 13g To a solution of Example 13f (400 mg, 1.29 mmol) in DCM (5 mL) was added HCl / dioxane (2 mL, 4 M in dioxane, 8 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated in vacuo to give the desired product, Example 13g (360 mg, 98.6% yield), as a yellow oil. LCMS [M+1] + =211.2.

[0340] Step 6: Example 13i To a solution of Example 13h (238 mg, 0.7 mmol, from Example 6f) in DCM (20 mL) was added DIEA (752 mg, 5.8 mmol) and HATU (443 mg, 1.2 mmol). The solution was stirred for 0.5 h, and then Example 13g (330 mg, 1.2 mmol) was added. The reaction solution was stirred at room temperature for 2 h. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 13i (41 mg, 10.8% yield), as a yellow solid. LCMS [M+1] + =519.3.

[0341] Step 7: Example 13j To a solution of Example 13i (41 mg, 0.08 mmol) in 1,4-dioxane (10 mL) was added CsCO (51 mg, 0.16 mmol) and tert-Bu-Xphos-Pd (7 mg, 0.01 mmol). The reaction mixture was stirred at 85 °C under N for 4 hours. After cooling to room temperature, the solvent was removed and the residue was purified by preparative TLC to give the product Example 13j (25 mg, 65.5% yield) as a yellow solid. LCMS [M+1] + =483.2.

[0342] Step 8: Example 13 To a solution of Example 13j (25 mg, 0.05 mmol) in DCM (3 mL) was added HCl / dioxane (0.2 mL, 4 M in dioxane, 0.8 mmol). The reaction mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was dissolved in MeOH (5 mL), and then the pH valve was adjusted to 8 with saturated aqueous NaHCO3. The solvent was removed, and the residue was purified by preparative TLC to give the product Example 13 (11.8 mg, 59.6% yield) as an off-white solid. LCMS [M+1] + =383.3. 1H NMR(300MHz,DMSO-d6)δ 8.80(s,1H),8.42(s,1H),8.03(d,1H),7.80(s,1H),7.41(d,1H),7.00(d,1H),6.90(dd,1H),6.21(s,1H),4.45(q,1H) ),3.88(s,3H),3.75-3.71(m,1H),3.53-3.43(m,1H),3.42-3.37(m,1H),3.26-3.23(m,1H),2.89(d,3H),1.30(d,3H). Example 14: [ka]

[0343] Step 1: Example 14b A solution of Example 14a (15.0 g, 87.2 mmol) and MeONa (14.1 g, 261.6 mmol) in MeOH (100 mL) was stirred at 70° C. for 3 hours. The mixture was concentrated under reduced pressure and then diluted with water, which was then extracted with EtOAc, dried over anhydrous NaSO, and concentrated to give crude Example 14b (13.4 g, 92.2% yield) as a yellow solid. The residue was used directly in the next step without further purification. LCMS [M+1] + =169.1.

[0344] Step 2: Example 14c To a solution of Example 14b (5.0 g, 29.8 mmol) in CCl (150 mL) was added BPO (720 mg, 2.98 mmol) and NBS (5.3 g, 29.8 mmol). The reaction mixture was stirred at 80 °C overnight, then diluted with DCM, washed with water, and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure and then purified by silica gel column chromatography to give Example 14c (5.7 g, 77.6% yield) as a yellow solid. LCMS [M+1] + =247.0

[0345] Step 3: Example 14e To a solution of Example 14d (2.1 g, 12.1 mmol) in THF (40 mL) was added NaH (1.46 g, 36.4 mmol) at 0° C. The reaction mixture was warmed to room temperature and stirred at room temperature for 0.5 hours. Example 14c (3.0 g, 12.1 mmol) was then added. The mixture was stirred at room temperature for 6 hours, then quenched with aqueous NH4Cl, extracted with EtOAc, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and then purified by silica gel column chromatography to give Example 14e (1.0 g, yield: 24.4%) as a yellow solid. LCMS [M-174] + =167.1.

[0346] Step 4: Example 14f A solution of Example 14e (1.0 g, 2.93 mmol) and Pd / C (200 mg) in MeOH (5 mL) was stirred at room temperature for 2 hours under 1 atmosphere of H. After filtration, the filtrate was concentrated under reduced pressure to give Example 14f (850 mg, yield: 93.2%) as a yellow solid, which was used directly in the next step. LCMS [M-174] + =137.1

[0347] Step 5: Example 14g To a solution of Example 14f (800 mg crude, 1.3 mmol) in DCM (4 mL) was added TFA (1.0 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to give the crude product Example 14g (700 mg, crude, quantitative yield) as a black oil. LCMS [M-74] + =137.1.

[0348] Step 6: Example 14i To a solution of Example 14g (30 mg, 0.1 mmol), Example 14h (33 mg, 0.1 mmol, from Example 6f), and TEA (202 mg, 1.0 mmol) in DCM (2 mL) was added HATU (38 mg, 0.1 mmol). The reaction mixture was stirred at room temperature for 2 hours. Then, EtOAc (40 mL) was added to the reaction mixture, which was washed with brine (20 mL x 2), dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 14i (32 mg, yield: 62%), as a brown solid. LCMS [M+1] + =520.2.

[0349] Step 7: Example 14j To a mixture of Example 14i (32 mg, 0.06 mmol), CsCO (30 mg, 0.09 mmol) in dioxane (2 mL) was added tert-Bu-Xphos-Pd (5.5 mg, 0.006 mmol). The mixture was degassed with N three times and stirred at 80 °C for 3 h. The reaction mixture was then diluted with DCM, washed with water, dried over anhydrous NaSO, and concentrated under reduced pressure to give crude Example 14j (50 mg, crude, quantitative yield) as a white solid, which was used in the next step without further purification. LCMS [M+1] + =484.2

[0350] Step 8: Example 14 To a solution of Example 14j (50 mg, 0.1 mmol) in DCM (4 mL), TFA (1.0 mL) was added and stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired product, Example 14 (4.5 mg, yield: 31.4%) as a white solid. LCMS [M+1] += 384.2. 1H NMR (400 MHz, chloroform-d) δ 8.58 (s, 1H), 8.53 (s, 1H), 8.08 (s, 1H), 7.67 (s, 1H), 6.69 (s, 1H), 5.67 (s, 1H), 4.68 (d, 1H), 4.45 (d, 1H), 4.24 (br, 1H), 4.05 (s, 3H), 3.57-3.54 (m, 1H), 3.39-3.34 (m, 1H), 3.03 (d, 3H), 1.25 (d, 3H). Example 15: [ka]

[0351] Step 1: Example 15b To a solution of Example 15a (15.0 g, 87.2 mmol) in CCl (500 mL) was added NBS (31.0 g, 174.4 mmol) and AIBN (2.86 g, 17.4 mmol). The reaction mixture was stirred under N at 80 °C for 20 h. After filtration, the filtrate was concentrated, and the residue was purified by silica gel flash column chromatography to give the product Example 15b (7.5 g, yield: 34.2%) as a yellow oil. LCMS [M+1] + =252.9.

[0352] Step 2: Example 15d To a solution of Example 15c (5.8 g, 33.4 mmol) in THF (250 mL), NaH (1.3 g, 60% in mineral oil, 33.4 mmol) was added portionwise at 0° C. The mixture was stirred at the same temperature for 5 minutes, and then Example 15b (7.0 g, 27.8 mmol) in THF was added dropwise. The reaction mixture was stirred at room temperature for 1 hour. After concentration of the solvent, the residue was purified by silica gel flash column chromatography to give the product Example 15d (2.6 g, yield: 30.0%) as a yellow oil. LCMS [M+1] + =346.2.

[0353] Step 3: Example 15e To a mixture of Example 15d (2.5 g, 7.2 mmol) in HO (50 mL) was added NaOH (1.2 g, 28.9 mmol). The mixture was stirred at 50 °C for 16 h. After cooling to room temperature, the reaction solution was concentrated in vacuo to give the desired product, Example 15e (3.7 g, crude, quantitative yield) as a yellow solid. LCMS [M+1] + =328.3.

[0354] Step 4: Example 15f To a solution of Example 15e (3.7 g, crude, 7.2 mmol) in DMF (50 mL) was added CHCl (2.4 g, 17.0 mmol). The reaction mixture was stirred at room temperature for 6 hours. After concentration, the residue was diluted with EtOAc (100 mL), washed with H0 (100 mL), dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel flash column chromatography (THF / petroleum ether = 4 / 1) to give the product Example 15f (860 mg, yield: 35.0% for two steps) as a yellow oil. LCMS [M+1] + =342.2.

[0355] Step 5: Example 15g Example 15f (820 mg, 2.4 mmol) was dissolved in MeOH (20 mL), and then Pd / C (80 mg) was added portionwise under N protection. The mixture was degassed under vacuum and purged with H three times. The mixture was stirred under a H balloon at room temperature for 2 hours. The solid was filtered off, and the filtrate was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 15g (380 mg, yield: 50.8%) as a yellow oil. LCMS [M+1] + =312.2.

[0356] Step 6: Example 15h To a solution of Example 15g (370 mg, 1.2 mmol) in DCM (10 mL) was added TMSOTf (396 mg, 1.8 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The solvent was concentrated in vacuo to give the desired product, Example 15h (430 mg, crude), as a yellow oil. LCMS [M+1] + =212.2.

[0357] Step 7: Example 15j To a solution of Example 15i (260 mg, 0.8 mmol, from Example 6f) in DCM (20 mL) was added DIEA (411 mg, 3.2 mmol) and HATU (303 mg, 0.8 mmol). The mixture was stirred for 5 minutes, and then Example 15h (420 mg, crude, 2.0 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 15j (200 mg, 30.6% yield), as a yellow solid. LCMS [M+1] + =520.2.

[0358] Step 8: Example 15k To a solution of Example 15j (190 mg, 0.37 mmol) in dioxane (20 mL) was added KCO (101 mg, 0.73 mmol), BINAP (228 mg, 0.37 mmol), and Pd(dba)CHCl (189 mg, 0.18 mmol). The reaction mixture was stirred at 80 °C under N for 16 h. After cooling to room temperature, the solvent was removed and the residue was purified by preparative TLC to give the product Example 15k (50 mg, 28.3% yield) as a yellow solid. LCMS [M+1] + =484.4.

[0359] Step 9: Example 15 To a solution of Example 15k (45 mg, 0.09 mmol) in DCM (5 mL) was added TMSOTf (41 mg, 0.02 mmol) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated in vacuo, and the residue was purified by preparative TLC to give the product Example 15 (15.3 mg, yield: 42.9%) as an off-white solid. LCMS [M+1] + =384.3. 1H NMR(300MHz,DMSO-d6)δ 8.73-8.63(m,2H),8.10(d,1H),7.83(s,1H),7.46(q,1H),7.33(d,1H),6.34(s,1H),4.47(d,1H), 4.23(d,1H),4.05-4.03(m,1H),3.53(s,3H),3.48(d,1H),3.40(d,1H),2.87(d,3H),1.13(d,3H). Example 16: [ka]

[0360] Step 1: 2-Fluoro-4-methoxy-5-nitro-benzaldehyde (16B) 2-Fluoro-4-methoxy-benzaldehyde (16A) (5 g, 32.46 mmol) was dissolved in concentrated sulfuric acid (30 mL) and cooled to -10 °C. Concentrated nitric acid (2.1 mL) in concentrated sulfuric acid (4 mL) was added dropwise over 20 minutes. After stirring for an additional hour below -10 °C, the mixture was poured into crushed ice. The precipitate was collected by filtration and partitioned between dichloromethane (40 mL) and saturated sodium bicarbonate (30 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound (16B) (5.2 g, 80.50%) as a cream-colored solid. LC-MS (ESI): m / z = 200.1 [M+H] + .

[0361] Step 2: (2-Fluoro-4-methoxy-5-nitro-phenyl)methanol (16C) Sodium borohydride (0.304 g, 8.04 mmol) was added portionwise to a stirred solution of 2-fluoro-4-methoxy-5-nitro-benzaldehyde (16B) (0.8 g, 4.02 mmol) in methanol (10 mL) at 0 °C. After 2 h, methanol was removed in vacuo. The residue was treated with cold water and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and then evaporated in vacuo to give the title compound (16C) as a crude solid (0.79 g, 97.77%). LC-MS (ESI): m / z = 202.1 [M+H] +

[0362] Step 3: 1-(Bromomethyl)-2-fluoro-4-methoxy-5-nitro-benzene (16D) Carbon tetrabromide (2.64 g, 7.96 mmol) in anhydrous diethyl ether (5 mL) was added dropwise to a stirred solution of (2-fluoro-4-methoxy-5-nitro-phenyl)methanol (16C) (0.8 g, 3.98 mmol) and triphephosphine (2.08 g, 7.96 mmol) in anhydrous diethyl ether (15 mL). The mixture was stirred overnight before being concentrated. Chromatography using ethyl acetate (0-10%) in hexane afforded the title compound (16D) as a pale yellow solid (0.69 g, 66.34%). LC-MS (ESI): m / z = 264.1 [M+H] +

[0363] Step 4: tert-butyl N-[2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (16E) Sodium hydride (105 mg, 2.62 mmol) was added portionwise to a stirred solution of tert-butyl N-(2-hydroxy-1-methyl-ethyl)carbamate (0.46 g, 2.62 mmol) in THF (15 mL) at 0 °C, the mixture was stirred at 0 °C for 10 minutes, and then 1-(bromomethyl)-2-fluoro-4-methoxy-5-nitro-benzene (16D) (0.69 g, 2.62 mmol) was added to the mixture at 0 °C, and after 30 minutes, the mixture was treated with cold water and extracted with ethyl acetate. The combined organic layers were washed with brine and dried (Na SO ), and the residue was purified by flash chromatography to give the title compound (16E) (0.1 g, 10.65%) as a brown solid. LC-MS (ESI): m / z = 381.1 [M+23] + . 1 H NMR(400MHz,CDCl3)δ 8.02(d,1H),6.78(d,1H),4.60(s,1H),4.53(q,2H),3.96(s,3H),3.91-3.83(m,1H),3.49-3.43(m,2H),1.44(s,9H),1.18(d,3H).

[0364] Step 5: [2-[(5-amino-2-fluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]ammonium; 2,2,2-trifluoroacetate (16F) Trifluoroacetic acid (1 mL) was added to a solution of N-[2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (16E) (0.1 g, 0.28 mmol) in DCM (3 mL), the mixture was stirred for 2 hours, and the mixture was evaporated to dryness to give the title compound (16F) (0.1 g, 100%) as a brown liquid, which was used in the next step without further purification. LC-MS (ESI): m / z=259.2 [M+H] +

[0365] Step 6: tert-butyl N-[6-chloro-3-[[2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (16G) [2-[(5-amino-2-fluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]ammonium;2,2,2-trifluoroacetate (16F) (0.1 g, 0.27 mmol) was dissolved in DMF (5 mL), and HATU (0.153 g, 0.4 mmol), DIPEA (0.07 g, 0.54 mmol), and Intermediate 1 (0.09 g, 0.27 mmol) were added to the solution at room temperature. After 18 hours, the solution mixture was diluted with EA (30 mL), washed with water (2 × 30 mL) and brine (30 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography (PE / EA = 3:1) to give the title compound (16G) (0.06 g, 39.47%) as a white solid. LC-MS (ESI): m / z = 567.2 [M+H] +

[0366] Step 7: tert-butyl N-[3-[[2-[(5-amino-2-fluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]-6-chloro-imidazo[1,2-b]pyridazin-8-yl]-N-methyl-carbamate (H) tert-Butyl N-[6-chloro-3-[[2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (16G) (0.06 g, 0.1 mmol) was dissolved in ethanol (9 mL) and HO (3 mL). To this solution, Fe powder (60 mg, 1.06 mmol) and NH4Cl (34 mg, 0.64 mmol) were added. The reaction mixture was then heated to 85°C for 3 hours. After cooling to room temperature, the reaction mixture was filtered and the filtrate was removed in vacuo. The residue was purified by flash chromatography to give the title compound (16H) (0.044 g, 78.57%) as a white solid. LC-MS (ESI): m / z = 537.1 [M+H]+

[0367] Step 8: tert-Butyl (E)-(3 4 -Fluoro-3 6 -Methoxy-7-methyl-9-oxo-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphane-1 8 -yl)(methyl)carbamate (16I) To a solution of (16H) (44 mg, 0.082 mmol) in 1,4-dioxane (20 mL) was added CsCO (80 mg, 0.25 mmol) and tert-Bu-Xphos-Pd (30 mg). The reaction mixture was stirred at 85 °C under N for 2 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product (Example 16I) (22 mg, 53.65%) as a white solid. LC-MS (ESI): m / z = 501.3 [M+H] +

[0368] Step 9: tert-Butyl (E)-(3 4 -Fluoro-3 6 -Methoxy-7-methyl-9-oxo-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphane-1 8 -yl)(methyl)carbamate (16) A solution of (16I) (22 mg, 0.044 mmol) and trifluoroacetic acid (0.5 mL) in DCM (4 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was basified with NaHCO and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, evaporated, and the residue was purified by silica gel flash column chromatography to give product 16 (5 mg, 28.57%) as a white solid. 1H NMR(400MHz,CDCl3)δ 8.71(d,1H),8.28(d,1H),8.07(s,1H),6.74-6.60(m,3H),5.64(s,1H),4.69-2.59(m,2H),4.28-4.21(m,1 H),3.93(d,3H),3.57(dd,1H),3.43-3.37(m,1H),3.05(d,3H),1.29(d,3H).LC-MS(ESI):m / z=401.2[M+H] + Example 17: [ka]

[0369] Step 1: tert-butyl N-[(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (17E) Sodium hydride (228 mg, 5.70 mmol) was added portionwise to a stirred solution of tert-butyl N-[(1R)-2-hydroxy-1-methyl-ethyl]carbamate (1 g, 5.70 mmol) in THF (30 mL) at 0 °C, the mixture was stirred at 0 °C for 10 minutes, and then 1-(bromomethyl)-2-fluoro-4-methoxy-5-nitro-benzene (16D) (1.5 g, 5.70 mmol) was added to the mixture at 0 °C. After 30 minutes, the mixture was treated with cold water and extracted with ethyl acetate. The combined organic layers were washed with brine and dried (Na SO ), and the residue was purified by flash chromatography to give the title compound (17E) (0.57 g, 27.94%) as a white solid. LC-MS (ESI): m / z = 359.1 [M+H] +

[0370] Step 2: [(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium; 2,2,2-trifluoroacetate (17F) Trifluoroacetic acid (3 mL) was added to a solution of tert-butyl N-[(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (17E) (0.57 g, 1.53 mmol) in DCM (8 mL), the mixture was stirred overnight, and the mixture was evaporated to dryness to give the title compound (17F) (0.54 g, 91.21%) as a brown liquid, which was used in the next step without further purification. LC-MS (ESI): m / z = 259.2 [M+H] +

[0371] Step 3: tert-butyl N-[6-chloro-3-[[(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (17G) [(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium; 2,2,2-trifluoroacetate (17F) (0.54 g, 1.45 mmol) was dissolved in DMF (15 mL), and HATU (0.827 g, 2.17 mmol), DIPEA (0.374 g, 2.9 mmol), and Intermediate 1 (0.473 g, 1.45 mmol) were added to the solution at room temperature. After 18 hours, the solution mixture was diluted with EA (50 mL), washed with water (2 × 50 mL) and brine (50 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography to give the title compound (17G) (0.512 g, 62.36%) as a white solid. LC-MS(ESI): m / z=567.2[M+H] +

[0372] Step 4: tert-butyl N-[3-[[(1R)-2-[(5-amino-2-fluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]-6-chloro-imidazo[1,2-b]pyridazin-8-yl]carbamate (17H) tert-Butyl N-[6-chloro-3-[[(1R)-2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (17G) (0.512 g, 0.9 mmol) was dissolved in ethanol (50 mL) and HO (15 mL), Fe (506 mg, 9.04 mmol) and NH4Cl (290 mg, 5.42 mmol) were added, and the reaction mixture was heated to 85 °C for 3 h. After cooling to room temperature, it was filtered and the filtrate was removed in vacuo. The residue was purified by flash chromatography (PE / EA = 3:1) to give the title compound (17H) (0.44 g, 90.90%) as a white solid. LC-MS (ESI): m / z = 537.1 [M+H] +

[0373] Step 5: tert-Butyl ((7R,E)-3 4 -Fluoro-3 6 -Methoxy-7-methyl-9-oxo-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphane-1 8 -yl)(methyl)carbamate (17I) To a solution of (17H) (440 mg, 0.82 mmol) in 1,4-dioxane (80 mL) was added CsCO (802 mg, 2.46 mmol) and tert-Bu-Xphos-Pd (280 mg). The reaction mixture was stirred at 80 °C under N for 2 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the desired product (Example 17I) (230 mg, 56.09%) as a white solid. LC-MS (ESI): m / z = 501.3 [M+H] + .

[0374] Process 6:(E)-3 4 -Fluoro-3 6 -Methoxy-7-methyl-1 8 -(Methylamino)-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphan-9-one (17) A solution of 17 (230 mg, 0.46 mmol) and trifluoroacetic acid (2 mL) in DCM (10 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was quenched with NaHCO and extracted with DCM. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, evaporated, and the residue was purified by silica gel flash column chromatography (PE / EA=2:1) ​​to give product 17 (65 mg, 35.32%) as a white solid. 1 H NMR(400MHz,CDCl3)δ 8.74(d,1H),8.30(d,1H),8.05(s,1H),6.70-6.55(m,2H),6.21(s,1H),5.59(s,1H),4.72-4.55(m,2H),4.31-4.21( m,1H),3.92(s,3H),3.59-3.55(dd,1H),3.44-3.38(m,1H),3.04(d,3H),1.29(d,3H).LC-MS(ESI):m / z=401.2[M+H] + . Example 18: [ka]

[0375] Step 1: 3-Fluoro-4-methoxy-5-nitro-benzaldehyde (18B) 3-Fluoro-4-methoxy-benzaldehyde (18A) (3.6 g, 23.37 mmol) was dissolved in concentrated sulfuric acid (30 mL) and cooled to -10 °C. Concentrated nitric acid (2.5 mL) in concentrated sulfuric acid (4 mL) was added dropwise over 20 min. After stirring below -10 °C for an additional 1 h, the mixture was poured onto crushed ice. The precipitate was collected by filtration and partitioned between dichloromethane (40 mL) and saturated sodium bicarbonate (30 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound (18B) (2.5 g, 53.76%) as an oil. LC-MS (ESI): m / z = 200.1 [M+H] + .

[0376] Step 2: (3-Fluoro-4-methoxy-5-nitro-phenyl)methanol (18C) Sodium borohydride (0.38 g, 10.04 mmol) was added portionwise to a stirred solution of 3-fluoro-4-methoxy-5-nitro-benzaldehyde (1 g, 5.02 mmol) in methanol (20 mL) at 0° C. After 2 h, methanol was removed in vacuo. The residue was treated with cold water and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and then evaporated in vacuo to give the title compound (18C) as a crude solid (1 g, 99.0%). LC-MS (ESI): m / z=202.1 [M+H] + .

[0377] Step 3 1-(Bromomethyl)-3-fluoro-4-methoxy-5-nitro-benzene (18D). To a solution of (3-fluoro-4-methoxy-5-nitro-phenyl)methanol (1 g, 4.97 mmol) and triphenylphosphine (2.61 g, 9.95 mmol) in anhydrous diethyl ether (30 mL) was added dropwise carbon tetrabromide (3.3 g, 9.95 mmol) in anhydrous diethyl ether (5 mL). The mixture was stirred overnight and then concentrated to a viscous oil. Silica gel chromatography afforded the title compound (18D) as a pale yellow solid (0.95 g, 73.07%). LC-MS (ESI): m / z=264.1 [M+H] +

[0378] Step 4: tert-butyl N-[(1R)-2-[(3-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (18E) Sodium hydride (144 mg, 3.61 mmol) was added portionwise to a stirred solution of tert-butyl N-(2-hydroxy-1-methyl-ethyl)carbamate (0.63 g, 3.61 mmol) in THF (15 mL) at 0 °C, the mixture was stirred at 0 °C for 10 minutes, and then 1-(bromomethyl)-3-fluoro-4-methoxy-5-nitro-benzene (18D) (0.95 g, 3.61 mmol) was added to the mixture at 0 °C. After 30 minutes, the mixture was quenched with cold water and extracted with ethyl acetate. The combined organic layers were washed with brine and dried (Na SO ), and the residue was purified by flash chromatography to give the title compound (18E) (0.63 g, 48.83%) as a brown solid. LC-MS (ESI): m / z = 359.1 [M+H] + .

[0379] Step 5: [(1R)-2-[(3-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium; 2,2,2-trifluoroacetate (18F) Trifluoroacetic acid (1.5 mL) was added to a solution of N-[2-[(3-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (18E) (0.63 g, 1.76 mmol) in DCM (5 mL), the mixture was stirred for 2 h, and the mixture was evaporated to dryness to give the title compound (18F) (0.6 g, 91.46%) as a brown liquid, which was used in the next step without further purification. LC-MS (ESI): m / z=259.2 [M+H] +

[0380] Step 6: tert-butyl N-[6-chloro-3-[[(1R)-2-[(3-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]-N-methyl-carbamate (18G) [(1R)-2-[(3-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium;2,2,2-trifluoroacetate (18F) (0.6 g, 1.6 mmol) was dissolved in DMF (10 mL), and HATU (0.91 g, 2.41 mmol), DIPEA (0.41 g, 3.2 mmol), and Intermediate 1 (0.52 g, 1.6 mmol) were added to the solution at room temperature. After 18 hours, the solution mixture was diluted with EA (50 mL), washed with water (2 × 50 mL) and brine (50 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography to give the title compound (18G) (545 mg, 59.89%) as a white solid. LC-MS (ESI): m / z = 567.2 [M+H] +

[0381] Step 7: tert-butyl N-[3-[[(1R)-2-[(3-amino-5-fluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]-6-chloro-imidazo[1,2-b]pyridazin-8-yl]carbamate (18H) tert-Butyl N-[6-chloro-3-[[2-[(2-fluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (18G) (545 mg, 0.96 mmol) was dissolved in ethanol (45 mL) and HO (15 mL), iron powder (540 mg, 9.62 mmol) and NH4Cl (310 mg, 5.77 mmol) were added to the solution, and the reaction mixture was then heated to 85 °C for 3 hours. After cooling to room temperature, the reaction mixture was filtered, the filtrate was removed in vacuo, and the residue was purified by flash chromatography (PE / EA = 2:1) to give the title compound (18H) (450 mg, 87.2%) as a white solid. LC-MS (ESI): m / z = 537.1 [M+H] +

[0382] Step 8: tert-Butyl ((7R,E)-3 5 -Fluoro-3 6-Methoxy-7-methyl-9-oxo-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphane-1 8 -yl)(methyl)carbamate (18I) To a solution of 18H (450 mg, 0.84 mmol) in 1,4-dioxane (100 mL) was added CsCO (820 mg, 2.51 mmol) and tert-Bu-Xphos-Pd (250 mg). The reaction mixture was stirred at 80 °C under N for 2 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product 18I (220 mg, 52.50%) as a white solid. LC-MS (ESI): m / z = 501.3 [M+H] + .

[0383] Process 9:(7R,E)-3 5 -Fluoro-3 6 -Methoxy-7-methyl-1 8 -(Methylamino)-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphan-9-one (18) A solution of (18I) (220 mg, 0.44 mmol) and trifluoroacetic acid (1 mL) in DCM (5 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was basified with NaHCO and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, evaporated, and the residue was purified by silica gel flash column chromatography to give product 18 (71 mg, 40.34%) as a white solid. 1H NMR(400MHz,CDCl3)δ 8.76(d,1H),8.20(s,1H),8.07(s,1H),6.87(s,1H),6.63-6.58(m,1H),6.40(s,1H),5.63(s,1H),4.67(d,1H),4.38(d,1H),4 .30-4.20(m,1H),4.05(d,3H),3.60-3.56(m,1H),3.48-3.38(m,1H),3.06(d,3H),1.29(d,3H).LC-MS(ESI):m / z=401.2[M+H] + . Example 19: [ka]

[0384] Step 1: 2,3-Difluoro-4-methoxy-5-nitro-benzaldehyde (19B) 2,3-Difluoro-4-methoxy-benzaldehyde (19A) (3 g, 17.43 mmol) was dissolved in concentrated sulfuric acid (18 mL) and cooled to -10 °C. Concentrated nitric acid (1.5 mL) in concentrated sulfuric acid (3 mL) was added dropwise over 10 min. After stirring below -10 °C for an additional 1 h, the mixture was poured onto crushed ice. The precipitate was collected by filtration and partitioned between dichloromethane (30 mL) and saturated sodium bicarbonate (30 mL). The organic layer was dried (NaSO) and evaporated in vacuo to give the title compound (19B) (3.1 g, 82.01%) as a white solid. LC-MS (ESI): m / z = 218.1 [M+H] +

[0385] Step 2: (2,3-Difluoro-4-methoxy-5-nitro-phenyl)methanol (19C) Sodium borohydride (1.08 g, 28.56 mmol) was added portionwise to a stirred solution of 2,3-difluoro-4-methoxy-5-nitro-benzaldehyde (19B) (3.1 g, 14.28 mmol) in methanol (60 mL) at 0 °C. After 2 h, methanol was removed in vacuo. The residue was treated with cold water and extracted with dichloromethane. The combined organic layers were washed with brine, dried (Na2SO4), and then evaporated in vacuo to give the title compound (19C) as a pale yellow solid (2.8 g, 89.51%). LC-MS (ESI): m / z = 220.1 [M+H] +

[0386] Step 3: 1-(Bromomethyl)-2,3-difluoro-4-methoxy-5-nitro-benzene (19D) Carbon tetrabromide (8.47 g, 25.56 mmol) in anhydrous diethyl ether (30 mL) was added dropwise to a stirred solution of (2,3-difluoro-4-methoxy-5-nitro-phenyl)methanol (19C) (2.8 g, 12.78 mmol) and triphephosphine (6.7 g, 25.56 mmol) in anhydrous diethyl ether (100 mL). The mixture was stirred overnight and then concentrated to a viscous oil. Silica gel chromatography with ethyl acetate (0-10%) in hexanes afforded the title compound (19D) as a pale yellow solid (2.12 g, 59.05%). LC-MS (ESI): m / z = 281.9 [M+H] +

[0387] Step 4: tert-butyl N[(1R)-2-[(2,3-difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (19E) Sodium hydride (92 mg, 2.31 mmol) was added portionwise to a stirred solution of tert-butyl N-[(1R)-2-hydroxy-1-methyl-ethyl]carbamate (0.405 g, 2.31 mmol) in THF (15 mL) at 0 °C, the mixture was stirred at 0 °C for 10 minutes, and then 1-(bromomethyl)-2,3-difluoro-4-methoxy-5-nitro-benzene (19D) (0.65 g, 2.31 mmol) was added to the mixture at 0 °C, and after 10 minutes, the mixture was treated with cold water and extracted with ethyl acetate. The combined organic layers were washed with brine and dried (Na SO ), and the residue was purified by flash chromatography to give the title compound (19E) (0.3 g, 34.48%) as a brown solid. LC-MS (ESI): m / z = 377.1 [M+H] +

[0388] Step 5: [(1R)-2-[(2,3-difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium; 2,2,2-trifluoroacetate (19F) Trifluoroacetic acid (1.5 mL) was added to a solution of tert-butyl N-[(1R)-2-[(2,3-difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamate (19E) (0.3 g, 0.8 mmol) in DCM (5 mL), the mixture was stirred for 2 hours, and the mixture was evaporated to dryness to give the title compound (19F) (0.28 g, 90.03%) as a brown liquid, which was used in the next step without further purification. LC-MS (ESI): m / z = 277.2 [M+H] +

[0389] Step 6: tert-butyl N-[6-chloro-3-[[(1R)-2-[(2,3-difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (19G) [(1R)-2-[(2,3-Difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]ammonium;2,2,2-trifluoroacetate (19F) (0.28 g, 0.71 mmol) was dissolved in DMF (5 mL), and HATU (0.41 g, 1.07 mmol), DIPEA (0.185 g, 1.43 mmol), and Intermediate 1 (0.24 g, 0.71 mmol) were added to the solution at room temperature. After 18 hours, the solution mixture was diluted with EA (50 mL), washed with water (2 × 50 mL) and brine (50 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography (PE / EA = 2:1) to give the title compound (19G) (0.18 g, 42.95%) as a white solid. LC-MS(ESI): m / z=585.2[M+H] +

[0390] Step 7: tert-butyl N-[3-[[(1R)-2-[(5-amino-2,3-difluoro-4-methoxy-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]-6-chloro-imidazo[1,2-b]pyridazin-8-yl]carbamate (19H) tert-Butyl N-[6-chloro-3-[[(1R)-2-[(2,3-difluoro-4-methoxy-5-nitro-phenyl)methoxy]-1-methyl-ethyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]carbamate (19G) (0.18 g, 0.3 mmol) was dissolved in ethanol (30 mL) and HO (10 mL), Fe powder (172 mg, 3.08 mmol) and NH4Cl (100 mg, 1.85 mmol) were added to the solution, and the reaction mixture was then heated to 85°C for 3 hours. After cooling to room temperature, the reaction was filtered, the filtrate was removed in vacuo, and the residue was purified by flash chromatography to give the title compound (19H) (80 mg, 47.05%) as a white solid. LC-MS (ESI): m / z = 555.2 [M+H] +

[0391] Step 8: tert-Butyl ((7R,E)-3 4 ,3 5-Difluoro-36-methoxy-7-methyl-9-oxo-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphane-1 8 -yl)(methyl)carbamate (19I) To a solution of 19H (80 mg, 0.14 mmol) in 1,4-dioxane (40 mL) was added CsCO (141 mg, 0.43 mmol) and tert-Bu-Xphos-Pd (50 mg). The reaction mixture was stirred at 80 °C under N for 2 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product 19I (42 mg, 47.05%) as a white solid. LC-MS (ESI): m / z = 519.3 [M+H] +

[0392] Process 9:(7R,E)-3 4 ,3 5 -difluoro-3 6 -Methoxy-7-methyl-1 8 -(Methylamino)-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphan-9-one A solution of 19I (42 mg, 0.081 mmol) and trifluoroacetic acid (0.3 mL) in DCM (4 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was basified with NaHCO and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, evaporated, and the residue was purified by silica gel flash column chromatography to give the product 19 (12 mg, 36.36%) as a white solid. 1H NMR(400MHz,CDCl3)δ 8.67(d,1H),8.14(dd,1H),8.08(s,1H),6.72(s,1H),6.58(s,1H),5.63(s,1H),4.71-4.60(m,2H),4.31-4.21 (m,1H),4.10(d,3H),3.61(dd,1H),3.46-3.39(m,1H),3.06(d,3H),1.31(d,3H).LC-MS(ESI):m / z=419.2[M+H] + . Example 20: [ka]

[0393] Step 1: tert-butyl N-[1-(hydroxymethyl)cyclopropyl]carbamate (20B) Triethylamine (4.93 g, 48.76 mmol) was added dropwise to a stirred solution of (1-aminocyclopropyl)methanol hydrochloride (20A) (2 g, 16.25 mmol) in THF (50 mL) at 0 °C. After stirring for 10 minutes, di-tert-butyl dicarbonate (7.09 g, 32.50 mmol) in THF (5 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred overnight at room temperature, and the solvent was removed in vacuo. The residue was diluted with ethyl acetate (60 mL), washed with water (2 × 60 mL) and brine (50 mL), dried over Na SO , and concentrated. The title compound (20B) (3 g, 100%) was then obtained as a white solid, which was used in the next step without further purification. 1 H NMR(400MHz,CDCl3)δ 5.05(s,1H),3.59(s,2H),2.40(s,1H),1.44(s,9H),0.83(m,4H).

[0394] Step 2: tert-butyl N-[1-[(4-methoxy-3-nitro-phenyl)methoxymethyl]cyclopropyl]carbamate (20C) Sodium hydride (480 mg, 12.02 mmol) was added portionwise to a stirred solution of tert-butyl N-[1-(hydroxymethyl)cyclopropyl]carbamate (20B) (1.5 g, 8.01 mmol) in THF (60 mL) at 0 °C, and the mixture was stirred at 0 °C for 30 min. 4-(bromomethyl)-1-methoxy-2-nitrobenzene (1.96 g, 8.01 mmol) was then added to the mixture at 0 °C, and the mixture was stirred at room temperature overnight. The mixture was treated with cold water (80 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine, dried over Na SO , and concentrated. The residue was then purified by flash chromatography to give the title compound (20C) (2.4 g, 85.40%) as a pale yellow solid. 1 H NMR(400MHz,CDCl3)δ 7.76(d,1H),7.46(dd,1H),7.02(d,1H),5.13(s,1H),4.46(s,2H),3.89(s,3H),3.44(s,2H),1.34(s,9H),0.81-0.66(m,4H).

[0395] Step 3: [1-[(4-Methoxy-3-nitro-phenyl)methoxymethyl]cyclopropyl]ammonium; 2,2,2-trifluoroacetate (20D) Trifluoroacetic acid (1.5 mL) was added to a solution of tert-butyl N-[1-[(4-methoxy-3-nitro-phenyl)methoxymethyl]cyclopropyl]carbamate (20C) (0.55 g, 1.56 mmol) in DCM (5 mL), the mixture was stirred overnight, and the mixture was evaporated to dryness to give the title compound (20D) (0.54 g, 94.57%) as a brown liquid, which was used in the next step without further purification. LC-MS (ESI): m / z = 253.2 [M+H] +

[0396] Step 4: tert-butyl N-[6-chloro-3-[[1-[(4-methoxy-3-nitro-phenyl)methoxymethyl]cyclopropyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]-N-methyl-carbamate (20E) [1-[(4-Methoxy-3-nitro-phenyl)methoxymethyl]cyclopropyl]ammonium; 2,2,2-trifluoroacetate (20D) (0.54 g, 1.47 mmol) was dissolved in DMF (10 mL), and HATU (0.84 g, 2.21 mmol), DIPEA (0.38 g, 2.95 mmol), and Intermediate 1 (0.1 g, 1.47 mmol) were added to the solution at room temperature. After 18 hours, the solution mixture was diluted with EA (50 mL), washed with water (2 × 50 mL) and brine (50 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography to give the title compound (20E) (0.52 g, 62.95%) as a pale solid. LC-MS (ESI): m / z = 561.3 [M+H] +

[0397] Step 5: tert-butyl N-[3-[[1-[(3-amino-4-methoxy-phenyl)methoxymethyl]cyclopropyl]carbamoyl]-6-chloro-imidazo[1,2-b]pyridazin-8-yl]-N-methyl-carbamate (20F) tert-Butyl N-[6-chloro-3-[[1-[(4-methoxy-3-nitrophenyl)methoxymethyl]cyclopropyl]carbamoyl]imidazo[1,2-b]pyridazin-8-yl]-N-methyl-carbamate (20E) (0.52 g, 0.93 mmol) was dissolved in ethanol (60 mL) and HO (15 mL). To this solution, iron powder (520 mg, 9.28 mmol) and NH4Cl (0.3 g, 5.57 mmol) were added. The reaction mixture was then heated to 85 °C for 3 h. After cooling to room temperature, the reaction mixture was filtered and the filtrate was removed in vacuo. The residue was purified by flash chromatography (PE / EA = 2:1) to give the title compound (20F) (0.32 g, 65.04%) as a white solid. LC-MS (ESI): m / z = 531.3 [M+H] +

[0398] Step 6: tert-butyl (E)-(6'-methoxy-9'-oxospiro[cyclopropane-1,7'-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphan-8'-yl)(methyl)carbamate (20G) To a solution of 20F (320 mg, 0.6 mmol) in 1,4-dioxane (40 mL) was added CsCO (590 mg, 1.81 mmol) and tert-Bu-Xphos-Pd (180 mg). The reaction mixture was stirred at 85 °C under N for 2 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product 20G (175 mg, 58.72%) as a white solid. LC-MS (ESI): m / z = 495.3 [M+H] +

[0399] Step 7: (E)-6'-Methoxy-8'-(methylamino)spiro[cyclopropane-1,7'-5-oxa-2,8-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzenacyclononaphan-9'-one (20H) A solution of 20G (175 mg, 0.35 mmol) and p-toluenesulfonic acid monohydrate (101 mg, 0.53 mmol) in DCM (4 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was basified with NaHCO and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, evaporated, and the residue was purified by silica gel flash column chromatography to give product 20 (35 mg, 25.17%) as a white solid. 1H NMR(400MHz,CDCl3)δ 8.99(s,1H),8.36(d,1H),7.97(s,1H),6.90-6.73(m,3H),6.34(s,1H),5.63(s,1H),4.60(s,2H) ,3.93(s,3H),3.49(s,2H),3.04(d,3H),1.82(q,2H),0.68(q,2H).LC-MS(ESI):m / z=395.2[M+H] + Example 21: [ka]

[0400] Step 1: tert-butyl (4-(5-methoxy-6-nitro-1H-indazol-1-yl)butan-2-yl)carbamate A solution of 5-methoxy-6-nitro-1H-indazole (1.0 g, 5.18 mmol), tert-butyl (4-bromobutan-2-yl)carbamate (1.7 g, 6.73 mmol), and K2CO3 (1.4 g, 10.36 mmol) in DMF (30 mL) was stirred at 60 °C overnight. After completion of the reaction, the reaction was cooled in an ice bath, diluted with EA (100 mL), and the solution was extracted with water (3 × 20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by column chromatography (PE / EtOAc = 3 / 1) to give the desired product (0.8 g, 42%) as a white solid. LM-MS: m / z = 365.4 [M+H] +

[0401] Step 2: 4-(5-methoxy-6-nitro-1H-indazol-1-yl)butan-2-amine tert-Butyl(4-(5-methoxy-6-nitro-1H-indazol-1-yl)butan-2-yl) A solution of carbamate (0.7 g, 1.92 mmol) and trifluoroacetic acid (0.5 mL) in DCM (4 mL) was stirred at room temperature for 2 hours. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was quenched with NaHCO3 and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and evaporated to give the crude product, which was purified by column chromatography (PE / EtOAc = 3 / 1) to give the desired product (0.4 g, 79%) as a white solid. LM-MS: m / z = 265.3 [M+H] +

[0402] Step 3: tert-butyl (6-chloro-3-((4-(5-methoxy-6-nitro-1H-indazol-1-yl)butan-2-yl)carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate 4-(5-Methoxy-6-nitro-1H-indazol-1-yl)butan-2-amine (0.2 g, 0.76 mmol) was dissolved in DCM (5 mL), and to this solution was added HATU (0.58 g, 1.515 mmol), DIPEA (0.15 g, 1.14 mmol), and 8-((tert-butoxycarbonyl)(methyl)amino)-6-chloroimidazo[1,2-b]pyridazine-3 -carboxylic acid (0.25 g, 0.76 mmol) was added at room temperature. The mixture was stirred at room temperature for 1 h, then diluted with EA (20 mL), washed with water (10 mL) and brine (10 mL), dried over Na2SO4 and concentrated. The crude product was purified by flash chromatography (PE / EtOAc = 3 / 1) to give the title compound (0.3 g, 69%) as a white solid. LM-MS: m / z = 574.0 [M+H] +

[0403] Step 4: tert-butyl (3-((4-(6-amino-5-methoxy-1H-indazol-1-yl)butan-2-yl)carbamoyl-6-chloroimidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate ert-butyl (6-chloro-3-((4-(5-methoxy-6-nitro-1H-indazol-1-yl)butan-2-yl) Carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (0.3 g, 0.52 mmol) and NH4Cl (330 mg, 6.24 mmol) were dissolved in MeOH (5 mL) at room temperature, and Zn powder (405 mg, 6.24 mmol) was added to the solution, and the reaction mixture was then stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was filtered, and the filtrate was removed in vacuo. The residue was purified by flash chromatography to give the title compound (0.27 g, 96%) as a white solid. LM-MS: m / z=543.0 [M+H] +

[0404] Step 5: tert-Butyl (E)-(3 5 -Methoxy-6-methyl-8-oxo-3 1 H-2,7-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(6,1)-indazolacyclooctaphane-1 8 -yl)(methyl)carbamate ert-butyl(3-((4-(6-amino-5-methoxy-1H-indazol-1-yl) To a solution of (butan-2-yl)carbamoyl)-6-chloroimidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (270 mg, 0.5 mmol) in 1,4-dioxane (20 mL) was added CsCO (325 mg, 1.0 mmol) and tert-Bu-Xphos-Pd (120 mg). The reaction mixture was stirred at 80 °C under N for 3 h. After cooling to room temperature, the reaction was filtered, the solvent was removed, and the residue was purified by silica gel flash column chromatography to give the desired compound (150 mg, 59%) as a white solid. LM-MS: m / z = 507.7 [M+H] +

[0405] Process 6:(E)-3 5 -Methoxy-6-methyl-1 8 -(methylamino)-3 1 H-2,7-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(6,1)-indazolacyclooctaphan-8-one tert-butyl(E)-(3 5 -Methoxy-6-methyl-8-oxo-3 1 H-2,7-diaza-1(6,3) -Imidazo[1,2-b]pyridazina-3(6,1)-indazolacyclooctaphane-1 8 A solution of 21-yl)(methyl)carbamate (0.15 g, 0.3 mmol) and trifluoroacetic acid (0.2 mL) in DCM (4 mL) was stirred at room temperature for 2 h. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was quenched with NaHCO3 and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was directly purified by preparative HPLC to give the desired product 21 (125 mg, yield: 42%) as a brown solid. LM-MS: m / z = 407.5 [M+H] + . 1 H NMR(400MHz,CD3OD)δ 8.88(s,1H),7.93(s,1H),7.85(s,1H),7.22(s,1H),6.19(s,1H),4.61-4.48(m,3H),4.00(s,3H),3.04(s,3H),2.14(d,2H),1.01(d,3H). Example 22: [ka]

[0406] Step 1: tert-Butyl ((1s,3s)-3-(hydroxycyclobutyl)carbamate (22B) Triethylamine (4.93 g, 48.76 mmol) was added dropwise to a stirred solution of (1s,3s)-3-hydroxycyclobutan-1-aminium chloride (22A) (2 g, 16.25 mmol) in THF (50 mL) at 0 °C. After stirring for 10 min, di-tert-butyl dicarbonate (7.09 g, 32.50 mmol) in THF (5 mL) was added dropwise to the mixture at 0 °C. The mixture was stirred at room temperature overnight, and the solvent was removed in vacuo. The residue was diluted with ethyl acetate (60 mL), washed with water (2 × 60 mL) and brine (50 mL), dried over Na SO , and concentrated. The title compound (22B) (3 g, 100%) was then obtained as a colorless oil, which was used in the next step without further purification. LC-MS(ESI): m / z=188.1[M+H] + Step 2: tert-butyl ((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamate (22C) Sodium hydride (577 mg, 14.43 mmol) was added portionwise to a stirred solution of tert-butyl ((1S,3S)-3-hydroxycyclobutyl)carbamate (22B) (1.5 g, 8.02 mmol) in THF (60 mL) at 0° C., and the mixture was stirred at 0° C. for 30 minutes. To the mixture was then added 4-(bromomethyl)-1-methoxy-2-nitrobenzene (0.69 g, 2.62 mmol) at 0° C., and the mixture was stirred at room temperature overnight. The mixture was treated with cold water (80 mL) and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over NaSO, and concentrated. The residue was then purified by flash chromatography to give the title compound (22C) (0.2 g, 21.30%) as a white solid. LC-MS (ESI): m / z=353.1 [M+H] + Step 3: (1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutane-1-aminium chloride (22D) To a solution of tert-butyl ((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamate (222C) (0.55 g, 2.79 mmol) in DCM (5 mL) was added trifluoroacetic acid (1.5 mL), the mixture was stirred at room temperature overnight, and the mixture was evaporated to dryness to give the title compound (22D) (0.39 g, 100%) as a white solid, which was used in the next step without further purification. LC-MS (ESI): m / z=253.1 [M+H] +

[0407] Step 4: tert-butyl tert-butyl (6-chloro-3-(((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (22E) (1s,3s)-3-((4-Methoxy-3-nitrobenzyl)oxy)cyclobutan-1-aminium chloride (22D) (200 mg, 0.79 mmol) was dissolved in DMF (5 mL), and HATU (360 mg, 0.94 mmol), DIPEA (180 mg, 1.18 mmol), and Intermediate 1 (257 mg, 0.79 mmol) were added to the solution at room temperature. The mixture was stirred at room temperature for 18 hours, then diluted with EA (50 mL), washed with water (2 × 50 mL) and brine (50 mL), dried over NaSO, and concentrated. The crude product was purified by flash chromatography (PE / EA = 2:1) to give the title compound (22E) (400 mg, 90.00%) as a white solid. LC-MS (ESI): m / z = 561.2 [M+H] +

[0408] Step 5: tert-butyl (6-chloro-3-(((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (22F) (6-chloro-3-(((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (22E) (280 mg, 0.5 mmol) was dissolved in ethanol (9 mL) and HO (3 mL). To this solution was added iron powder (560 mg, 10 mmol) and NH4Cl (530 mg, 10 mmol). The reaction mixture was then heated to 85°C for 3 h. After cooling to room temperature, the reaction was filtered and the filtrate was removed in vacuo. The residue was purified by flash chromatography to give the title compound (22H) (200 mg, 75.47%) as a white solid. LC-MS (ESI): m / z = 531.2 [M+H] + .

[0409] Step 6: tert-Butyl ((6 1 s,6 3 s,E)-3 6 -Methoxy-8-oxy-5-oxa-2,7-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzena-6(1,3)-cyclobutanacyclooctaphane-18-yl)(methyl)carbamate (22G) To a solution of (6-chloro-3-(((1s,3s)-3-((4-methoxy-3-nitrobenzyl)oxy)cyclobutyl)carbamoyl)imidazo[1,2-b]pyridazin-8-yl)(methyl)carbamate (22F) (265 mg, 0.5 mmol) in 1,4-dioxane (10 mL) was added CsCO (326 mg, 1.0 mmol) and tert-Bu-Xphos-Pd (35 mg, 0.04 mmol). The reaction mixture was stirred at 80 °C under N for 3 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel flash column chromatography to give the product compound (22G) (50 mg, 20.24%) as a white solid. LC-MS (ESI): m / z = 495.1 [M+H] +

[0410] Step 7:6 1 s,6 3s,E)-36-Methoxy-1 8 -(Methylamino)-5-oxa-2,7-diaza-1(6,3)-imidazo[1,2-b]pyridazina-3(1,3)-benzena-6(1,3)-cyclobutanacyclooctaphan-8-one (22) tert-Butyl tert-Butyl ((6 1 s,6 3 s,E)-3 6 A solution of 22G (50 mg, 1.02 mmol) and p-toluenesulfonic acid monohydrate (50 mg, 0.29 mol) in DCM (4 mL) was stirred at room temperature for 2 h. The solvent was evaporated, and the crude product was partitioned between water and DCM. The aqueous layer was basified with NaHCO3 and extracted with DCM. The combined organic layers were evaporated, and the residue was purified by TLC to give 22 (2 mg, 5.01%). LC-MS (ESI): m / z = 395.1 [M+H]. + . 1 H NMR(400MHz,DMSO-d6)δ 9.15(d,1H),8.29(s,1H),8.18(d,1H),7.82(s,1H),7.38(d,1H),7.00(d,1H),6.85(dd,1H),6.23(d,1 H),4.50(s,2H),4.34(dd,1H),4.21(s,1H),3.88(s,3H),2.89(d,3H),2.72-2.65(m,2H),1.75(d,2H). Example 24: [ka]

[0411] Step 1: Example 24b To a solution of Example 24a (10.0 g, 60.24 mmol, 1.0 equiv.) in AcOH (150 mL) was added dropwise a solution of NaNO (4.99 g, 72.29 mmol, 1.2 equiv.) in HO (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. Water (100 mL) was then added to the mixture, which was stirred for 30 minutes. The precipitated solid was collected by filtration and washed with HO and MTBE. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 24b (3.9 g, 36.6% yield), as a yellow solid. LCMS [M+1] + =178.2.

[0412] Step 2: Example 24c To a solution of Example 24b (3.9 g, 22.03 mmol, 1.0 equiv) in CHCN (50 mL) was added CHI (15.6 g, 110.17 mmol, 5.0 equiv) and KCO (7.6 g, 55.08 mmol, 2.5 equiv). The reaction mixture was stirred at 80 °C for 16 h. The solvent was concentrated, and the crude was purified by silica gel flash column chromatography to give the desired product, Example 24c (3.17 g, 75.3% yield), as a brown solid and its isomer (200 mg) as a brown solid. LCMS [M+1] + =192.2.Example 24c: 1 H NMR(300MHz,DMSO-d6)δ 8.21(d,1H),8.05(s,1H),7.79(s,1H),4.33(s,3H),2.51(s,3H).Isomers: 1 H NMR(300MHz,DMSO-d6)δ 8.04(s,1H),7.96(s,1H),7.79(s,1H),4.23(s,3H),2.51(s,3H).

[0413] Step 3: Example 24d A solution of Example 24c (500 mg, 2.62 mmol, 1.0 equiv) in CCl4 (12 mL) was heated to 80°C, and NBS (559 mg, 3.14 mmol, 1.2 equiv) and AIBN (429 mg, 2.62 mmol, 1.0 equiv) were added. The reaction mixture was stirred at 80°C for 4 hours. After cooling to room temperature, the reaction mixture was concentrated, and the crude was purified by silica gel flash column chromatography to give the desired product, Example 24d (577 mg, 81.7% yield), as a yellow solid. 1 H NMR(300MHz,DMSO-d6)δ 8.78(s,1H),8.39(d,1H),8.36(d,1H),4.95(s,2H),4.28(s,3H).

[0414] Step 4: Example 24f To a solution of Example 24e (681 mg, 3.89 mmol, 2.0 equiv) in THF (10 mL) was added NaH (117 mg, 60% in mineral oil, 2.92 mmol, 1.5 equiv) at 0 °C. After stirring for 30 min, Example 24d (525 mg, 1.94 mmol, 1.0 equiv) was added to the mixture, which was stirred at room temperature for an additional 2 h. The mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel flash column chromatography to give the desired product, Example 24f (306 mg, 43.2% yield), as a yellow solid. LCMS [M+1-56] + =309.2.

[0415] Step 5: Example 24g Example 24f (306 mg, 0.84 mmol, 1.0 equiv) was dissolved in MeOH (10 mL) and, under N protection, 10% Pd / C (200 mg) was added slowly in several portions. The system was evacuated and then refilled with hydrogen. The mixture was stirred at room temperature under a H balloon for 1 hour. The reaction mixture was filtered through a Celite pad and the filtrate was concentrated. The residue was purified by preparative TLC to give the desired product, Example 24g (150 mg, 53.3% yield), as a pale yellow solid. LCMS [M+1+22] + =357.3.

[0416] Step 6: Example 24h To a solution of Example 24g (130 mg, 0.39 mmol, 1.0 equiv) in DCM (6 mL) was added HCl / dioxane (2 mL, 4 M in dioxane). The reaction solution was stirred at room temperature for 0.5 hours and concentrated to give the desired product, Example 24h (240 mg, crude) as a yellow solid. LCMS [M+1] + =235.3.

[0417] Step 7: Example 24j To a solution of Example 24i (173 mg, 0.53 mmol, 1.0 equiv) in DCM (10 mL) was added DIEA (545 mg, 4.23 mmol, 8.0 equiv) and HATU (221 mg, 0.58 mmol, 1.1 equiv). After stirring for 30 min, Example 24h (215 mg, 0.79 mmol, 1.5 equiv) was added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed and the crude was purified by preparative TLC (EtOAc) to give the desired product, Example 24j (250 mg, 87.0% yield), as a yellow oil. LCMS [M+1] + =543.3.

[0418] Step 8: Example 24k To a solution of Example 24j (150 mg, 0.28 mmol, 1.0 equiv) in dioxane (20 mL) was added CsCO (180 mg, 0.55 mmol, 2.0 equiv) and tert-Bu-Xphos-Pd (25 mg, 0.028 mmol, 0.1 equiv). The reaction mixture was stirred at 80 °C under N for 16 h. The reaction mixture was concentrated and purified by preparative TLC to give the desired product, Example 24k (50 mg, 35.7% yield), as a yellow solid. LCMS [M+1] + =507.3.

[0419] Step 9: Example 24 To a solution of Example 24k (45 mg, 0.089 mmol, 1.0 equiv) in DCM (3 mL) was added HCl / dioxane (1 mL, 4 M in dioxane). The reaction solution was stirred at room temperature for 1 hour, and the solvent was concentrated. The crude product was dissolved in MeOH, and Na2CO3 was added. The mixture was stirred at room temperature for 10 minutes, then filtered. The filtrate was concentrated, and the residue was purified by preparative TLC to give the desired product, Example 24 (20.0 mg, 55.4% yield), as an off-white solid. LCMS [M+1] + =407.3. 1 H NMR(300MHz,DMSO-d6)δ 9.19(s,1H),8.95(d,1H),8.32(s,1H),7.95(s,1H),7.83(s,1H),7.44(d,1H),7.20(s,1H),6.36(s,1H),4.73( d,1H),4.45(d,1H),4.21(s,3H),4.08-3.96(m,1H),3.48(d,1H),3.26-3.20(m,1H),2.90(d,3H),1.11(d,3H). Example 25: [ka]

[0420] Step 1: Example 25c To a solution of Example 25b (2.3 g, 13.4 mmol) in THF (40 mL) was added NaH (0.9 g, 60% in mineral oil, 22.4 mmol) in several portions at 0 °C. After stirring for 10 minutes, a solution of Example 25a (2.2 g, 8.9 mmol) in THF (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 3 hours. The reaction was quenched with saturated aqueous NH4Cl (20 mL) at 0 °C and extracted with EtOAc (50 mL × 2). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 25c (2.1 g, 69.4% yield), as a yellow solid. LCMS [M+1] + =341.3.

[0421] Step 2: Example 25d Example 25c (1.1 g, 3.2 mmol) was dissolved in MeOH (50 mL) and, under N protection, 10% Pd / C (110 mg) was added in portions. The system was evacuated and then refilled with hydrogen. The mixture was stirred at room temperature under a H balloon for 1 hour and then filtered. The filtrate was concentrated, and the crude product was purified by silica gel flash column chromatography to give the desired product, Example 25d (850 mg, 85.7% yield), as a colorless oil. LCMS [M+1] + =311.3.

[0422] Step 3: Example 25e To a solution of Example 25d (840 mg, 2.7 mmol) in DCM (5 mL) and MeOH (1 mL) was added HCl / dioxane (1 mL, 4 M in dioxane, 4 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated in vacuo to give the desired product, Example 25e (800 mg, crude), as a white solid. LCMS [M+1] + =211.2.

[0423] Step 4: Example 25g To a solution of Example 25f (607 mg, 1.9 mmol) in DCM (30 mL) was added DIEA (1.92 g, 14.9 mmol) and HATU (1.06 g, 2.8 mmol). After stirring for 0.5 h, Example 25e (790 mg, 2.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed, and the residue was purified by silica gel flash column chromatography to give the desired product, Example 25g (310 mg, 21.4% yield), as a yellow solid. LCMS [M+1] + =519.3.

[0424] Step 5: Example 25h To a solution of Example 25g (300 mg, 0.6 mmol) in dioxane (50 mL) was added CsCO (377 mg, 1.2 mmol) and tert-Bu-Xphos-Pd (154 mg, 0.2 mmol). The reaction mixture was stirred at 90 °C under N for 6 h. After cooling to room temperature, the solvent was removed and the residue was purified by silica gel column chromatography to give the product Example 25h (110 mg, 39.4% yield) as a yellow solid. LCMS [M+1] + =483.2.

[0425] Step 6: Example 25 To a solution of Example 25h (110 mg, 0.23 mmol) in DCM (5 mL) was added HCl / dioxane (1 mL, 4 M in dioxane, 4 mmol). The reaction mixture was stirred at room temperature for 5 hours and then concentrated in vacuo. The residue was dissolved in MeOH (5 mL) and basified with NaHCO3 (pH = 8). The precipitate was filtered and the filtrate was concentrated. The residue was purified by preparative TLC to give the desired product Example 25 (57.3 mg, 65.7% yield) as an off-white solid. LCMS [M+1] + =383.2. 1 H NMR(300MHz,DMSO-d6)δ 8.92(s,1H),8.36(d,1H),8.24(d,1H),8.11(s,1H),7.81(d,1H),6.99(d,1H),6.92(d,1H),5.94(s,1H) ,4.57(d,1H),4.40(d,1H),3.94-3.83(m,4H),3.47(d,1H),3.29-3.25(m,1H),2.92(d,3H),1.14(d,3H). Example 26: [ka]

[0426] Step 1: Example 26b To a solution of Example 26a (30.0 g, 179.0 mmol) in CCl (150 mL) was added BPO (4.4 g, 17.9 mmol) and NBS (38.2 g, 216.0 mmol). The reaction mixture was stirred at 100 °C overnight, then diluted with DCM, washed with water, and dried over anhydrous NaSO. The solution was concentrated under reduced pressure to give the crude residue, Example 26b (37.0 g, 84.4% yield), as a yellow solid, which was used directly in the next step without further purification. LCMS [M+1] + =246.0. 1 H NMR (400 MHz, chloroform-d) δ 7.87 (d, 1H), 7.57 (dd, 1H), 7.07 (d, 1H), 4.46 (s, 2H), 3.96 (d, 3H).

[0427] Step 2: Example 26d To a solution of Example 26b (2.4 g, 9.8 mmol) in THF (20 mL) was added NaH (400 mg, 60% in mineral oil, 10.0 mmol) at 0° C. The reaction mixture was warmed to room temperature and stirred at room temperature for 0.5 h. Example 26c (1.7 g, 9.7 mmol) was then added, and the mixture was stirred at room temperature for 6 h. The reaction mixture was quenched with saturated NH4Cl (aq), extracted with EtOAc, and dried over anhydrous Na2SO4. The solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give Example 26d (3.3 g, 96.8% yield) as a yellow solid. LCMS [M+1-100] + =241.1.

[0428] Step 3: Example 26e A solution of Example 26d (688 mg, 2.0 mmol) and 10% Pd / C (34 mg) in MeOH (10 mL) was stirred at room temperature for 2 hours under 1 atmosphere of H2. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue, Example 26e (640 mg, quantitative yield), was obtained as a yellow solid and used directly in the next step. LCMS [M-174] + =136.1

[0429] Step 4: Example 26f To a solution of Example 26e (crude 550 mg, 1.77 mmol) in DCM (10 mL) was added TFA (2.0 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was treated with EtOAc (30 mL) to give the crude product Example 26f (340 mg, quantitative yield) as a white solid. LCMS [M-74] + =137.1.

[0430] Step 5: Example 26h To a solution of Example 26f (crude 300 mg, 1.42 mmol), Example 26g (464 mg, 1.42 mmol), and DIPEA (916 mg, 7.1 mmol) in DCM (10 mL) was added HATU (538 mg, 1.42 mmol). The reaction mixture was stirred at room temperature for 1 hour. EtOAc (40 mL) was then added to the reaction mixture, which was washed with brine (20 mL x 2), dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 26h (600 mg, 81.4% yield), as a white solid. LCMS [M+1] + =520.2.

[0431] Step 6: Example 26i To a mixture of Example 26h (330 mg, 0.97 mmol), CsCO (652 mg, 2.0 mmol) in dioxane (10 mL) was added tert-t-Bu-Xphos-Pd (89 mg, 0.1 mmol). The mixture was degassed with N three times and stirred at 80 °C for 3 h. The reaction mixture was then diluted with DCM, washed with water, dried over anhydrous NaSO, and concentrated under reduced pressure to give crude Example 26i (400 mg, crude yield >100%) as a white solid, which was used in the next step without further purification. LCMS [M+1] + =484.2

[0432] Step 7: Example 26: To a solution of Example 26i (400 mg, 0.82 mmol) in DCM (4 mL) was added TFA (1.0 mL) and stirred at room temperature for 1 hour. The mixture was concentrated, and the residue was purified by preparative HPLC to give the desired product, Example 26 (18.3 mg, 5.8% yield over two steps), as a white solid. LCMS [M+1] + =384.1. 1 H NMR(400MHz,DMSO-d6)δ 9.11(s,1H),8.60-8.54(m,1H),8.10(s,1H),8.04(d,1H),7.89(d,1H),7.71(s,1H),5.90(s,1H),4.5 3(d,1H),4.43(d,1H),3.94(s,3H),3.86(s,1H),3.46(d,1H),3.25(s,1H),2.89(d,3H),1.11(d,3H). Example 27: [ka]

[0433] Step 1: Example 27b To a solution of Example 27a (30.0 g, 277.8 mmol, 1.0 equiv.), NaCO (20.6 g, 194.5 mmol, 0.7 equiv.) in HO (150 mL) was added a solution of KI (59.9 g, 361.1 mmol, 1.3 equiv.) and I (56.4 g, 222.2 mmol, 0.8 equiv.) in HO (50 mL) at 100 °C, which was stirred for 16 h. After cooling to room temperature, the reaction mixture was quenched with NaSO (35.0 g, 277.8 mmol, 1.0 equiv.) and extracted with DCM (300 mL × 2). The combined organic layers were washed with brine, dried over NaSO, and concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 27b (8.4 g, 12.9% yield) as a yellow solid. LCMS[M+1] + =235.1

[0434] Step 2: Example 27c To a solution of Example 27b (7.0 g, 50.7 mmol, 1.0 equiv.) in dioxane (50 mL), BocO (33.2 g, 152.1 mmol, 3.0 equiv.) was added and stirred at 100° C. for 16 hours. The reaction mixture was concentrated, and the residue was purified by silica gel flash column chromatography to give the product Example 27c (3.5 g, 35% yield) as a white solid. LCMS [M+1] + =335.1.

[0435] Step 3: Example 27d To a solution of Example 27c (3.5 g, 10.5 mmol, 1.0 equiv.) and MeONa (2.82 g, 52.25 mmol, 5.0 equiv.) in MeOH (30 mL), CsCO (10.2 g, 21.0 mmol, 2.0 equiv.), CuI (199 mg, 1.05 mmol, 0.1 equiv.), and L-proline (343 mg, 2.1 mmol, 0.2 equiv.) were added. The reaction mixture was stirred at 60 °C under N protection for 8 hours. The reaction mixture was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 27d (750 mg, 30.1% yield) as a white solid. LCMS [M+1] + =239.3.

[0436] Step 4: Example 27e To a solution of Example 27d (550 mg, 2.3 mmol, 1.0 equiv) in DCM (10 mL) at 0 °C (ice-water bath), m-CPBA (596 mg, 3.45 mmol, 1.5 equiv) was added portionwise. After the addition, the reaction was stirred at room temperature for 1 h. The solution was quenched with NaSO (150 mg, 1.15 mmol, 0.5 equiv) and extracted with DCM (30 mL × 2). The combined organic layers were washed with brine, dried over NaSO, and concentrated to give Example 27e (550 mg, 93.8% yield) as a yellow solid. LCMS [M+1] + =255.3.

[0437] Step 5: Example 27f A solution of Example 27e (400 mg, 1.65 mmol, 1.0 equiv) in AcO (10 mL) was stirred at 100° C. for 1 h. The mixture was concentrated to give the crude product Example 27f (550 mg, quantitative yield) as a brown oil. LCMS [M+1] + =297.3.

[0438] Step 6: Example 27g To a solution of Example 27f (450 mg, 1.52 mmol, 1.0 equiv) in MeOH (15 mL) and H2O (5 mL) was added K2CO3 (418.2 mg, 3.04 mmol, 2.0 equiv) at 0 °C. The mixture was stirred for 2 h at 50 °C. After the reaction was complete, the mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the desired product, Example 27g (250 mg, 64.6% yield), as a white solid. LCMS [M+1] + =255.2.

[0439] Step 7: Example 27h To a solution of Example 27g (230 mg, 0.90 mmol, 1.0 equiv.) and CBr4 (597 mg, 1.80 mmol, 2.0 equiv.) in DCM (15 mL) was added PPh3 (355 mg, 1.35 mmol, 1.5 equiv.) in DCM (5 mL) at 0 °C, and the mixture was stirred at room temperature for 1 h under N2 protection. The mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the product Example 27h (150 mg, 52.7% yield) as a yellow oil. LCMS [M+1] + =317.2.

[0440] Step 8: Example 27j To a solution of Example 27i (165.6 mg, 0.94 mmol, 1.5 equiv) in THF (5 mL) was added NaH (75.7 mg, 60% in mineral oil, 1.89 mmol, 3.0 equiv) in several portions at 0 °C. After stirring for 0.5 h, a solution of Example 27h (200 mg, 0.63 mmol, 1.0 equiv) in THF (1 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1.5 h. The reaction was quenched with saturated aqueous NH4Cl (10 mL) at 0 °C and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash column chromatography to give the desired product, Example 27j (105 mg, 40.4% yield), as a pale yellow solid. LCMS [M+1] + =412.4. Step 9: Example 27k To a solution of Example 27j (105 mg, 0.25 mmol, 1.0 equiv) in DCM (15 mL) was added HCl / dioxane (0.2 mL, 4 mol / L in dioxane) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated in vacuo to give the desired product, Example 27k (150 mg, quantitative yield) as a white solid. LCMS [M+1] + =212.3.

[0441] Step 10: Example 27m To a solution of Example 27l (121 mg, 0.37 mmol, 1.0 equiv) and DIEA (239 mg, 1.85 mmol, 5.0 equiv) in DCM (30 mL) was added HATU (167 mg, 0.44 mmol, 1.2 equiv). After stirring for 10 minutes, Example 27k (crude 105 mg, 0.37 mmol, 1.0 equiv) was added, and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give the product Example 27m (65 mg, 33.8% yield) as a white solid. LCMS [M+1] + =520.3.

[0442] Step 11: Example 27n To a solution of Example 27m (60 mg, 0.12 mmol, 1.0 equiv.) in dioxane (2 mL) was added CsCO (75.1 mg, 0.24 mmol, 2.0 equiv.) and tert-Bu-XphosPd (10.2 mg, 0.012 mmol, 0.1 equiv.). The reaction mixture was stirred under N at 80° C. for 3 hours. The reaction solution was filtered, and the filtrate was concentrated in vacuo. The crude product was purified by preparative TLC to give the desired product, Example 27n (25 mg, 44.7% yield), as a white solid. LCMS [M+1] + =484.4.

[0443] Step 12: Example 27 To a solution of Example 27n (25 mg, 0.052 mmol, 1.0 equiv) in DCM (2 mL) was added HCl / dioxane (0.2 mL, 4 mol / L dioxane) at 0° C., and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated in vacuo. The crude product was dissolved in MeOH, and Na2CO3 (excess) was added. The resulting mixture was stirred at room temperature for 10 minutes, and the precipitate was filtered. The filtrate was concentrated, and the residue was purified by preparative TLC to give the desired product, Example 27 (7.2 mg, 36.4% yield), as a white solid. LCMS [M+1] + =384.3. 1 H NMR(300MHz,DMSO-d6)δ 9.31(s,1H),8.67(s,1H),8.25(d,1H),8.20(d,1H),8.02-8.04(m,1H),6.13(s,1H),4.62(d,2H),4.47( d,2H),3.98(s,3H),3.89-3.96(m,1H),3.54-3.62(m,1H),3.32-3.45(m,1H),2.93(d,3H),1.19(d,3H). Example 28: [ka]

[0444] Step 1: Example 28b To a solution of Example 28a (20.0 g, 0.12 mol, 1.0 equiv.) in CCl4 (400 mL) was added NBS (72.4 g, 0.41 mol, 3.5 equiv.) and AIBN (13.4 g, 0.08 mol, 0.7 equiv.). The reaction mixture was stirred at 80 °C for 16 h. After cooling to room temperature, the solid was filtered and the filtrate was concentrated. The residue was purified by silica gel flash column chromatography to give the product Example 28b (15.1 g, 52% yield) as a yellow solid. LCMS [M+1] + =251.2.

[0445] Step 2: Example 28d To a solution of Example 28c (12.7 g, 72.5 mmol, 1.2 equiv.) in THF (400 mL) was added NaH (2.9 g, 60% in mineral oil, 72.5 mmol, 1.2 equiv.) in several portions at 0 °C. The mixture was stirred at the same temperature for 5 minutes, and then Example 28b (15.1 g, 60.4 mmol, 1.0 equiv.) in THF (50 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour. The reaction was quenched with H2O (100 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel chromatography to give the desired product, Example 28d (5.2 g, 25% yield), as a yellow oil. LCMS [M+1] + =346.3.

[0446] Step 3: Example 28e To a solution of Example 28d (5.1 g, 14.7 mmol, 1.0 equiv.) in t-BuOH / HO (100 mL / 30 mL) was added NaOH (2.9 g, 73.7 mmol, 5.0 equiv.). The mixture was stirred at 80° C. for 16 hours. After cooling to room temperature, the mixture was acidified with 0.2 M aqueous HCl and then extracted with a mixed solvent of DCM / MeOH (200 mL×3, v / v=10 / 1). The combined organic layer was washed with brine, dried over NaSO, and concentrated. The residue was purified by silica gel chromatography to give the desired product, Example 28e (650 mg, 14% yield), as a yellow solid. LCMS [M+1] + =328.3.

[0447] Step 4: Example 28g To a solution of Example 28e (600 mg, 1.84 mmol, 1.0 equiv.) and Example 28f (580 mg, 3.67 mmol, 2.0 equiv.) in DMF (12 mL) was added CuI (348.6 mg, 1.84 mmol, 1.0 equiv.), 1,10-phenanthroline (182 mg, 0.92 mmol, 0.5 equiv.), and KPO (778 mg, 3.67 mmol, 2.0 equiv.). The mixture was stirred under N at 110 °C for 16 h. The reaction solution was diluted with EtOAc (100 mL), washed with brine (100 mL × 3), dried over NaSO, and concentrated. The residue was purified by silica gel chromatography to give the desired product, Example 28g (120 mg, 16.2% yield), as a yellow solid. LCMS [M+1] + =405.3.

[0448] Step 5: Example 28h To a solution of Example 28g (115 mg, 0.284 mmol, 1.0 equiv) in EtOH (2.2 mL) and water (0.7 mL) was added Zn (92.5 mg, 1.423 mmol, 5.0 equiv) and NH₄Cl (76.8 mg, 1.423 mmol, 5.0 equiv). The reaction mixture was stirred at 80°C for 1 h. After cooling to room temperature, the mixture was filtered and the filtrate was concentrated. The crude product was purified by silica gel flash column chromatography to give the product Example 28h (85 mg, 80% yield) as a yellow solid. LCMS [M+1] + =375.3.

[0449] Step 6: Example 28i To a solution of Example 28h (80 mg, 0.214 mmol, 1.0 equiv) in DCM (1 mL) was added HCl / dioxane (0.3 mL, 4 M in dioxane), which was stirred at room temperature for 1 hour. After the reaction was complete, the solvent was concentrated to give Example 28i (70 mg, crude) as a yellow solid. The crude was used directly in the next step without further purification. LCMS [M+1] + =275.3.

[0450] Step 7: Example 28k To a solution of Example 28j (57 mg, 0.175 mmol, 0.8 equiv) in DCM (1 mL) was added HATU (99.8 mg, 0.263 mmol, 1.2 equiv) and DIEA (113 mg, 0.876 mmol, 4.0 equiv). The mixture was stirred for 20 minutes, and then Example 28i (60 mg, 0.219 mmol, 1.0 equiv) was added. The reaction mixture was stirred at room temperature for 2 hours. The solution was concentrated in vacuo, and the crude was purified by preparative TLC to give the product Example 28k (70 mg, 69% yield) as a yellow solid. LCMS [M+1] + =583.3.

[0451] Step 8: Example 28l To a solution of Example 28k (70 mg, 0.12 mmol, 1.0 equiv.) in dioxane (1 mL) was added CsCO (78 mg, 0.24 mmol, 2.0 equiv.) and tert-Bu-Xphos-Pd (11 mg, 0.012 mmol, 0.1 equiv.). The reaction mixture was stirred at 80°C under N protection for 4 hours. The solid was filtered and the filtrate was concentrated. The residue was purified by preparative TLC to give Example 28l (45 mg, 69% yield) as a yellow solid. LCMS [M+1] + =547.3.

[0452] Step 9: Example 28: To a solution of Example 28l (40 mg, 0.073 mmol, 1.0 equiv) in DCM (1 mL) was added TFA (0.3 mL) dropwise at 0°C. The reaction mixture was stirred at room temperature for 2 hours. Upon completion, the reaction mixture was concentrated. The crude product was dissolved in MeOH (2 mL) and basified with NaHCO3. The solid was filtered and the filtrate was concentrated. The residue was purified by preparative TLC to give Example 28 (4.2 mg, 13% yield) as a yellow solid. LCMS [M+1] + =447.1. 1H NMR(300MHz,DMSO-d6)δ 9.19(s,1H),8.64(d,1H),8.48(d,1H),8.22-8.15(m,2H),8.08-8.01(m,1H),7.96-7.90(m,1H),7.86(d,1H), 7.59-7.51(m,2H),6.11(s,1H),4.43(s,2H),4.06-3.93(m,1H),3.63-3.48(m,2H),2.92(d,3H),1.19(d,3H). Example 29: [ka]

[0453] Step 1: Example 29b A solution of Example 29a (2.40 g, 12.57 mmol, 1.0 equiv) in CCl (100 mL) was heated to 80 °C, and then NBS (2.68 g, 15.08 mmol, 1.2 equiv) and AIBN (2.06 g, 12.57 mmol, 1.0 equiv) were added. The reaction mixture was stirred at 80 °C for 4 h. The reaction solution was concentrated and purified by silica gel flash column chromatography to give the desired product, Example 29b (2.16 g, 63.7% yield), as a yellow solid.

[0454] Step 2: Example 29d To a solution of Example 29c (2.80 g, 16.00 mmol, 2.0 equiv) in THF (100 mL) was added NaH (480 mg, 60% in mineral oil, 12.00 mmol, 1.5 equiv) in several portions at 0 °C. After stirring for 30 min, Example 29b (2.16 g, 8.00 mmol, 1.0 equiv) was added, and the mixture was stirred at room temperature for an additional 2 h. The reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel flash column chromatography to give the desired product, Example 29d (1.27 g, 43.6% yield), as a yellow solid. LCMS [M+1-56] + =309.2.

[0455] Step 3: Example 29e Example 29d (1.27 g, 0.84 mmol, 1.0 equiv) was dissolved in MeOH (30 mL) and, under N protection, 10% Pd / C (500 mg) was added in several portions. The system was evacuated and then refilled with hydrogen. The mixture was stirred at room temperature under a H balloon for 1 hour. The reaction mixture was filtered through a Celite pad, and the filtrate was concentrated to give the desired product, Example 29e (1.14 g, 97.8% yield), as a yellow oil. LCMS [M+1+22] + =357.3.

[0456] Step 4: Example 29f To a solution of Example 29e (1.14 g, 3.41 mmol, 1.0 equiv) in DCM (30 mL) was added HCl / dioxane (10 mL, 4 M in dioxane). The reaction was stirred at room temperature for 0.5 h, and the solvent was removed to give the crude desired product, Example 29f (1.64 g, quantitative yield) as a yellow solid. LCMS [M+1] + =235.3.

[0457] Step 5: Example 29h To a solution of Example 29g (300 mg, 0.92 mmol, 1.0 equiv) in DCM (15 mL) was added DIEA (947 mg, 7.34 mmol, 8.0 equiv) and HATU (383 mg, 1.01 mmol, 1.1 equiv). After stirring for 30 minutes, Example 29f (373 mg, 1.38 mmol, 1.5 equiv) was added. The reaction solution was stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified by silica gel flash column chromatography to give the desired product, Example 29h (280 mg, 56.2% yield), as a yellow solid. LCMS [M+1] + =543.3.

[0458] Step 6: Example 29i To a solution of Example 29h (240 mg, 0.44 mmol, 1.0 equiv) in dioxane (10 mL) was added CsCO (288 mg, 0.88 mmol, 2.0 equiv) and tert-Bu-Xphos-Pd (39 mg, 0.044 mmol, 0.1 equiv). The reaction mixture was stirred at 80 °C under N for 16 h. The reaction mixture was concentrated and purified by preparative TLC to give the desired product, Example 29i (75 mg, 33.5% yield), as a yellow solid. LCMS [M+1] + =507.3.

[0459] Step 7: Example 29 To a solution of Example 29i (65 mg, 0.13 mmol, 1.0 equiv) in DCM (6 mL) was added HCl / dioxane (3 mL, 4 M in dioxane). The reaction solution was stirred at room temperature for 1 hour and concentrated. The crude product was dissolved in MeOH, and solid NaCO (excess) was added to the mixture, which was stirred at room temperature for 10 minutes. The mixture was filtered, and the filtrate was concentrated. The residue was purified by preparative TLC to give the desired product, Example 29 (33.8 mg, 64.8% yield), as an off-white solid. LCMS [M+1] + =407.3. 1 H NMR(300MHz,DMSO-d6)δ 9.60(s,1H),8.39(d,1H),8.31(s,1H),8.23(d,1H),8.13(s,1H),7.84(d,1H),7.22(s,1H),6.08(s,1H),4. 65(d,1H),4.51(d,1H),4.20(s,3H),4.01-3.90(m,1H),3.51(d,1H),3.38(d,1H),2.93(d,3H),1.13(d,3H). Example 30 and Example 31 [ka]

[0460] Step 1: Example 30b To a solution of Example 30a (2.6 g, 15.0 mmol) in THF (30 mL) was added MeLi (18.7 mL, 1.6 mol / L) dropwise at −78° C. under N protection. The reaction mixture was stirred at −78° C. for 2 hours. The mixture was then quenched with NH4Cl (aq), diluted with DCM, washed with water, and dried over anhydrous Na2SO4. The solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give Example 30b (1.8 g, 63% yield) as a white solid.

[0461] Step 2: Example 30d To a solution of Example 30b (380 mg, 2.0 mmol) and TBAI (75 mg, 0.2 mmol) in THF (5 mL) was added NaH (173 mg, 60% in mineral oil, 3.0 mmol) at 0° C. The reaction mixture was warmed to room temperature and stirred for 0.5 hours. Example 30c (492 mg, 2.0 mmol) was then added. The mixture was stirred at room temperature for an additional 6 hours. The reaction mixture was quenched with aqueous NH4Cl, extracted with EtOAc, and dried over anhydrous Na2SO4. The solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give Example 30d (230 mg, yield: 32%) as a yellow solid. LCMS [M+1-100] + =255.1.

[0462] Step 3: Example 30e A solution of Example 30d (230 mg, 0.65 mmol) and 10% Pd / C (50 mg) in MeOH (10 mL) was stirred at room temperature for 2 hours under 1 atmosphere of H2. Upon completion, the mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue, Example 30e (178 mg, quantitative yield), was obtained as a yellow solid, which was used directly in the next step. LCMS [M-188] + =137.1 Step 4: Example 30f To a solution of Example 30e (178 mg, 0.75 mmol) in DCM (4 mL) was added TFA (1.0 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to give the crude product Example 30f (138 mg, crude, yield: 82%) as a black oil. LCMS [M+1] + =225.1.

[0463] Step 5: Example 30h To a solution of Example 30f (138 mg, 0.62 mmol), Example 30g (200 mg, 0.62 mmol), and TEA (311 mg, 3.1 mmol) in DCM (5 mL) was added HATU (236 mg, 0.62 mmol). The reaction mixture was stirred at room temperature for 2 hours. DCM (40 mL) was then added to the reaction mixture, which was washed with brine (20 mL x 2), dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 30h (150 mg, 45% yield), as a brown solid. LCMS [M+1] + =533.2

[0464] Step 6: Example 30i To a mixture of Example 30h (150 mg, 0.28 mmol), CsCO (137 mg, 0.42 mmol) in dioxane (2 mL) was added tert-Bu-Xphos-Pd (25 mg, 0.028 mmol). The mixture was degassed with N three times and stirred at 80 °C for 3 h. The reaction mixture was then diluted with DCM, washed with water, dried over anhydrous NaSO, and concentrated under reduced pressure to give crude Example 30i (170 mg, crude, quantitative yield) as a white solid, which was used in the next step without further purification. LCMS [M+1] + =497.2.

[0465] Step 7: Examples 30 and 31 To a solution of Example 30i (120 mg, crude, 0.34 mmol) in DCM (4 mL) was added TFA (1.0 mL), which was stirred at room temperature for 2 hours. The mixture was concentrated, and the residue was purified by preparative HPLC to give the following desired products: Example 30 (6.7 mg, RT=1.743 min, yield: 5%), white solid LCMS [M+1] + =397.2. 1H NMR(400MHz,DMSO-d6)δ 8.81(s,1H),8.54(s,1H),8.15(d,1H),8.10(s,1H),7.77(d,1H),6.89(q,2H),5.98(s,1H),4.58(d,1H), 4.31(d,1H),3.84(s,3H),3.81(d,1H),3.73(d,1H),3.28(s,1H),2.88(d,3H),1.17(d,3H),1.08(d,3H). and Example 31 (3.1 mg, RT=1.652 min, yield: 2%), white solid LCMS [M+1] + =397.2. 1 H NMR(400MHz,DMSO-d6)δ 8.94(s,1H),8.33(s,1H),8.15(s,1H),8.07(s,1H),7.79(s,1H),6.92(d,2H),5.85(s,1H), 4.56(d,1H),4.39(d,1H),3.84(s,3H),3.59(s,1H),2.88(d,3H),1.12(d,3H),1.03(d,3H). Example 32 and Example 33 [ka]

[0466] Step 1: Example 32b To a solution of DMSO (3.3 mL, 47.9 mmol) in DCM (10 mL) was added (COCl) (3.0 mL, 34.2 mmol) at −78° C., and the mixture was stirred at −78° C. for 15 minutes. Then, Example 32a (3.0 g, 17.1 mmol) in THF (2 mL) was added dropwise, and the mixture was stirred at −78° C. for 2 hours. Then, TEA (3.3 mL, 85.6 mmol) was added dropwise, and the resulting mixture was stirred at −78° C. for 0.5 hours. The reaction mixture was quenched with brine, diluted with DCM, washed with water, and dried over anhydrous NaSO. The solution was concentrated under reduced pressure, and purified by silica gel column chromatography to give Example 32b (2.1 g, 71% yield) as a white solid.

[0467] Step 2: Example 32c To a solution of Example 32b (1.2 g, 6.9 mmol) in THF (10 mL) was added MeLi (10.8 mL, 17.3 mmol, 1.6 mol / L) dropwise under N protection at −78° C. The reaction mixture was stirred at −78° C. for 2 hours. The reaction mixture was then quenched with aqueous NH4Cl, diluted with DCM, washed with water, and dried over anhydrous Na2SO4. The solution was concentrated under reduced pressure, and purified by silica gel column chromatography to give Example 32c (600 mg, 46% yield) as a white solid.

[0468] Step 3: Example 32e To a solution of Example 32c (500 mg, 2.64 mmol) and TBAI (96 mg, 0.26 mmol) in THF (5 mL) was added NaH (127 mg, 60% in mineral oil, 5.28 mmol) in portions at 0° C. The reaction mixture was warmed to room temperature and stirred at room temperature for 0.5 hours. Example 32d (780 mg, 3.17 mmol) was then added. The mixture was stirred at room temperature overnight. The reaction mixture was quenched with aqueous NH4Cl solution, then extracted with EtOAc and dried over anhydrous Na2SO4. The solution was concentrated under reduced pressure and purified by silica gel column chromatography to give Example 32e (160 mg, yield: 18%) as a yellow solid. LCMS [M+1-100] + =255.1.

[0469] Step 4: Example 32f A mixture of Example 32e (160 mg, 0.45 mmol) and 10% Pd / C (20 mg) in MeOH (10 mL) was stirred at room temperature for 2 h under 1 atmosphere of H. The suspension was then filtered and the organic phase was concentrated under reduced pressure to give crude Example 32f (140 mg, quantitative yield) as a yellow solid, which was used directly in the next step. LCMS [M-188] + =137.1.

[0470] Step 5: Example 32g To a solution of Example 32f (140 mg, 0.43 mmol) in DCM (4 mL) was added TFA (2.0 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to give the crude product Example 32g (100 mg, crude, quantitative yield) as a black oil. LCMS [M+1] + =225.1.

[0471] Step 6: Example 32i To a solution of Example 32g (97 mg, 0.43 mmol), Example 32h (141 mg, 0.43 mmol), and TEA (112 mg, 0.86 mmol) in DCM (5 mL) was added HATU (246 mg, 0.65 mmol). The reaction mixture was stirred at room temperature for 2 hours. Then, DCM (40 mL) was added to the reaction mixture, which was washed with brine (20 mL x 2), dried over anhydrous NaSO, and concentrated. The residue was purified by silica gel column chromatography to give the desired product, Example 32i (110 mg, 48% yield), as a brown solid. LCMS [M+1] + =533.2.

[0472] Step 7: Example 32j To a mixture of Example 32i (110 mg, 0.21 mmol), CsCO (134 mg, 0.41 mmol) in dioxane (2 mL) was added tert-Bu-Xphos-Pd (17 mg, 0.021 mmol). The mixture was degassed with N three times and stirred at 80 °C for 3 h. The reaction mixture was then diluted with DCM, washed with water, dried over anhydrous NaSO, and then concentrated under reduced pressure to give crude Example 32j (100 mg crude, yield: 97%) as a white solid, which was used in the next step without further purification. LCMS [M+1] + =497.2.

[0473] Step 8: Examples 32 and 33 To a solution of Example 32j (100 mg, 0.201 mmol) in DCM (4 mL) was added TFA (1.0 mL), which was stirred at room temperature for 2 hours. The mixture was concentrated, neutralized with aqueous NaHCO3, extracted with DCM, washed with water, dried over anhydrous Na2SO4, and then concentrated under reduced pressure. The residue was purified by preparative HPLC to give the desired product, Example 32 (5.7 mg, 16% yield), as a white solid. LCMS [M+1] as peak 1 += 397.2;Rt=1.609 minutes 1 H NMR(400MHz,DMSO-d6)δ 8.97(s,1H),8.34(d,1H),8.16(d,1H),8.08(s,1H),7.81(d,1H),6.98-6.88(m,2H),5.86(s,1H), 4.57(d,1H),4.40(d,1H),3.85(s,3H),3.59(q,1H),3.25-3.15(m,1H),1.13(d,3H),1.04(d,3H). and Example 33 (5.1 mg, yield: 13%) as a white solid. Peak 2: LCMS [M+1] += 397.2;Rt=1.675 minutes. 1 H NMR (400 MHz, methanol-d₄) δ 8.64-8.56 (m, 1H), 8.42 (s, 1H), 8.15 (s, 1H), 6.89 (t, 2H), 5.77 (s, 1H), 5.49 (s, 1H), 4.65 (d, 1H), 4.36 (d, 1H), 3.91 (s, 4H), 3.82 (d, 1H), 3.02 (s, 3H), 1.23 (d, 6H). Example 34: [ka]

[0474] Step 1: Example 34b To a solution of Example 34a (15.0 g, 54.0 mmol) in DMF (225 mL) was added SnCl (35.8 g, 189.0 mmol). The mixture was degassed with N three times and stirred at 25 °C for 1 h. Water was then added, and the organics were extracted three times with EtOAc. The combined organics were dried over anhydrous NaSO and then concentrated under reduced pressure. This was purified by silica gel column chromatography to give the desired product, Example 34b (8.1 g, 61% yield), as a red solid. LCMS [M+1] += 246.0.

[0475] Step 2: Example 34d To a solution of Example 34a (8.1 g, 32.5 mmol) in Example 34c (100 mL) was added TsOH.HO (627 mg, 3.3 mmol). The mixture was degassed with N three times and stirred at 80 °C for 1 h. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography to give the desired product, Example 34d (5.5 g, yield: 61%) as a yellow solid. LCMS [M+1] += 269.9.

[0476] Step 3: Example 34e To a solution of Example 34d (5.97 g, 22.10 mmol) in THF (90 mL) was added LiAlH (1.00 g, 26.47 mmol) at -20 °C. The mixture was degassed with N three times and stirred at -20 °C for 1 h. The reaction was then quenched by the addition of water (1.2 mL) at -20 °C. The resulting solution was diluted with aqueous NaOH (15%, 3.6 mL) and EtOAc (1.2 mL) at room temperature. The solid was filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography to give the desired product, Example 34e (2.31 g, 46% yield), as a yellow solid. LCMS [M+1] += 241.9.

[0477] Step 4: Example 34f To a solution of Example 34e (2.31 g, 9.79 mmol) in DCM (45 mL) was added PPh3 (3.30 g, 12.70 mmol). The mixture was cooled to 0 °C. Then, a solution of CBr4 (4.20 g, 12.70 mmol) in DCM (5 mL) was added dropwise. After the addition, the reaction mixture was stirred at 0 °C for 2 hours. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography to give the desired product, Example 34f (2.51 g, yield: 82%) as a yellow solid. LCMS [M+1] += 305.9

[0478] Step 5: Example 34h To a solution of Example 34f (2.20 g, 7.26 mmol) and Example 34g (1.52 g, 8.59 mmol) in THF (40 ...

Claims

1. A compound of formula (IIa) or (IIb) below, or a pharma- ceutically acceptable salt or stereoisomer thereof: [Formula 1] [chemical 2] During the ceremony: L is, [C3] is selected from the group consisting of Ring A is selected from the group consisting of phenyl, pyridyl, pyrimidyl, pyridazinyl, indazolyl, benzoxazolyl, and benzotriazolyl; Each R A are independently deuterium, halogen, —CN, —OR b , —NR c R d , -C(=O)NR c R d, -C(=O)R a , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 or two R on the same carbon; A together to form oxo, n is 0 to 4; Y 8 is N, Y 6 is CR6, Y 3 is CR3, Y 9 is N, R 3 and R6 is hydrogen; R 4 is hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6is selected from the group consisting of deuteroalkyl; R 5 is hydrogen, R 7 is hydrogen or C 1 -C 6 is alkyl, Each R a is independent, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 is selected from the group consisting of deuteroalkyl; Each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 deuteroalkyl; and Each R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 and deuteroalkyl.

2. R 4 is C 1 -C 6 Alkyl or C 1 -C 6 2. The compound of claim 1, or a pharma- ceutically acceptable salt or stereoisomer thereof, which is deuteroalkyl.

3. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, wherein Ring A is phenyl.

4. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt or stereoisomer thereof, wherein Ring A is selected from the group consisting of pyridyl, pyrimidyl, pyridazinyl, indazolyl, benzoxazolyl, and benzotriazolyl.

5. Each R A are independently deuterium, halogen, -CN, -OR b , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, and C 1 -C 6 5. The compound of any one of claims 1 to 4, or a pharma- ceutically acceptable salt or stereoisomer thereof, selected from the group consisting of deuteroalkyl.

6. L is, [C4] 6. The compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt or stereoisomer thereof, selected from the group consisting of:

7. L is, [C5] 7. The compound according to any one of claims 1 to 6, wherein:

8. The compound is [C6-1] [C6-2] 2. The compound of claim 1, selected from the group consisting of:

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt or stereoisomer thereof, and a pharma- ceutically acceptable excipient.

10. 10. A method of inhibiting TYK2 enzyme in a biological sample, comprising contacting said biological sample with a compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt or stereoisomer thereof.

11. 10. A pharmaceutical composition according to claim 9 for use in a method for treating a TYK2 mediated disorder, said method comprising administering to a patient in need thereof a compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt or stereoisomer thereof.

12. The pharmaceutical composition of claim 11, wherein the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a transplant-related disorder.

13. The pharmaceutical composition of claim 11, wherein the disorder is associated with type I interferon, IL-10, IL-12, or IL-23 signaling.

Citation Information

Patent Citations

  • Pyrazolo(1,5-a)(1,3,5)triazine and pyrazolo(1,5-a)pyrimidine derivatives useful as protein kinase inhibitors

    JP2010503690A

  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and / or IFNα responses

    JP2017500304A

  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and / or IFNα responses

    JP2019501125A

  • TYK2 inhibitors and uses thereof

    WO2019023468A1

  • TDO small molecule inhibitor derivative and antitumor conjugate thereof, and preparation method

    WO2020019376A1

Cited By

  • TYK2 inhibitors and uses thereof

    JP2023541203A